Gross Profit Increased to $28 Million in 2025 Compared to $25 Million in 2024, Representing a $3 Million (13%) Increase in Gross Profit
Operating Cash Used in 2025 Amounted to $13 Million Compared to $18 Million in 2024, Representing a $5 Million (27%) Reduction in Cash Used in Operating Activities
SKYX Raised $29 Million in Q1 2026 Investments from Fundamental Institutions
SKYX Announced Collaboration with NVIDIA AI Ecosystem Connect Program, Expecting to Grow Its Collaboration with NVIDIA into Future Smart Home Projects
SKYX Announced Launch of Its Advanced SKYFAN and Turbo Heater on Its E-Commerce Platform with 60 Websites, 1stoplighting.com, and U.S. Leading Retailers Including Home Depot, Target, Lowe’s, and Walmart
Based on the Growing Sales of Its Patented Turbo Heater Fan, SKYX Is Expanding the Category of the “All-Season Ceiling Fan” — Heat in Winter and Cool in Summer — to Provide Additional Products in New Designs and Larger Sizes
Company Expects to Continue Its Growth in 2026 to Advance Its Path to Cash-Flow Positive
SKYX Anticipates Securing Significant Business Opportunities in the Hotel and Builder Segments in the First Half of 2026
SKYX’s Enhanced Safety Code Standardization Team Continues Its Progress Toward Its Goal of a Safety-Mandated Standardization in Homes/Buildings of Its Life-Saving Ceiling Outlet/Receptacle Technology
SKYX Is Expected to Supply Its Advanced Smart Home Technologies to Upcoming and Future Key Projects in the U.S. and Globally, Including New York, North Carolina, Austin, San Antonio, South Florida (Including Miami’s New $4 Billion Smart City), Saudi Arabia, and Egypt
SKYX Is Expected to Deploy Over 1 Million Units of Its Advanced Smart Home Plug-and-Play Technologies During These Projects
SKYX Continues to Grow Its Market Penetration and Expects to Deploy Over 100,000 of Its Products into Homes/Units by the End of 2026 Through Retail and Pro Segments
SKYX’s Technology Expansion Provides Additional Opportunities for Future Recurring Revenues Through Interchangeability, Upgrades, AI Services, Monitoring, Subscriptions, and More
SKYX Will Be Launching a New AI-Driven Software in 2026 for Its E-Commerce Platform of 60 Websites, Which Is Expected to Increase Conversion Rates and Sales Up to 30%
MIAMI, March 26, 2026 (GLOBE NEWSWIRE) — SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the “Company” or “SKYX”), an award winning, highly disruptive advanced and smart home platform technology company with over 100 U.S. and Global pending and issued patents and a portfolio of 60 lighting and home décor websites, with a mission to make homes and buildings become advanced-safe-smart instantly as the new standard, today reported its financial and operational results for the Fourth Quarter and Fiscal Year ended December 31, 2025.
Fourth Quarter 2025 and Subsequent Highlights:
SKYX reports record sales $92.0 million in 2025 compared with $86 million in 2024.
Generated a record $25 million in revenue in Q-4 2025 compared to $24 million in Q-4 2024.
Gross profit in 2025 increased to $28 million, from $25 million, representing a 13% increase.
SKYX is armed with cash, cash equivalents and restricted cash of $10 million as of December 31, 2025, together with $29 million the Company subsequently raised in January 2026 (from one fundamental investors in straight equity with no warrants), as compared to $16 million as of September 30, 2025.
Management expects significant growth in 2026 to advance its path to becoming cash-flow positive.
SKYX’s e-commerce sales are converted into cash rapidly, advancing it cash position often referred to as the “Dell Working Capital Model”, lowering its cost of capital.
In light of its strengthened balance sheet following recent capital raises, management believes the Company is well capitalized to execute its growth initiatives while progressing toward sustained cash-flow generation and profitability.
SKYX has successfully demonstrated its technology during a Marriott Hotel renovation and expects to grow its hotel segment during 2026.
Marriott Hotel chain owner, The Shaner Group, led a $16.5 million investment round. The Shaner Group is an owner and developer of more than 70 hotels worldwide.
Company is expecting to secure additional significant business opportunities in 2026.
SKYX continues its growth and expects to deploy over 100,000 of its products into homes/units during 2026 through retail and pro segments.
SKYX announced the launch of its patented advanced SKYFAN and Turbo Heater to the leading U.S. retailer Home Depot, including a new SkyPlug branding page on HomeDepot.com.
SKYX recently announced the launch of its Turbo Heater fan at leading U.S. retailers Target, Walmart, and Lowe’s, and on its e-commerce platform across 60 websites.
SKYX anticipates securing additional significant business opportunities on several fronts during 2026.
SKYX is expected to supply its advanced smart home technologies to upcoming and future key projects in the U.S. and globally, including projects in Pittsford, New York; North Carolina; Austin, Texas; San Antonio, Texas; South Florida including the new $4 billion smart city in Miami, Florida; Saudi Arabia; and Egypt, among others.
SKYX is expected to deploy over 1 million units of its advanced smart home plug-and-play technologies during these projects.
Technology Roadmap
SKYX announced a collaboration with the NVIDIA AI Ecosystem Connect Program. SKYX expects to grow its collaboration with NVIDIA through its existing and future smart home projects.
SKYX will be launching a new AI driven software for its e-commerce platform of 60 websites, expected to increase its conversion rate and sales up to 30%.
The Company secured U.S. and global strategic manufacturing partnerships with premier manufacturers including in the U.S., Vietnam, Taiwan, China, and Cambodia.
SKYX’s technologies expansion provides additional opportunities for future recurring revenues through interchangeability, upgrades, AI services, monitoring, subscriptions, and more.
Financing Highlights
We extended and converted $13.5 million in notes coming due with maturity out to 5 years until 2030.
We raised $29 million in equity during January 2026.
Safety Standardization Mandatory Code / Insurance Specification and Recommendation
SKYX’s Safety Code Standardization Team is receiving support from a new significant prominent leader with its government safety agency’s process for a safety mandatory standardization of its electrical ceiling outlet/receptacle technology.
SKYX’s code team is led by industry veterans Mark Earley, former head of the National Electrical Code (NEC), and Eric Jacobson, former President and CEO of the American Lighting Association (ALA). The Company’s safety Code Standardization team believes it will garner assistance from additional safety organizations with its code mandatory safety standardization efforts based on the product’s significant safety aspects. Mr. Earley and Mr. Jacobson were instrumental in numerous code and safety changes in both the electrical and lighting industries. Both strongly believe that, considering the Company’s standardization progress including its product specification approval voting for by ANSI / NEMA (American National Standardization Institute / National Electrical Manufacturers Association) and being voted into 10 segments in the NEC Code Book, it has met the necessary safety conditions for becoming a ceiling safety standardization requirement for homes and buildings.
With respect to insurance companies, the Company strongly believes its products can save insurance companies many billions of dollars annually by reducing fires, ladder fall injuries, and electrocutions among other things. Management expects that once it completes an entire range and variations of its safe advanced plug & play products it will start being recommended by insurance companies.
2025 Financial Results
Revenue in 2025 increased to a record $92.0 million, including record sales of $25 million in the fourth quarter, including e-commerce sales, smart home products and advanced plug & play products. Gross profit in 2025 increased to $28 million, or 30% of revenue from $25 million, or 29% of revenue in 2024. We are armed with cash, cash equivalents and restricted cash of $10 million as of December 31, 2025, in addition to $29 million we raised in January 2026, as compared to $16 million as of September 30, 2025. Cash used in operating activities for 2025 amounted to $13 million, as compared to $18 million in 2024. Net loss per share decreased by $0.04 to $0.32 per share in 2025 compared to $0.36 in 2024. Adjusted EBITDA loss per share, a non-GAAP measure, decreased to $0.10 per share in 2025, as compared to $0.13 per share, in 2024.
The Company’s annual report on Form 10-K will be filed with the SEC and will be made available on the Company’s investor relations website: https://ir.skyplug.com/sec-filings/.
Management Commentary
Our year ended December 31, 2025, was highlighted by our four quarters of consecutive growth including sales and rollout of our advanced ceiling smart and standard plug & play platform products on many leading U.S. and Canadian websites. We believe we are accelerating sales momentum while driving toward a stronger gross margin profile, supported in part by contributions from the Turbo Heater Fan, and continuing to actively manage SKYX’s cash burn. Our e-commerce platform with 60 websites is expected to continue providing additional cash flow to the Company. Management anticipates that in 2026 the Company will continue to advance its path towards cash flow positive.
About SKYX Platforms Corp.
As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced-safe-smart platform technologies, with over 100 U.S. and global patents and patent pending applications. Additionally, the Company owns 60 lighting and home decor websites for both retail and commercial segments. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at https://www.skyx.com/ or follow us on LinkedIn.
Forward-Looking Statements
Certain statements made in this press release are not based on historical facts but are forward-looking statements. These statements can be identified by the use of forward-looking terminology such as “aim,” “anticipate,” “believe,” “can,” “could,” “continue,” “estimate,” “expect,” “evaluate,” “forecast,” “guidance,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “outlook,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “target” “view,” “will,” or “would,” or the negative thereof or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements reflect the Company’s reasonable judgment with respect to future events and are subject to risks, uncertainties and other factors, many of which have outcomes difficult to predict and may be outside our control, that could cause actual results or outcomes to differ materially from those in the forward-looking statements. Such risks and uncertainties include statements relating to the Company’s ability to successfully launch, commercialize, develop additional features and achieve market acceptance of its products and technologies and integrate its products and technologies with third-party platforms or technologies; the Company’s ability to achieve positive cash flows; the Company’s efforts and ability to drive the adoption of its products and technologies as a standard feature, including their use in homes, hotels, offices and cruise ships; the Company’s ability to capture market share; the Company’s estimates of its potential addressable market and demand for its products and technologies; the Company’s ability to raise additional capital to support its operations as needed, which may not be available on acceptable terms or at all; the Company’s ability to continue as a going concern; the Company’s ability to execute on any sales and licensing or other strategic opportunities; the possibility that any of the Company’s products will become National Electrical Code (NEC)-code or otherwise code mandatory in any jurisdiction, or that any of the Company’s current or future products or technologies will be adopted by any state, country, or municipality, within any specific timeframe or at all; risks arising from mergers, acquisitions, joint ventures and other collaborations; the Company’s ability to attract and retain key executives and qualified personnel; guidance provided by management, which may differ from the Company’s actual operating results; the potential impact of unstable market and economic conditions on the Company’s business, financial condition, and stock price; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including its periodic reports on Form 10-K and Form 10-Q. There can be no assurance as to any of the foregoing matters. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by U.S. federal securities laws.
Non-GAAP Financial Measures
Management considers earnings (loss) before interest, taxes, depreciation and amortization, or EBITDA, as adjusted, an important indicator in evaluating the Company’s business on a consistent basis across various periods. Due to the significance of non-recurring items, EBITDA, as adjusted, enables management to monitor and evaluate the business on a consistent basis. The Company uses EBITDA, as adjusted, as a primary measure, among others, to analyze and evaluate financial and strategic planning decisions regarding future operating investments and potential acquisitions. The Company believes that EBITDA, as adjusted, eliminates items that are not part of the Company’s core operations, such as interest expense, amortization expense, and impairment charges associated with intangible assets, or items that do not involve a cash outlay, such as share-based payments and non-recurring items, such as transaction costs. EBITDA, as adjusted, should be considered in addition to, rather than as a substitute for, pre-tax income (loss), net income (loss) and cash flows used in operating activities. This non-GAAP financial measure excludes significant expenses that are required by GAAP to be recorded in the Company’s financial statements and is subject to inherent limitations. Investors should review the reconciliation of this non-GAAP financial measure to the comparable GAAP financial measure. Investors should not rely on any single financial measure to evaluate the Company’s business.
SKYX Platforms – Q4 2025 and 2025 Full Year Corporate Update Call Date: March 26, 2026 Time: 4:30 p.m. Eastern Time U.S./Canada Dial-in: 1-412-317-5180 International Dial-in: 1-844-825-9789
Company Reports Record Full-Year Revenues of $189.3 million, a 10.7% Year-Over-Year Increase, Outpacing Election-Year Comparison
Broadcast Revenues Increase to $153.3 million, a 17.3% Increase Year-Over-Year
Newsmax Remains the Fourth Highest-Rated Cable News Channel, Reaching More Than 58 Million Total Viewers
Company Projects Accelerated Revenue Growth in 2026
BOCA RATON, FL / ACCESS Newswire / March 26, 2026 / Newsmax Inc. (NYSE:NMAX) (“Newsmax” or the “Company”) today announced its financial results for the fourth quarter and full-year ended December 31, 2025.
2025 Business and Operational Highlights
Delivered record full-year 2025 revenues of $189.3 million, representing a 10.7% year-over-year increase and achieving results at the high end of the Company’s full-year guidance range, despite a challenging post-election year comparison.
Expanded domestic distribution through new and renewed multi-year carriage agreements, including a multi-year renewal with YouTube TV, maintaining Newsmax’s placement in the platform’s base package and extending Newsmax+ availability through YouTube Prime-time Channels beginning in 2026.
Advanced the Company’s international expansion strategy through new multi-year distribution agreements across Europe and the Middle East, including launches in France, Israel and Cyprus, and a brand license agreement to launch Newsmax Ukraine, extending the Company’s reach to more than 100 countries worldwide.
Continued to scale the Company’s streaming and digital platforms through the expansion of Newsmax2 across major FAST and connected TV platforms and ongoing investment in exclusive content for the Newsmax+ subscription service.
Maintained Newsmax’s position as the fourth highest-rated cable news channel in the United States while expanding total audience reach across cable, streaming, digital and social media platforms, reaching more than 58 million total viewers in 2025 and finishing #6 among all cable channels in total day ratings, according to Nielsen.
Management Commentary
“Fiscal year 2025 was a defining year for Newsmax,” said Christopher Ruddy, Chief Executive Officer of Newsmax. “In our first year as a public company, we delivered double digit revenue growth and expanded our audience reach across cable, FAST and digital platforms, even in a non-election year when industry-wide viewership and advertising demand typically normalize. We broadened both our domestic and international distribution footprint, extending Newsmax to new platforms and markets around the world, while reinforcing our position as the fourth highest-rated cable news network. These achievements underscore the strength of our multi-platform model and diversified revenue streams that benefit from the continued demand for independent, values-driven journalism, which resonates with audiences across all of our platforms.”
Ruddy continued, “Looking ahead, with key milestones completed and the costs of becoming a public company largely absorbed, we are well positioned to accelerate our growth trajectory with strategic investment initiatives across content, distribution and technology. As we enter 2026 , we believe Newsmax is entering this next chapter from a position of strength, supported by a solid financial foundation, expanding distribution and a clear focus on sustainable, long-term growth for our shareholders.”
Financial Results:
Revenue by Segment by Component Summary Table (unaudited):
Fourth Quarter 2025 Financial Highlights:
Newsmax reported total quarterly revenues of $52.2 million for the three-month period ended December 31, 2025, representing a 9.6% year-over-year increase.
Total broadcasting revenues grew 12.6% year-over year to $42.5 million for the fourth quarter of 2025, underscoring continued growth even in a non-election year. This was driven by affiliate fee revenue growth, higher ratings and pricing for broadcasting ad revenue, and licensing growth.
Newsmax reported a quarterly Net Loss of $(3.0) million as compared to a net loss of $(6.9) million reported in same quarter in the prior year, primarily driven by higher strategic investments in headcount, programming and production capabilities to support the ongoing expansion and enhancement of our content offering, stock-based compensation costs, offset by higher broadcasting advertising, affiliate fees, book sales and licensing revenue.
Quarterly adjusted EBITDA was $(1.3) million, a decrease of $(3.8) million from the amount reported in the same quarter last year, primarily due to higher production and programming expense, increased personnel, increase legal, consulting and public company costs. (See reconciliation of net loss to adjusted EBITDA below).
The Company ended the quarter with $131.3 million in cash and short-term investments. cash and cash equivalents were $20.4 million and short-term investments were $110.9 million.
Fiscal Year 2025 Financial Highlights:
Newsmax reported total revenues of $189.3 million for the year ended December 31, 2025, representing a 10.7% year-over-year increase.
Total broadcasting revenues increased 17.3% year-over-year to $153.3 million, driven by an increase in advertising revenue due to higher ratings and pricing, timing of new affiliate contractual relationships and growth of subscription revenue from Newsmax+.
Newsmax reported a net loss of $(99.5) million for full year 2025, largely driven by approximately $79 million in legal settlement expenses, along with stock-based compensation costs, non-cash derivative and warrant liability adjustment and higher production and programming investments, partially offset by higher Broadcasting advertising revenues, affiliate fees and licensing fees.
Full-year adjusted EBITDA was $(6.5) million, reflecting continued strategic investments in content, talent, technology and public company infrastructure. (See reconciliation of net loss to adjusted EBITDA below).
Fiscal Year 2026 Outlook
The Company is issuing full-year 2026 guidance as follows:
Full-year revenue of $212 million to $216 million, representing 13% year-over-year growth at the midpoint of the range.
“Our full-year 2025 results reflect disciplined execution across the business, with revenue performance at the high end of our guidance range despite a challenging post-election comparison,” commented Darryle Burnham, Chief Financial Officer of Newsmax. “We ended the year with a strong balance sheet and increased financial flexibility following our transition to a public company, and as we look ahead, we are confident in our financial outlook and are focused on prudent investment in content, technology and distribution initiatives that support sustainable, long-term shareholder value.”
About Newsmax
Newsmax Inc. is listed on the NYSE (NMAX) and operates, through Newsmax Broadcasting LLC, one of the nation’s leading news outlets, the Newsmax channel. The fourth highest-rated network is carried on all major pay TV providers. Newsmax’s media properties reach more than 50 million Americans regularly through Newsmax TV, the Newsmax App, its popular website Newsmax.com, and publications such as Newsmax Magazine. Through its social media accounts, Newsmax reaches over 24 million combined followers. Reuters Institute says Newsmax is one of the top U.S. news brands and Forbes has called Newsmax “a news powerhouse.”
This communication contains forward-looking statements. From time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Forward-looking statements can be identified by those that are not historical in nature. The forward-looking statements discussed in this communication and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. Newsmax does not guarantee future results, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. Forward-looking statements should not be relied upon as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this communication to conform our prior statements to actual results or revised expectations, and we do not intend to do so. Factors that may cause actual results to differ materially from current expectations include various factors, including but not limited changes in domestic and global general economic and macro-economic conditions and the volatility of the price of Common Stock that may result from, among other things, comments by securities analysts or other third parties, including blogs, articles, message boards and social and other media, large shareholders exiting their position in our Common Stock, any negative public perception of us, sales of shares previously registered for resale, or other uncertainties and the factors set forth in the sections entitled “Risk Factors” in Newsmax’s Annual Report on Form 10-K for the twelve months ended December 31, 2025 and other filings Newsmax makes with the Securities and Exchange Commission. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Undue reliance should not be placed on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein.
USE AND DEFINITION OF NON-GAAP FINANCIAL MEASURES
This press release contains a financial measure that has not been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”). This financial measure is Adjusted EBITDA.
Non-GAAP financial measures are used to supplement the financial information presented on a U.S. GAAP basis and should not be considered in isolation or as a substitute for the relevant U.S. GAAP measures and should be read in conjunction with information presented on a U.S. GAAP basis. Because not all companies use identical calculations, our presentation of Non-GAAP measures may not be comparable to other similarly titled measures of other companies.
Adjusted EBITDA1 is defined as revenues less cost of revenues and general and administrative expenses and does not include depreciation and amortization, interest expense, net, impairment charges, unrealized gains (losses) on marketable securities, other corporate matters (consisting primarily of certain litigation expenses, and related fees, for specific legal proceedings that the Company has determined are infrequent and unusual in terms of their magnitude), other, net, and income tax expense.
You are encouraged to evaluate each adjustment used in calculating our non-GAAP financial measure and the reasons we consider our non-GAAP financial measure appropriate for supplemental analysis. In evaluating our non-GAAP financial measure, you should be aware that in the future we may incur expenses similar to the adjustments in our presentation. Our non-GAAP financial measure has limitations as an analytical tool, and you should not consider this measure in isolation or as a substitute for analysis of our results as reported under GAAP. Our presentation of our non-GAAP financial measure should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. Our non-GAAP financial measure may not be comparable to other companies. Please see a historical reconciliation of this measure to the most comparable GAAP measure presented in our consolidated financial statements below.
_________________
1 The Company compensates for limitations of the adjusted EBITDA measure by prominently disclosing GAAP net income (loss), which the Company believes is the most directly comparable GAAP measure, and providing investors with a reconciliation from GAAP net loss to adjusted EBITDA on page 11.
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology, products, system and software company in defense, national security, and global markets, announced today that it has been selected by the Naval Surface Warfare Center, Port Hueneme Division (NSWC PHD) for production and delivery of up to 36 Oriole™ solid rocket motors and three Thrust Vector Control (TVC) nozzle kits. The contract includes a funded base award for Oriole with options that, if fully exercised, bring the total contract value for solid rockets to $39,077,237. An option for 3 Oriole TVC production kits, valued at $10,136,009, is also included in the award.
The Oriole rocket system is an affordable, mission-relevant flight test solution, supporting the Navy’s critical suborbital target and experimental hypersonic test requirements with rapid delivery and fielding. Kratos’ proven capability and flawless track record delivering Oriole rocket systems and vehicle hardware components enables customers to maintain robust test and evaluation schedules in support of emerging national security requirements.
“Kratos continues to provide the Department of War with proven, affordable, and rapid turn-key launch vehicle solutions,” said Dave Carter, President of Kratos Defense & Rocket Support Services. “Our Oriole rocket motor and TVC kit systems deliver critical capability to our Navy and DoW customers, supporting operational needs and test objectives on accelerated timelines.”
This award continues Kratos’ long-standing partnership with NSWC PHD in support of ballistic missile defense, hypersonic research, and other test programs. With repeated program successes and regular technology refreshes, Kratos continues to reinforce its industry leading position in the design, production, and sustainment of mission-critical solutions for national security applications.
“Kratos is honored to support our Navy and defense customers with real, existing, mission-relevant products and systems, rapidly fielded to address today’s most pressing challenges,” said Eric DeMarco, President and CEO of Kratos Defense & Security Solutions. “Our approach—making internal investments to deliver affordable, first-to-market national security hardware—remains central to our growth and our commitment to our customers’ evolving needs.”
About Kratos Defense & Security Solutions Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com.
Notice Regarding Forward-Looking Statements Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 28, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.
Intranasal oxytocin blocks the release of calcitonin gene-related peptide (CGRP) in animal models and is the core technology of TNX-1900 for craniofacial pain conditions, including migraine and trigeminal neuralgia
TNX-1900 will be studied in the trigeminal neurovascular reactivity model, by measuring the forehead skin blood flow response to capsaicin and electrical stimulation by Laser Speckle Contrast Imaging (LSCI)
Oxytocin treatment affects a pathway distinct from the recently available CGRP migraine treatment drug class
BERKELEY HEIGHTS, N.J., March 26, 2026 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully integrated, commercial biotechnology company, today announced that the first participant has been dosed in a Phase 1 investigator-initiated study to evaluate the effect of TNX-1900 (intranasal potentiated oxytocin) on trigeminal nerve-mediated vasodilation of the forehead using capsaicin as well as electrical stimulation, a model for trigeminal neurovascular reactivity, in healthy female human volunteers. Dr. Antoinette Maassen van den Brink, Professor of Neurovascular Pharmacology, Erasmus University Medical Center, is serving as principal investigator and sponsor for the study in a collaborative research agreement with Tonix.
In animal studies, intranasal oxytocin has been shown to bind to oxytocin receptors in the trigeminal ganglion, blocking the release of calcitonin gene-related peptide (CGRP), a potent vasodilator critically involved in the pathogenesis of migraine.1 Dr. Maassen van den Brink has previously found a CGRP inhibitor and a triptan to inhibit the forehead dermal blood flow response to capsaicin in migraineurs and healthy volunteers, respectively.2,3
“We are excited to collaborate with Professor Maassen van den Brink on this proof-of-concept study investigating the potential for TNX-1900 for treating migraine, craniofacial pain, and other related conditions,” said Seth Lederman, MD, Chief Executive Officer of Tonix Pharmaceuticals. “While there are several CGRP inhibitors approved for the treatment of migraine, TNX-1900’s oxytocin treatment affects a distinct pathway that could address unmet needs. The results of the new study will guide future development of this potential non-opioid treatment for migraine and other craniofacial pain conditions.”
As part of the preliminary work in support of this study, Dr. Maassen van den Brink’s team recently validated a newer detection method for dermal blood flow known as Laser Speckle Contrast Imaging (LSCI) in the trigeminal neurovascular reactivity model.4
“We are excited to be using LSCI in this study of TNX-1900, which adds to our established model by providing real-time and higher resolution dermal blood flow measurements, compared to Laser Doppler Perfusion Imaging used in earlier studies,” said Dr. Maassen van den Brink. “Oxytocin represents a potential new therapeutic option, targeting a pathway in migraine and craniofacial pain that is distinct from both the triptan and CGRP inhibitor migraine treatment drug classes.”
About Migraine
Migraine is a neurovascular condition that typically manifests in a throbbing moderate to severe headache which lasts at least four hours, often on one side of the head and aggravated by routine physical activity. It can also be accompanied by nausea, vomiting, visual disturbances, and sensitivity to bright light and loud noises.5 Epidemiological studies indicate that globally, approximately 1.2 billion individuals suffer from migraines annually.6 In the U.S., approximately 39 million Americans suffer from migraines, and among these individuals, approximately four million experience chronic migraines (15 or more headache days per month, at least eight of which are migraines).6
About TNX-1900
TNX-1900 (intranasal potentiated oxytocin) is a proprietary formulation of oxytocin in development as a candidate for the treatment of migraine and craniofacial pain. TNX-1900 is a drug-device combination product, based on an intranasal actuator device that delivers oxytocin into the nasal cavity. Oxytocin is a naturally occurring human peptide hormone that also acts as a neurotransmitter in the brain. Oxytocin has no recognized addiction potential. Oxytocin when delivered via the nasal route, concentrates in the trigeminal system7 resulting in binding of oxytocin to receptors on neurons in the trigeminal system, inhibiting the release of CGRP and transmission of pain signals returning from the site of CGRP release.1 Blocking CGRP release is a distinct mechanism compared with CGRP receptor antagonist and anti-CGRP antibody drugs, which block the binding of CGRP to its receptor, or bind to the peptide CGRP. The addition of magnesium to the oxytocin formulation in TNX-1900 enhances oxytocin receptor binding8 as well as having an inhibitory effect on trigeminal neurons and resultant craniofacial analgesic effects, as demonstrated in animal models.9 Intranasal oxytocin has been shown to be well tolerated in several clinical trials in both adults and children.10 Targeted nasal delivery results in low systemic exposure and lower risk of non-nervous system, off-target effects, which could potentially occur with systemic CGRP receptor antagonists and anti-CGRP (receptor) antibodies.11 For example, CGRP has roles in dilating blood vessels in response to ischemia, including in the heart. The Company believes nasally targeted delivery of oxytocin could translate into selective blockade of CGRP release from neurons in the trigeminal ganglion and not throughout the body, which could be a potential safety advantage over systemic CGRP inhibition. This mechanism is being investigated in a Phase 1 study to evaluate the effect of TNX-1900 on trigeminal nerve-mediated vasodilation of the forehead model for craniofacial pain. In addition, daily dosing is more rapidly reversible, in contrast to monthly or quarterly dosing, as is the case with anti-CGRP antibodies, giving physicians and their patients greater control. In addition to craniofacial pain conditions, TNX-1900 is being developed for treatment of binge eating disorder, adolescent obesity, bone health in pediatric autism and arginine-vasopressin deficiency. Tonix also has a license with the University of Geneva to use TNX-1900 for the treatment of insulin resistance and related conditions.
Citations
1Tzabazis A, et al. Oxytocin receptor: Expression in the trigeminal nociceptive system and potential role in the treatment of headache disorders. Cephalalgia. 2016. 36(10):943-50. 2de Vries Lentsch S, et al. CGRP-mediated trigeminovascular reactivity in migraine patients treated with erenumab. J Neurol Neurosurg Psychiatry. 2022 Aug;93(8):911-912. 3Ibrahimi K, et al. A human trigeminovascular biomarker for antimigraine drugs: A randomized double-blind, placebo-controlled, crossover trial with sumatriptan. Cephalalgia. 2017 Jan;37(1):94-98. 4van Lohuizen et al. 2025. Trigeminovascular activity using a forehead dermal blood flow model: preliminary results of a validation study. J Headache and Pain 26 (Suppl 2): 138. 5The International Classification of Headache Disorders, 3rd Edition. Cephalalgia. 2018. 38(1):1-211. 6Burch et al. Migraine: Epidemiology, Burden, and Comorbidity. Neurol Clin 37 (2019):631–649. 7Yeomans DC, et al. Nasal oxytocin for the treatment of psychiatric disorders and pain: achieving meaningful brain concentrations. Transl Psychiatry. 2021. 11(1):388. 8Antoni FA and Chadio SE. Essential role of magnesium in oxytocin-receptor affinity and ligand specificity. Biochem J. 1989. 257(2):611-4. 9Cai Q, et al. Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder. Psychiatry Clin Neurosci. 2018. 72(3):140-151. 10Yeomans, DC et al. 2017. US patent US2017368095. 11MaassenVanDenBrink A, et al. Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci. 2016. 37(9):779-788.
Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals* is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg), is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. In addition, the Company’s CNS portfolio includes TNX-2900 (intranasal oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including long-acting human monoclonal antibody TNX-4800 for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X.
*Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize TONMYA and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Virginia City, Nevada, March 26, 2026 – Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) is pleased to announce that its 2026 Annual Meeting of Shareholders has been scheduled for Thursday, May 28, 2026, starting at 9:00 a.m. Pacific Daylight Time in Reno, Nevada, at the Peppermill Hotel. The meeting will feature Comstock Metals, strategic investments, and clean energy systems.
The 2026 Annual Meeting schedule for May 28, 2026, is as follows:
8:00 am to 9:00 am PDT – Continental Breakfast 9:00 am to 11:30 am PDT – 2026 Annual Shareholders Meeting, Company Presentations, Q & A 12:00 pm to 1:00 pm PDT – Lunch and Conversations with Company Management and Directors
The record date for the Annual Meeting is March 31, 2026. Only shareholders of record at the close of business on March 31, 2026, may vote at the meeting. The Company’s proxy statement will be sent to shareholders of record and will describe all matters to be voted on. Shareholders are invited to register for the 2026 Annual Meeting: Register to Attend. About Comstock Inc.
Comstock Inc. (NYSE: LODE) innovates and commercializes technologies, systems and supply chains that enable, support and sustain clean energy systems by efficiently, effectively, and expediently extracting and converting under-utilized natural resources into reusable metals, like silver, aluminum, gold, and other critical minerals, primarily from end-of-life photovoltaics.
Comstock Inc. has used, and intends to continue using, its investor relations link and main website at www.comstock.inc in addition to its X.com, LinkedIn and YouTube accounts, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
For investor inquiries: Judd B. Merrill, Chief Financial Officer Tel (775) 413-6222 ir@comstockinc.com
For media inquiries: Zach Spencer, Director of External Relations Tel (775) 847-7573 media@comstockinc.com
Forward-Looking Statements
This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “forecast,” “seek,” “target,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: expectations regarding the completion of the proposed securities offering, future market conditions; future explorations or acquisitions, divestitures, spin-offs or similar distribution transactions; future changes in our research, development and exploration activities; future financial, natural, and social gains; future prices and sales of, and demand for, our products and services; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land and asset sales; investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; and future working capital needs, revenues, variable costs, throughput rates, operating expenses, debt levels, cash flows, margins, taxes and earnings. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: sales of, and demand for, our products, services, and/or properties; industry market conditions, including the volatility and uncertainty of commodity prices; the speculative nature, costs, regulatory requirements, and hazards of natural waste resource identification, exploration, development, availability, recycling, extraction, processing, and refining activities, including operational or technical difficulties, and risks of diminishing quantities or insufficiency of grades of qualified resources;; changes in our planning, exploration, research and development, production, and operating activities; research and development, exploration, production, operating, and other variable and fixed costs; throughput rates, margins, earnings, debt levels, contingencies, taxes, capital expenditures, net cash flows, and growth; restructuring activities, including the nature and timing of restructuring charges and the impact thereof; employment and contributions of personnel, including our reliance on key management personnel; the costs and risks associated with developing new technologies; our ability to commercialize existing and new technologies; the impact of new, emerging, and competing technologies on our business; the possibility of one or more of the markets in which we compete being impacted by political, legal, and regulatory changes, or other external factors over which we have little or no control; the effects of mergers, consolidations, and unexpected announcements or developments from others; the impact of laws and regulations, including permitting and remediation requirements and costs; changes in or elimination of laws, regulations, tariffs, trade, or other controls or enforcement practices, including the potential that we may not be able to comply with applicable regulations; changes in generally accepted accounting principles; adverse effects of climate changes, natural disasters, and health epidemics, such as the COVID-19 outbreak; global economic and market uncertainties, changes in monetary or fiscal policies or regulations, the impact of terrorism and geopolitical events, volatility in commodity and/or other market prices, and interruptions in delivery of critical supplies, equipment and/or raw materials; assertion of claims, lawsuits, and proceedings against us; potential inability to satisfy debt and lease obligations, including because of limitations and restrictions contained in the instruments and agreements governing our indebtedness; our ability to raise additional capital and secure additional financing; interruptions in our production capabilities due to equipment failures or capital constraints; potential dilution from stock issuances, recapitalization, and balance sheet restructuring activities; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to maintain the listing of our securities on any securities exchange or market; and our ability to implement additional financial and management controls, reporting systems and procedures and comply with Section 404 of the Sarbanes-Oxley Act, as amended. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund, or any other issuer.
German consumer goods giant Henkel AG is writing one of the largest checks in prestige hair care history, agreeing to acquire OLAPLEX Holdings (NASDAQ: OLPX) for approximately $1.4 billion in a cash deal that values shares at $2.06 apiece — a 55% premium over where the stock closed on March 25.
For small and microcap investors, this transaction is a textbook case study in what a strategic acquirer will pay for a brand with durable IP, a loyal professional channel, and a story of operational recovery.
From Lab Disruptor to Acquisition Target
OLAPLEX launched in 2014 with a singular innovation: Complete Bond Technology, a chemistry-driven approach to repairing hair bonds during and after chemical services. The product found its home in salons first, building a credibility-driven distribution model that competitors struggled to replicate.
Private equity firm Advent International backed the company and took it public, helping scale it from a single-product disruptor into a multi-SKU hair health platform. But OLAPLEX’s post-IPO journey has been rocky. The stock, which once traded well above $20, has languished amid slowing consumer demand, intense competition in the prestige hair segment, and a multi-year transformation program the company undertook to reset its cost structure, marketing engine, and go-to-market model.
That turnaround, while painful for shareholders who held on too long, appears to have made the company an attractive acquisition for Henkel, which recognized the rebuilt infrastructure and brand credibility as assets worth paying a premium for.
What Henkel Gets
Henkel is acquiring more than a brand — it is acquiring distribution leverage. OLAPLEX has established direct-to-consumer channels and specialty retail presence across North America that complement Henkel’s broader international footprint. The deal gives Henkel immediate access to the professional stylist and salon community, a channel both companies serve but through different product lines.
For Henkel, the acquisition represents an accelerated path into the premium science-led hair care category without years of organic brand-building. The company gains OLAPLEX’s product innovation pipeline and its recognition among consumers across demographics and hair types.
The Private Equity Exit
Advent International, which controlled a majority of OLAPLEX’s voting stock, approved the transaction by written consent — effectively sealing the deal without requiring a broader shareholder vote. Advent will fully exit its position at closing, bookending an investment that helped build a globally recognized brand even if the public market returns disappointed many retail investors.
J.P. Morgan Securities is advising OLAPLEX on the transaction, which is expected to close in the second half of 2026, pending regulatory approval.
What This Signals for the Market
The OLAPLEX deal underscores a persistent theme in the consumer sector: global strategics are still willing to pay substantial premiums for brands with defensible science-based positioning and professional channel relationships, even when the public market has long since moved on. For small and microcap investors tracking M&A, OLPX is a reminder that a beaten-down stock with genuine brand equity is not always a broken business — sometimes it is just a business waiting for the right buyer.
Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.
Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Initiating coverage with an Outperform. Resolution Minerals Ltd (ASX: RML, OTCQB: RLMLF) is advancing the Horse Heaven Gold–Antimony–Tungsten–Silver Project in Idaho, now covering 14,580 hectares. Following China’s December 2024 ban on antimony exports to the U.S., the country faces a structural supply deficit with no meaningful domestic mining or processing capacity. Resolution is positioned to address this gap through both resource development and intention to build a commercial-scale hydrometallurgical processing facility, aligning the project with U.S. policy priorities around domestic critical mineral supply chains.
Golden Gate. Phase 1 drilling at the Golden Gate Prospect confirmed a fault-controlled Intrusion Related Gold System with indications of meaningful scale. All 14 holes intersected mineralization from surface, including intercepts of 253m at 1.50 g/t Au, 265m at 0.60 g/t Au, and 189m at 1.30 g/t Au, all open at depth, while a second discovery at Golden Gate South expanded the mineralized footprint to more than 1.5km of strike. Importantly, the historical Golden Gate Tungsten Mine, last in production in 1980, is located within Resolution’s property boundary, with management evaluating a restart. A Phase 2 program of up to 45 diamond holes across 13,700 meters commences in early May 2026.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Mpox Vaccine Clinical Supplies Expected To Be Ready Soon. GeoVax announced the completion of clinical supply testing of GEO-MVA, its modified vaccinia ankara (MVA) vaccine for Mpox/smallpox. The release of vaccine that can be used in clinical trials is expected in early April. This is an important milestone in preparation for the Phase 3 trial planned for late FY2026.
Preparation for Phase 3 Bridging Study and Commercialization. GeoVax is preparing for an immune bridging study to show GEO-MVA stimulates an immune response that is non-inferior to a commercial Mpox vaccine. The study was designed to meet requirements for the European Medicines Agency’s expedited development pathway for Marketing Authorization.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Cardiff Oncology Held A KOL Discussion. On March 25, Cardiff Oncology held a webcast with two world-renown oncologists with experience in drug development and patient treatment. The discussion began with a review of the Phase 2 data by Dr. Mani Mohindru, the Interim CEO. The discussion centered on aspects of the trial, including the outcome data, practical use, and competitive therapies.
The Discussion Included Significance Of Phase 2 Outcomes. The presentation began with a review of Phase 2 data announced in January 2026, with comments by the KOLs. They pointed to the response rate (RR) of 72.2% and the median progression-free survival (PFS) that has not yet been reached. Importantly, onvansertib did not cause additional toxicities to the combination chemotherapy regimen.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Noble Capital Markets Research Report Thursday, March 26, 2026
Companies contained in today’s report:
Cardiff Oncology (CRDF)/OUTPERFORM – KOL Discussion Of Onvansertib Supports Our Outperform Rating GeoVax Labs (GOVX)/OUTPERFORM – MVA Vaccine Makes Progress Toward Phase 3 For Mpox Resolution Minerals Ltd (RLMLF)/OUTPERFORM – Idaho’s Next Gold and Critical Minerals District
Cardiff Oncology (CRDF/$1.73 | Price Target: $12) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 KOL Discussion Of Onvansertib Supports Our Outperform Rating Rating: OUTPERFORM
Cardiff Oncology Held A KOL Discussion. On March 25, Cardiff Oncology held a webcast with two world-renown oncologists with experience in drug development and patient treatment. The discussion began with a review of the Phase 2 data by Dr. Mani Mohindru, the Interim CEO. The discussion centered on aspects of the trial, including the outcome data, practical use, and competitive therapies.
The Discussion Included Significance Of Phase 2 Outcomes. The presentation began with a review of Phase 2 data announced in January 2026, with comments by the KOLs. They pointed to the response rate (RR) of 72.2% and the median progression-free survival (PFS) that has not yet been reached. Importantly, onvansertib did not cause additional toxicities to the combination chemotherapy regimen.
GeoVax Labs (GOVX/$1.5 | Price Target: $10) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 MVA Vaccine Makes Progress Toward Phase 3 For Mpox Rating: OUTPERFORM
Mpox Vaccine Clinical Supplies Expected To Be Ready Soon. GeoVax announced the completion of clinical supply testing of GEO-MVA, its modified vaccinia ankara (MVA) vaccine for Mpox/smallpox. The release of vaccine that can be used in clinical trials is expected in early April. This is an important milestone in preparation for the Phase 3 trial planned for late FY2026.
Preparation for Phase 3 Bridging Study and Commercialization. GeoVax is preparing for an immune bridging study to show GEO-MVA stimulates an immune response that is non-inferior to a commercial Mpox vaccine. The study was designed to meet requirements for the European Medicines Agency’s expedited development pathway for Marketing Authorization.
Resolution Minerals Ltd (RLMLF/$0.04 | Price Target: $0.15) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Idaho’s Next Gold and Critical Minerals District Rating: OUTPERFORM
Initiating coverage with an Outperform. Resolution Minerals Ltd (ASX: RML, OTCQB: RLMLF) is advancing the Horse Heaven Gold–Antimony–Tungsten–Silver Project in Idaho, now covering 14,580 hectares. Following China’s December 2024 ban on antimony exports to the U.S., the country faces a structural supply deficit with no meaningful domestic mining or processing capacity. Resolution is positioned to address this gap through both resource development and intention to build a commercial-scale hydrometallurgical processing facility, aligning the project with U.S. policy priorities around domestic critical mineral supply chains.
Golden Gate. Phase 1 drilling at the Golden Gate Prospect confirmed a fault-controlled Intrusion Related Gold System with indications of meaningful scale. All 14 holes intersected mineralization from surface, including intercepts of 253m at 1.50 g/t Au, 265m at 0.60 g/t Au, and 189m at 1.30 g/t Au, all open at depth, while a second discovery at Golden Gate South expanded the mineralized footprint to more than 1.5km of strike. Importantly, the historical Golden Gate Tungsten Mine, last in production in 1980, is located within Resolution’s property boundary, with management evaluating a restart. A Phase 2 program of up to 45 diamond holes across 13,700 meters commences in early May 2026.
Noble Capital Markets Research Report Wednesday, March 25, 2026
Companies contained in today’s report:
Bitcoin Depot (BTM)/OUTPERFORM – Leadership Reset Amid Regulatory Pressure and Revenue Diversification Efforts Comstock (LODE)/MARKET PERFORM – Review of 2025 and Outlook for 2026 First Phosphate Corp. (FRSPF)/OUTPERFORM – NRCan Contribution Agreement Signed; Funding Secured Ocugen (OCGN)/OUTPERFORM – Raising Price Target After Positive OCU410 Data Reported
Bitcoin Depot (BTM/$2.8 | Price Target: $13) Patrick McCann pmccann@noblefcm.com | (314) 724-6266 Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Leadership Reset Amid Regulatory Pressure and Revenue Diversification Efforts Rating: OUTPERFORM
Leadership transition introduces seasoned external operator. The company announced that CEO Scott Buchanan has stepped down effective March 23, 2026, with founder Brandon Mintz stepping down as Executive Chairman and remaining on the Board in an advisory capacity. The Board appointed Alex Holmes as CEO and Chairman. Mr. Holmes brings relevant experience from his tenure as CEO of MoneyGram, particularly in payments infrastructure and regulatory compliance.
Transition comes at a pivotal time for the business. The leadership changes follow a quarter impacted by regulatory headwinds and ahead of a guided 30% to 40% decline in core BTM revenue in 2026. At the same time, the company is beginning to pursue new business initiatives, including its expansion into peer-to-peer betting and merchant cash advances. While the company noted the departures were not due to disagreements, in our view, the timing suggests the Board may be positioning the company for its next phase of execution as it navigates both regulatory pressure and early-stage diversification efforts.
Comstock (LODE/$2.78) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Review of 2025 and Outlook for 2026 Rating: MARKET PERFORM
A year of repositioning. During 2025, Comstock Inc. repositioned itself around two scalable growth businesses: Comstock Metals, which targets solar panel recycling and critical mineral recovery, and its investment in Bioleum Corporation, which is advancing biomass-based renewable fuels.
Near-term revenue visibility. Comstock Metals represents the most immediate catalyst for value creation. Comstock has validated a zero-landfill solar panel recycling process and completed permitting for its first industry-scale facility in Nevada, with operations expected to commence in the second quarter of 2026. The company has also secured logistics infrastructure and customer agreements across key U.S. regions, reflecting growing demand for end-of-life solar panel processing. Over time, the strategy could include multiple facilities and integrated refining capabilities that target recovery of higher-value metals such as silver.
First Phosphate Corp. (FRSPF/$0.69 | Price Target: $1.65) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | NRCan Contribution Agreement Signed; Funding Secured Rating: OUTPERFORM
Investor webinar. CEO John Passalacqua recently presented to investors via Simone Capital. During the call, Mr. Passalacqua commented on the signed contribution agreement with Natural Resources Canada, the ongoing drill program and future feasibility study, the ADR launch, and the strength of the stock in recent weeks relative to a difficult broader market. Management attributed the stock’s resilience to the quality of the shareholder base, consistent milestone execution, and the visible de-risking effect of government backing.
NRCan contribution agreement signed. First Phosphate has executed a formal agreement with Natural Resources Canada providing up to C$16.7 million in non-repayable government funding under the Global Partnerships Initiative. The structure is a reimbursement model, whereby the company incurs eligible expenditures and receives reimbursement of up to 75% within approximately three months, supporting technical and engineering validation work through 2028. Combined with approximately C$20-C$22 million in cash on hand, we estimate total accessible financial resources of approximately C$36-C$38 million, sufficient to fund the company through drill completion, feasibility study, and final investment decision.
Ocugen (OCGN/$1.92 | Price Target: $12) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 Raising Price Target After Positive OCU410 Data Reported Rating: OUTPERFORM
Top-Line Phase 2 ArMaDa Trial Data Reported. Ocugen reported Phase 2 data for OCU410, its gene therapy for geographic atrophy in dry age-related macular degeneration (GA-dAMD). The data shows clinically meaningful and statistically significant benefit of 31% for treated patients compared with placebo. Based on the trial results, we are including OCU410 revenues in our FY2029 earnings model and raising our price target to $12 per share.
Results Show Preservation of Function and Cell Structure. The primary endpoint showed 31% reduction in lesion growth at the optimal dose (medium) group compared to controls (p< 0.05). A secondary endpoint of photoreceptor cell loss, correlating with visual function, showed a 27% slower rate compared to controls. In addition, 55% of treated patients demonstrated a lesion size reduction of greater than 30% compared with controls.
Solid Q4 results. The company reported Q4 revenue of $90.0 million and adj. EBITDA of $15.0 million. While revenue was modestly below our estimate of $99.0 million, adj. EBITDA was in line with our estimate of $15.1 million. Notably, the strong adj. EBITDA figure was largely driven by more efficient use of marketing spend, which decreased approximately 25% compared to the prior year period.
Key operating metrics. Bookings and monthly paying users (MPU) decreased by 7% and 10%, respectively, compared with the prior year period, but the decrease was expected as the company is focused on the quality of gameplay and retaining high-quality users. Furthermore, the company’s strategy appears to be paying off, as average bookings per paying user (ABPPU) increased from $102 in Q4’24 to $106 in Q4’25.
Noble Capital Markets Research Report Monday, March 23, 2026
Companies contained in today’s report:
1-800-Flowers.com (FLWS)/OUTPERFORM – Raising Rating: Unleashing AI To Drive Efficiency And Growth Eledon Pharmaceuticals (ELDN)/OUTPERFORM – FY2025 Reported With Tegoprubart Updates and Phase 3 Expectations Titan International (TWI)/OUTPERFORM – Production Consolidation
1-800-Flowers.com (FLWS/$3.01 | Price Target: $3.75) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Raising Rating: Unleashing AI To Drive Efficiency And Growth Rating: OUTPERFORM
Highlights from a fireside chat. This report highlights a fireside chat with Adolfo Villagomez, CEO, who discussed the company’s four pillar initiative to transform the company into a more efficient, growth focused company.
Improving the company’s cost structure. Management has implemented a comprehensive review of the organization’s operations with the goal of reducing redundancies and improving productivity. The company is targeting approximately $50 million in run-rate cost savings across fiscal years 2026 and 2027, achieved through initiatives such as workforce streamlining, supply chain optimization, procurement improvements, and the reduction of organizational layers.
Eledon Pharmaceuticals (ELDN/$2.88 | Price Target: $10) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 FY2025 Reported With Tegoprubart Updates and Phase 3 Expectations Rating: OUTPERFORM
Tegoprubart Trials To Advance In FY2026. Eledon reported a 4Q loss of $10.4 million or $(0.11) per share and a FY2025 loss of $45.6 million or $(0.52) per share. The FY Total Operating Expenses were $83.3 million, with non-cash items (including changes in the fair value of warrant liabilities) of $33.4 million. Net Loss excluding these items would have been $79.1 million for full year. Updates for tegoprubart clinical development were also confirmed with the announcement. Cash on December 31, 2025 was $45.6 million.
Clinical Trials In Transplantation Have Several Milestones Ahead. Eledon expects to meet with the FDA to discuss plans for a Phase 3 tegoprubart trial for prevention of kidney transplant rejection. We expect the guidance to clarify required endpoints and could lead to the start of Phase 3 by year-end. Guidance is also expected for Islet cell transplantation in diabetes and xenotransplantation.
Titan International (TWI/$6.81 | Price Target: $11) Joe Gomes jgomes@noblefcm.com | 561-999-2262 Production Consolidation Rating: OUTPERFORM
Consolidation. Last week, Titan announced a decision to consolidate production within its North American manufacturing footprint, which will result in the closure of its manufacturing facility in Jackson, Tennessee, by the end of October 2026. The Company expects production currently performed in Jackson to be transitioned to other existing Titan facilities over the coming months. We view this action as part of the Company’s ongoing efforts to optimize its manufacturing footprint and improve capacity utilization, given the uncertain operating environment.
Details. The Jackson closure is part of the ongoing synergies the Company expected to deliver from the Carlstar acquisition. The one-time costs for the plant closure and manufacturing relocation are estimated to be in the $7 million range, likely to hit in relatively equal amounts over the next three quarters. Estimated annual savings are in the $5 million range, with the full amount likely to begin in 2027.
Noble Capital Markets Research Report Friday, March 20, 2026
Companies contained in today’s report:
Euroseas (ESEA)/OUTPERFORM – Diversification into Specialized High-Reefer Containerships Kratos Defense & Security (KTOS)/OUTPERFORM – Awarded Another Significant Contract NN (NNBR)/OUTPERFORM – Moving Into Higher Return Verticals Sky Harbour Group (SKYH)/OUTPERFORM – Delivery Pipeline Supports Revenue Growth Outlook Snail (SNAL)/OUTPERFORM – Release Roadmap Shifts Focus To 2027
Euroseas (ESEA/$70.37 | Price Target: $90) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Diversification into Specialized High-Reefer Containerships Rating: OUTPERFORM
Two newbuilds. Euroseas announced contracts for the construction of two 2,800 TEU high-reefer containership newbuilds, with deliveries expected sequentially in the second and third quarters of 2028. The total acquisition price for each of the two newbuild vessels is $46.35 million, with financing expected to include a combination of debt and equity.
Strategic expansion. The vessels will be built to EEDI Phase 3 and IMO NOx Tier III standards and will be equipped with more than 1,000 reefer plugs, optimizing them for high-reefer-density trades. This enhances Euroseas’ exposure to growing refrigerated cargo demand. Importantly, the agreement includes options for up to four additional vessels of similar design, with either reefer or conventional configurations. In our view, this aligns with the company’s strategy of modernizing and diversifying its fleet, lowering the average age, and improving environmental efficiency.
Kratos Defense & Security (KTOS/$92.78 | Price Target: $145) Joe Gomes jgomes@noblefcm.com | 561-999-2262 Awarded Another Significant Contract Rating: OUTPERFORM
Space Force. The Space Force’s Space Systems Command awarded Kratos a $447 million follow-on contract for Ground Management and Integration for the first two sets of Medium-Earth Orbit Missile Warning and Tracking satellites, according to a press release from the Agency. This follow-on award continues the positive award environment for Kratos, in our view.
Focus. SSC’s Resilient MWT MEO program under SYD 84 is focused on the rapid acquisition of robust infrared sensing technology and integrating it into an entirely new satellite constellation in MEO. The system is designed to detect and track a range of threats, from large, bright intercontinental ballistic missile launches to dim, maneuvering hypersonic missiles, integrating it with the broader national missile defense architecture
NN (NNBR/$1.48 | Price Target: $6) Joe Gomes jgomes@noblefcm.com | 561-999-2262 Moving Into Higher Return Verticals Rating: OUTPERFORM
Data Centers. NN continues to grow its presence in the data center market, a key targeted growth market for the Company. The AI data center market fits precisely into NN’s decades of know-how in fluid management and Six Sigma quality levels. For NN, it is a strategic and straightforward application of existing know-how with managing gas, diesel, and hydraulic fluids and applying that know-how to managing cooling fluids.
Opportunity. NN has secured multiple new awards with a leading global provider of AI infrastructure and data center computing equipment. In response, NN is investing in a large installation of 17 next-generation high-speed, high-precision CNC machines that will meet and exceed requirements. This expansion and ramp-up is happening now across 2026. These machines will add to NN’s portfolio of over 100 of these similar machines already in-house.
Sky Harbour Group (SKYH/$9.47 | Price Target: $23) Patrick McCann pmccann@noblefcm.com | (314) 724-6266 Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Delivery Pipeline Supports Revenue Growth Outlook Rating: OUTPERFORM
Q4 results. Sky Harbour reported Q4 revenue of $8.1 million and an adj. EBITDA loss of $1.0 million compared with our estimates of $8.6 million and a loss of $0.4 million, respectively. Notably, the company reached an adj. EBITDA breakeven on a run-rate exiting December.
Leasing trends. Management highlighted lease-up progress at Phoenix, Dallas, and Denver, with the former two ahead of expectations and Denver improving after a slower start. The company also emphasized growing use of pre-leasing, targeting roughly 50% of a campus leased by opening.
Snail (SNAL/$0.62 | Price Target: $2.75) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Release Roadmap Shifts Focus To 2027 Rating: OUTPERFORM
Q4 results in line with expectations. Revenue of $25.1M and adj. EBITDA loss of $1.3 million was better than our expectations of $23.0 million and a loss estimate of $1.77 million, respectively. The quarter was supported by deferred revenue recognition and strong sequential revenue improvement.
ARK franchise momentum remains strong, with ASA surpassing 4M units sold and continued engagement across ASA, ASE, and ARK Mobile, reinforcing long-term durability. There appears to be a robust multi-year content pipeline which provides visibility, though updated timing shifts a portion of expected revenue and adj. EBITDA from 2026 into 2027.
Noble Capital Markets Research Report Thursday, March 19, 2026
Companies contained in today’s report:
Kuya Silver (KUYAF)/OUTPERFORM – Driving Mineral Resource Growth Perfect (PERF)/OUTPERFORM – Founder-Led Take-Private Proposal SelectQuote (SLQT)/OUTPERFORM – Launching Franchise-Based Distribution Channel Star Equity Holdings, Inc. (STRR)/OUTPERFORM – Fourth Quarter 2025 Results
Kuya Silver (KUYAF/$0.52 | Price Target: $3.5) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Driving Mineral Resource Growth Rating: OUTPERFORM
Kuya Silver is significantly scaling its exploration efforts at Bethania. The company has expanded its fully funded 2026 drill program to approximately 20,000 meters, making it the largest drilling campaign in the project’s history. By combining 10,000 meters of surface and 10,000 meters of underground drilling, Kuya seeks to extend known mineralization near existing operations and test new district scale targets, positioning the project for meaningful resource growth.
High-grade regional targets highlight strong expansion potential. Exploration has identified multiple vein systems beyond the current mine area, with high priority prospects such as Millococha, Tito PH, and Carmelitas demonstrating encouraging grades and geological continuity. These areas, supported by historic artisanal mining and recent sampling, suggest the presence of a broader mineralized system that could materially increase the overall resource base
Take Private Proposal. Perfect Corp. received a preliminary, non-binding proposal from a consortium led by CEO Alice H. Chang and CyberLink to take the company private at $1.95 per share. The transaction would be funded through rollover equity, company cash, and potential debt. The board intends to form a special committee to evaluate the proposal, and there is no assurance that a transaction will be completed.
Ownership structure supports a high likelihood of completion. The consortium controls approximately 53.4% of shares and 81.2% of voting power. In our view, this significantly increases the likelihood of a transaction, subject to special committee approval.
SelectQuote (SLQT/$0.61 | Price Target: $5) Patrick McCann pmccann@noblefcm.com | (314) 724-6266 Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Launching Franchise-Based Distribution Channel Rating: OUTPERFORM
SelectQuote Local. SelectQuote announced SelectQuote Local, a new franchise model designed to complement its core telephonic insurance distribution platform by offering in-person sales and support. Management indicated the initiative leverages the company’s existing marketing, technology, and carrier relationships, positioning it as a natural extension of the platform rather than a shift in strategy.
Complementary model and TAM expansion. In our view, SelectQuote Local is unlikely to cannibalize the company’s core call center operations, as it targets a distinct subset of consumers who prefer in-person engagement. We believe the company can leverage excess lead flow and brand recognition to support early franchise success without significant incremental marketing investment. Additionally, we expect the in-person model could enhance cross-sell opportunities with Healthcare Services, as local relationships may improve customer engagement and trust.
Star Equity Holdings, Inc. (STRR/$9.6 | Price Target: $16) Joe Gomes jgomes@noblefcm.com | 561-999-2262 Fourth Quarter 2025 Results Rating: OUTPERFORM
Overview. Star Equity’s fourth quarter and full-year financial results reflect positive momentum and improvement over the prior year quarter, largely driven by the August 2025 merger. Overall, 2025 was a transformational year for Star. The merger strengthened the Company’s operating and financial position and accelerated the growth strategy.
4Q25 Results. Fourth quarter 2025 revenue of $56.8 million rose 69% y-o-y, but was slightly below our $58 million estimate. Adjusted EBITDA increased to $2.2 million versus $0.9 million last year. We had projected $2.3 million. Adjusted net loss was $0.10/sh, compared to adjusted net income of $0.04/sh in 4Q24.
Noble Capital Markets Research Report Wednesday, March 18, 2026
Companies contained in today’s report:
Century Lithium Corp. (CYDVF)/OUTPERFORM – Updated Feasibility Study Highlights Incremental Value Greenwich LifeSciences, Inc. (GLSI)/OUTPERFORM -Preliminary Phase 3 FLAMINGO-01 Update Shows Reduction In Breast Cancer Recurrence Rate Gyre Therapeutics, Inc (GYRE)/OUTPERFORM – Priority Review Received For Hydronidone In China Snail (SNAL)/OUTPERFORM – Quarterly Preview: Strategic Updates Provided At GDC Summit Midstream Corp (SMC)/OUTPERFORM – Double E Pipeline Underpins Favorable Growth Outlook
Century Lithium Corp. (CYDVF/$0.27 | Price Target: $3.05) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Updated Feasibility Study Highlights Incremental Value Rating: OUTPERFORM
Updated feasibility study. Century recently filed its updated 2026 NI 43-101 feasibility study for its 100%-owned Angel Island Lithium Project in Nevada. The updated study reflects engineering optimization and improvements that materially strengthen the project’s economic profile and highlight Angel Island as one of the most significant and economically robust sedimentary lithium developments in the United States.
Lower initial capital expenditures. Phase I initial capital expenditures are estimated to be $997 million, a significant reduction from the $1.5 billion outlined in the 2024 Study. The updated study streamlines development into a two-phase approach. Phase I contemplates 7,500 tonnes per day (tpd) of mill feed, expanding to 15,000 tpd in Phase II beginning in Year 5. Phase II expansion capital is estimated at $660 million. A previously planned third expansion phase was eliminated, lowering overall capital requirements. The economic analysis is based on a 40-year production schedule, with planned life-of-mine average production of 26,500 tonnes per annum of battery-grade lithium carbonate.
Greenwich LifeSciences, Inc. (GLSI/$30.05 | Price Target: $45.00) Robert LeBoyer rleboyer@noblecapitalmarkets.com | (212) 896-4625 Preliminary Phase 3 FLAMINGO-01 Update Shows Reduction In Breast Cancer Recurrence Rate Rating: OUTPERFORM
New Analysis Shows Less Than 1% Recurrence Rate. Greenwich Pharmaceuticals announced a preliminary update from its FLAMINGO-01 trial. The data from the open-label arm of the trial showed a recurrence rate of less than 1% per year compared to a recurrence rate of 4% per year for patients treated with Kadcyla (ado-trastuzumab emtansine or T-DM1, from Genentech) in the Phase 3 KATHERINE Study. This is a 70% to 80% reduction in the historical recurrence rate for these patients.
Background On The Phase 3 FLAMINGO-01 Trial. The trial tests GLSI-100, an immunotherapy to prevent recurrence of HER2-positive breast cancer. Its design has a doubleblind portion that enrolls patients with the immune marker HLA-A02 to receive either GLSI-100 or placebo, and an open-label arm that enrolls patients that have other HLA types (non-HLAA02). The new data is from the open-label arm of the trial.
Gyre Therapeutics, Inc (GYRE/$7.49 | Price Target: $20.00) Robert LeBoyer rleboyer@noblecapitalmarkets.com | (212) 896-4625 Priority Review Received For Hydronidone In China Rating: OUTPERFORM
Gyre Receives Priority Review. Hydronidone has been awarded Priority Review Status by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA). This is consistent with our expectations for an accelerated NDA review and late FY2026 approval for Hydronidone.
Meeting With The CMPA Was Positive. In early January, Gyre Pharmaceuticals (China) held a Pre-New Drug Application meeting with the CDE. At that time, the CDE agreed that data from the Hydronidone Phase 3 trial for treating chronic hepatitis B (CHB)-associated liver-fibrosis supported an application for conditional approval. It also met the criteria for Priority Review.
Snail (SNAL/$0.61 | Price Target: $3) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Quarterly Preview: Strategic Updates Provided At GDC Rating: OUTPERFORM
Strategic updates ahead of Q4 Earnings Call. At the Game Developers Conference (GDC) in San Francisco last week, the company provided updates across its game portfolio, outlining a steady pipeline of ARK franchise releases, expansions for existing titles, and new indie projects. The announcements were delivered ahead of the company’s Q4 and full-year 2025 earnings call scheduled for March 19, 2026, at 4:30 p.m. ET, providing a preview of its strategic product developments.
Strong Early Access sales. Notably, Bellwright has surpassed 1 million units sold on Steam during Early Access, demonstrating strong player engagement ahead of its 1.0 launch and planned expansion to Xbox and PlayStation. As a reminder, development is now fully in-house following the acquisition and integration of Donkey Crew, the Poland-based studio behind Bellwright, strengthening the franchise’s long-term potential.
Summit Midstream Corp (SMC/$30.73 | Price Target: $48.5) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Double E Pipeline Underpins Favorable Growth Outlook Rating: OUTPERFORM
Double E Pipeline growth. Summit recently signed two new long-term take-or-pay agreements totaling 540 MMcf/d of incremental firm capacity on the Double E Pipeline, an 11-year, 210 MMcf/d contract with a large investment-grade shipper and an 11-year, 230 MMcf/d agreement with an undisclosed shipper, alongside the previously announced 100 MMcf/d Producers Midstream II commitment, which received an affirmative FID during the quarter. These contracts are expected to grow the Permian Segment Adj. EBITDA from ~$34 million in 2025 to ~$60 million by 2029.
2026 guidance. Summit expects full-year 2026 Adj. EBITDA of $225 million to $265 million, with total capital expenditures of $85 million to $105 million, including approximately $35 million attributable to Double E. The outlook assumes WTI at approximately $64 per barrel and Henry Hub at approximately $3.40 per MMBtu, both materially below current strip prices, suggesting meaningful upside if the commodity environment is sustained. The company expects 116 to 126 well connections supported by seven active rigs and approximately 90 DUCs.
Noble Capital Markets Research Report Tuesday, March 17, 2026
Companies contained in today’s report:
Bitcoin Depot (BTM)/OUTPERFORM – Wave of Regulatory Action Weighs on Outlook NeuroSense Therapeutics Ltd. (NRSN)/OUTPERFORM – Phase 2b PARADIGM Study Published In JAMA Neurology Townsquare Media (TSQ)/OUTPERFORM – Were We On The Same Investor Call?
Bitcoin Depot (BTM/$4.03 | Price Target: $13) Patrick McCann pmccann@noblefcm.com | (314) 724-6266 Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Wave of Regulatory Action Weighs on Outlook Rating: OUTPERFORM
Q4 results. Bitcoin Depot reported Q4 revenue of $116.0 million, above our estimate of $112.0 million, reflecting somewhat stronger transaction activity than anticipated despite emerging regulatory headwinds. Adj. EBITDA of $1.6 million was below our forecast of $2.5 million due to higher operating expenses during the quarter.
Initial steps toward revenue diversification. The company is beginning to expand beyond the core Bitcoin ATM network through new fintech initiatives. It recently acquired Kutt, a peer-to-peer social betting platform, and launched ReadyBucks, a merchant cash advance platform targeting small businesses and gig workers. Management indicated that both initiative are starting small and not expected to materially impact near-term revenue.
NeuroSense Therapeutics Ltd. (NRSN/$0.81 | Price Target: $9) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 Phase 2b PARADIGM Study Published In JAMA Neurology Rating: OUTPERFORM
Presigious Journal Publishes The Phase 2b PARDIGM Study. JAMA Neurology has published an article dissussing the Phase 2b PARDIGM clinical trial. This peer-reviewed journal is published by the American Medical Association and regarded as one of the most prestigious journals in the field of neurology. We see this as a validation the clinical results and an acknowledgement of the impact PrimeC had on the amyotrophic lateral sclerosis (ALS) patients in the study.
PrimeC Addresses Important Mechanisms Of Neuron Degeneration. PrimeC is a proprietary fixed-dose oral combination of celecoxib and ciprofloxacin. These drugs target pathways of neuronal cell death, including regulation of microRNA synthesis, reduction in neuroinflammation, and modulation of iron accumulation. Additional testing by NeuroSense determined the optimal dosage combination of the two drugs for human studies and the extended releaase formulaton.
Townsquare Media (TSQ/$6.14 | Price Target: $15) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Were We On The Same Investor Call? Rating: OUTPERFORM
In-line Q4 results. The company reported Q4 revenue and adj. EBITDA of $106.5 million and $21.5 million, both of which were in line with our estimates of $106.1 million and $22.0 million, respectively. Notably, the company continued to face headwinds in its digital businesses, which have been its primary growth engine.
Advertising trends appear to be improving. Digital revenues remained the company’s largest contributor and primary growth engine, representing approximately 55% of total revenue in 2025, up from 52% in 2024, and generated 56% of segment profit, compared with 50% a year earlier. Despite the stronger mix, fourth quarter Digital Advertising revenue declined 1%, as weakness in remnant advertising offset growth in direct-sold and programmatic digital advertising.
Noble Capital Markets Research Report Monday, March 16, 2026
Companies contained in today’s report:
MariMed Inc (MRMD)/OUTPERFORM – Reports Fourth Quarter and Full Year Results ONE Group Hospitality (STKS)/OUTPERFORM – Fourth Quarter In-line with Pre-announced Results Tonix Pharmaceuticals (TNXP)/OUTPERFORM – Tonix Reports FY2025 With Tonmya Sales and Pipeline Updates
MariMed Inc (MRMD/$0.08 | Price Target: $0.25) Joe Gomes jgomes@noblefcm.com | 561-999-2262 Reports Fourth Quarter and Full Year Results Rating: OUTPERFORM
Overview. For the full year 2025, MariMed reported record revenue as well as the sixth consecutive year of positive adjusted EBITDA. Wholesale was once again the star performer, with sales increasing 11% y-o-y. MariMed increased its distribution footprint penetration to 85% of the dispensaries in its core markets.
4Q25 Results. Revenue of $41.7 million rose 7.2% y-o-y and exceeded our $40.5 million estimate. Better than expected retail sales drove the results. Adjusted gross margin came in at 39.9% versus 43.2% last year. Adjusted EBITDA totaled $4.4 million, down from $5.9 million in 4Q24. MariMed reported adjusted net income of $2.2 million, compared to a net loss of $3.1 million in 4Q24.
ONE Group Hospitality (STKS/$1.72 | Price Target: $5) Joe Gomes jgomes@noblefcm.com | 561-999-2262 Fourth Quarter In-line with Pre-announced Results Rating: OUTPERFORM
Overview. Fourth quarter and full year 2025 results came in-line with management’s January 12, 2026 pre-announcement, with fourth quarter revenue of $207 million and full year revenue of $806 million. Notably, all brands demonstrated a sequential improvement in comparable sales during the quarter. Fourth quarter consolidated comparable sales declined approximately 1.8%, representing about 4 points of sequential improvement from the third quarter. And this momentum has continued in the new year.
4Q25 Results. For the fourth quarter, total GAAP revenue was approximately $207 million compared to $222 million in the prior year quarter. Adjusted EBITDA was $28.1 million compared to $31 million in the prior year quarter, a decrease of 9.5%. ONE Group reported a net loss, before preferred stock dividends, of $6.4 million compared to net income of $1.6 million in 4Q24.
Tonix Pharmaceuticals (TNXP/$13.24 | Price Target: $34) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 Tonix Reports FY2025 With Tonmya Sales and Pipeline Updates Rating: OUTPERFORM
Tonix Reported Initial Tonmya Launch Results. Tonix reported a 4Q loss of $46.9 million or $(3.98) per share and a FY2025 loss of $124 million or $(14.57) per share. Initial sales of Tonmya for the six-week period after launch were $1.4 million, with total 4Q product sales of $5.4 million and FY2025 sales of $13.1 million. The company also gave updates on additional Tonmya indications and clinical trial progress. Total cash and equivalents balance on December 31, 2025 was $207.6 million.
Tonmya Sales Began In Mid-November. Sales of Tonmya (TNX-102 SL) started in November 2025 and recorded $1.4 million in 4Q. The company has 90 sales reps and reported meeting its expectations for the 14-week period through February 2026. Over 1,500 health care providers have written prescriptions for over 2,500 patients, with 4,200 prescriptions written. We believe this is an early indication of repeat use by the patients.
Noble Capital Markets Research Report Friday, March 13, 2026
Companies contained in today’s report:
Gyre Therapeutics, Inc (GYRE)/OUTPERFORM – 4Q25 Report Meets Expectations As A Transition Year Begins Hemisphere Energy (HMENF)/NOT RATED – Discontinuing Research Coverage Saga Communications (SGA)/OUTPERFORM – Stepping Up Digital Investments Seanergy Maritime (SHIP)/OUTPERFORM – Fleet Expansion Continues; Squireship Sale Summit Midstream Corp (SMC)/OUTPERFORM – Summit to Host FY2025 Earnings Call on March 17 The Oncology Institute, Inc. (TOI)/OUTPERFORM – Strong Results Driven By Covered Population Growth With Improving Margins
Gyre Therapeutics, Inc (GYRE/$7.81 | Price Target: $20) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 4Q25 Report Meets Expectations As A Transition Year Begins Rating: OUTPERFORM
4Q25 Revenues Showed Modest Increase. Gyre reported a 4Q loss of $1.7 million or $(0.02) per share and profit of $5.0 million or $0.06 per basic share and $0.02 per fully diluted share. Revenues of $116.6 million increased 10.2% over the $105.8 million in FY2024. These results are consistent with our view that FY2026 is a transition year, as the company focuses on approval and launch of Hydronidone plus the acquisition of Cullgen, Inc, adding its degrading protein technology platform (discussed in our Research Note on March 3).
Product Sales and Financials. FY2025 revenue of $116.6 million was driven by continued sales of Etuary and new product launches. Etuary sales of $106.1 million for FY2026 compare with $105.0 million in 4Q25. During the year, Gyre launched Contiva (avatrombopag maleate tablet) in March 2025 and Etorel (nintedanib ethanesulfonate capsules) in June 2025. Contiva sales were $5.5 million and Etorel sales were $4.6 million for the full year. The company expects the National Drug Procurement Program in China and market conditions to lower sales of $100.5 million to $111.0 million.
Saga Communications (SGA/$11.09 | Price Target: $18) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Stepping Up Digital Investments Rating: OUTPERFORM
Q4 Results. The company reported Q4 revenue and adj. EBITDA of $26.5 million and $0.8 million, respectively, modestly below our estimates of $27.7 million and $2.0 million, as illustrated in Figure #1 Q4 Results. Results were impacted by softness in traditional broadcast revenue, while digital Interactive revenue remained a bright spot, increasing 25.8% y-o-y.
Strong digital results. The company continued to implement its blended digital-radio strategy, integrating broadcast and digital solutions to enhance advertiser engagement and retention. Total Interactive revenue reached $4.3 million, an increase of 25.8% year over year, with full year growth reaching 19.1%. Furthermore, the growth was driven by several verticals, including search advertising, targeted display, and e-commerce platforms, reflecting growing adoption of integrated radio and digital advertising campaigns.
Seanergy Maritime (SHIP/$12.68 | Price Target: $18) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Fleet Expansion Continues; Squireship Sale Rating: OUTPERFORM
Newbuild program expands to five vessels. Seanergy announced the acquisition of two Japanese newbuild scrubber-fitted 181,500 dwt Capesize vessels, expanding the total newbuild program to five vessels, including four Capesize vessels and one Newcastlemax, with a combined contract value of approximately $384 million. The first Japanese vessel is a direct purchase with delivery expected between Q2 and Q3 2027, while the second is structured as a 10-year bareboat-in contract with a Q1 2029 delivery and a purchase option beginning at year five. The combined cost of both Japanese vessels is approximately $158 million.
Sale of M/V Squireship. Seanergyagreed to sell the 2010-built, 170,018 dwt M/V Squireship to a related party for $29.5 million with delivery expected between late April and early June 2026. The transaction is expected to generate net proceeds of approximately $13.5 million after debt repayment and produce an accounting gain of roughly $4 million. The sale is consistent with management’s capital recycling strategy, monetizing an older vessel at an attractive valuation while funding the newbuilding program and reducing average fleet age.
Summit Midstream Corp (SMC/$30.87 | Price Target: $47) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Summit to Host FY2025 Earnings Call on March 17 Rating: OUTPERFORM
Fourth quarter and FY2025 financial results. Summit will report operating and financial results after the market close on Monday, March 16. Management will host a teleconference at 10 am ET on Tuesday, March 17. We anticipate management will provide its outlook and corporate guidance for 2026.
Noble estimates. We forecasted fourth quarter and FY2025 EBITDA of $62.5 million and $246.6 million, respectively, and net losses of $0.4 million, or $(0.00) per share, and $11.5 million, or $(0.95) per share. Our fourth quarter and full year revenue estimates are $146.7 million and $566.5 million, respectively. Recall management previously communicated that it expected adjusted EBITDA to be at the low end of its $245 million to $280 million 2025 guidance range. For 2026, we are projecting revenue, EBITDA, net income and EPS of $591.3 million, $265.7 million, $12.7 million, and $1.03, respectively.
The Oncology Institute, Inc. (TOI/$2.62 | Price Target: $8) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 Strong Results Driven By Covered Population Growth With Improving Margins Rating: OUTPERFORM
4Q25 Had Strong Revenue Growth. The Oncology Institute reported a 4Q25 loss of $7.5 million or $(0.06) per share and a FY2026 loss of $60.6 million or $(0.54) per share. Importantly, 4Q25 Revenues of $142.0 million were up 41.6% over 4Q24, close to our estimate of $142.4 million, with a slightly different mix from Patient Services and Dispensary Revenues. EBITDA in 4Q25 was $0.15 million, turning positive for the first time, and compares with $(7.8) million in 4Q24. Cash balance on December 31, 2025 was $33.6 million.
Margins Improved During 4Q and For FY2025. Overall Gross Margin for 4Q2025 improved to 16.0% of revenues compared with 14.6% in 4Q2024. This reflects margins improvements in Patient Services of 11.9% compared with 8.9% in 4Q24, and Dispensary margins of 18.1% compared with 16.9% in 4Q24. FY2025 Overall Gross Margin was 15.2% compared with 13.7% for FY2024.
Noble Capital Markets Research Report Thursday, March 12, 2026
Companies contained in today’s report:
ACCO Brands (ACCO)/OUTPERFORM – Fourth Quarter and Full year 2025 Results Commercial Vehicle Group (CVGI)/OUTPERFORM – Making Progress
ACCO Brands (ACCO/$3.51 | Price Target: $9) Joe Gomes jgomes@noblefcm.com | 561-999-2262 Fourth Quarter and Full year 2025 Results Rating: OUTPERFORM
Overview. Despite continued demand challenges globally and tariff-related disruptions in the U.S., ACCO maintained or grew its market position in most categories, demonstrating the resilience and strength of the brand portfolio. ACCO delivered sales and adjusted EPS in-line with management’s outlook.
4Q25 Results. Net sales were $428.8 million, down 4.3% y-o-y, reflecting soft global demand for certain products, partially offset by growth in gaming accessories. We were at $435 million. Comp sales were down 7.8%. Adjusted EBITDA totaled $68.6 million, or a 16% margin, compared to $73.6 million and 16.4%, respectively, in 4Q24. ACCO reported adjusted EPS of $0.38, flat with the $0.39 reported in 4Q24. We were at $0.38.
Commercial Vehicle Group (CVGI/$2.03 | Price Target: $4) Joe Gomes jgomes@noblefcm.com | 561-999-2262 Making Progress Rating: OUTPERFORM
Overview. CVG delivered strong year-over-year improvement in profitability despite a challenging demand environment, particularly in the North American Class 8 truck market. The continued year-over-year improvement in profitability was again driven by management’s focus on operational efficiency improvement. Another highlight of the quarter is the continued strong performance within the Global Electrical Systems segment. During the third quarter, CVG saw segment performance inflect with revenues up 6% compared to the prior year. The fourth quarter saw further acceleration, with revenues up 13% y-o-y.
4Q25 Results. Fourth quarter revenue of $154.8 million was down 5.2% y-o-y, due primarily to North American demand. Adjusted EBITDA was $2.3 million, up 155.6%, with an adjusted EBITDA margin of 1.5% versus 0.6% last year. Adjusted net loss was $0.18/sh, compared to an adjusted net loss of $0.15/sh in 4Q24.
Noble Capital Markets Research Report Wednesday, March 11, 2026
Companies contained in today’s report:
FreightCar America (RAIL)/OUTPERFORM – FY2025 Review and Estimate Update NN (NNBR)/OUTPERFORM – Toward a Brighter Future Power Metallic Mines Inc. (PNPNF)/OUTPERFORM – High-Grade Lion Drilling Continues to Expand Near-Surface Potential The Beachbody Company (BODI)/OUTPERFORM – Turnaround Complete, Growth Phase Begins
FreightCar America (RAIL/$10.01 | Price Target: $16.5) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | FY2025 Review and Estimate Update Rating: OUTPERFORM
FY2025 financial results. FreightCar America generated 2025 adjusted earnings per share (EPS) of $0.50 per share compared to $0.15 per share in 2024. Gross margin as a percentage of revenue increased to 14.6% compared to 12.0% in FY2024. Revenue and rail car deliveries decreased to $501.0 million and 4,125, respectively, compared to $559.4 million and 4,362 in 2024. Adjusted EBITDA increased to $44.8 million compared to $43.0 million in 2024. Full year adjusted free cash flow amounted to $31.4 million versus $21.7 million in 2024.
FY2026 corporate guidance. Railcar deliveries are expected to be in the range of 4,000 to 4,500, revenue in the range of $500 to $550 million, and adjusted EBITDA of $41 to $50 million. Guidance for 2026 adj. EBITDA reflects facility lease expenses recorded in cost of goods sold instead of previously classified within interest expense. On a lease-adjusted basis, 2025 adj. EBITDA was $41.2 million.
NN (NNBR/$1.3 | Price Target: $6) Joe Gomes jgomes@noblefcm.com | 561-999-2262 Toward a Brighter Future Rating: OUTPERFORM
Momentum. NN is bringing solid momentum into 2026. A number of end markets are showing improvement, including the commercial vehicle market, where orders continue to show year-over-year strength. Management noted on the call that the electric grid, data center, defense, and electronics sectors are all growing in the first quarter and are expected to grow in the full year 2026.
Improved Margins. As the business mix moves up the value chain, NN is experiencing higher margins. Adjusted gross margin performance was 18.8% in the fourth quarter and 18.5% for the full year, which again has NN trending towards management’s five year goal of 20% consolidated gross margins.
Power Metallic Mines Inc. (PNPNF/$0.87 | Price Target: $2.65) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | High-Grade Lion Drilling Continues to Expand Near-Surface Potential Rating: OUTPERFORM
Best copper intercept to date. Power Metallic reported results from the first hole of the 2026 winter drill campaign. Hole PML-26-049 intersected 16.55 meters grading 10.08% copper (15.11% CuEq) within massive to brecciated copper sulphides, representing the strongest copper intersection reported at the Lion Zone to date. The hole was drilled to support interpretation of near-surface mineralization and to expand the deposit’s footprint in an area that management believes may be amenable to open-pit extraction.
Infill drilling is supportive. Results from holes PML-26-049 and PML-25-047 confirm strong grade continuity within the modeled Lion Zone geometry, improving confidence that portions of the deposit may ultimately support Indicated Resource classification. Deeper drilling has also expanded high-grade lenses within the system, including 7.60 meters grading 7.30% CuEq within an 18.0-meter interval grading 3.18% CuEq, further extending mineralization within the Lion zone.
The Beachbody Company (BODI/$8.33 | Price Target: $15) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Turnaround Complete, Growth Phase Begins Rating: OUTPERFORM
Q4 results exceeded expectations. Q4 revenue of $55.5 million and adjusted EBITDA of $12.9 million, surpassed our estimates of $53.0 million and $5.0 million, respectively. Although revenue declined 7.3% sequentially and 35.7% year over year due to the continued wind-down of the legacy MLM model, operating income reached $8.2 million, marking the second consecutive profitable quarter and a $41.1 million year-over-year improvement.
Lean cost structure continues to drive strong operating leverage and profitability. Consolidated gross margin expanded 400 basis points year over year to 74.5%, supported by improved operational efficiency and lower digital amortization costs. Total operating expenses declined 64.6% year over year to $33.2 million as restructuring initiatives and the elimination of MLM-related costs materially reduced SG&A. As a result, the company generated $5.2 million in net income and its ninth consecutive quarter of positive adjusted EBITDA.
FreightCar America (RAIL/$12.68 | Price Target: $18) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Q4′ 2025 Financial Results Below Our Estimates Rating: OUTPERFORM
Q4′ 2025 financial results. RAIL generated Q4′ 2025 adj. net income of $4.9 million or $0.16 per share, compared to net income of $8.0 million or $0.21 per share in Q4′ 2024. We had projected net income of $6.1 million or $0.18 per share. Gross margin as a percentage of revenue decreased to 13.4% compared to 15.3% in Q4′ 2024 and our estimate of 14.0%. Revenue declined to $125.6 million compared to $137.7 million during the prior year period, while rail car deliveries increased to 1,172 compared to 1,019 units. We had projected rail car deliveries of 1,557 and revenue of $139.9 million. Adj. EBITDA declined to $10.4 million compared to $13.9 million in Q4′ 2024. We had forecasted adj. EBITDA of $12.5 million.
FY2026 corporate guidance. Railcar deliveries are expected to be in the range of 4,000 to 4,500, revenue in the range of $500 to $550 million, and adjusted EBITDA of $41 to $50 million. In FY2025, railcar deliveries were 4,125, revenue amounted to $501.0 million, and adjusted EBITDA totaled $44.8 million. FY2026 guidance is below our current 2026 estimates. Following relatively soft industry orders during the fourth quarter of 2025, we think management is taking a conservative view based on an increasingly uncertain economic outlook and an EOY 2025 backlog of 1,926 units valued at $137.5 million. Moreover, 2026 adj. EBITDA guidance reflects facility lease expenses recorded in cost of goods sold instead of previously classified within interest expense. On a lease-adjusted basis, 2025 adj. EBITDA was $41.2 million.
Solid Q4 results. The company reported Q4 revenue of $90.0 million and adj. EBITDA of $15.0 million. While revenue was modestly below our estimate of $99.0 million, adj. EBITDA was in line with our estimate of $15.1 million, as illustrated in Figure #1 Q4 Results. Notably, the strong adj. EBITDA figure was largely driven by more efficient use of marketing spend, which decreased approximately 25% y-o-y.
Key operating metrics. Bookings and monthly paying users (MPU) decreased by 7% and 10%, respectively, compared with the prior year period, but the decrease was expected as the company is focused on the quality of gameplay and retaining high-quality users. Furthermore, the company’s strategy appears to be paying off, as average bookings per paying user (ABPPU) increased from $102 in Q4’24 to $106 in Q4’25.
Viewership Milestone. The company announced that more than four million viewers tuned in to its broadcast and streaming platforms for its live coverage of the President’s State of the Union address on February 24. Notably, the Newsmax channel garnered 2.8 million total viewers, with an additional 1.3 million streaming the coverage on Newsmax2. The strong viewership marked a major ratings and digital engagement milestone, reflecting the network’s growing reach across traditional and digital platforms.
Ratings Leadership. The network’s total audience exceeded the combined viewership of Fox Business, CNBC, and NewsNation by 23%. Throughout the evening, the Newsmax team provided continuous updates on Newsmax.com and engaged more than 23 million social media followers. Additionally, a wide range of lawmakers, administration officials, and political commentators joined the network on both broadcast and streaming coverage.
Noble Capital Markets Research Report Monday, March 9, 2026
Companies contained in today’s report:
Bit Digital (BTBT)/OUTPERFORM – February Ethereum Metrics Information Services Group (III)/OUTPERFORM – AI Demand Drives Solid Results
Bit Digital (BTBT/$1.62 | Price Target: $5.5) Joe Gomes jgomes@noblefcm.com | 561-999-2262 February Ethereum Metrics Rating: OUTPERFORM
Data. Bit Digital reported its monthly Ethereum (“ETH”) treasury and staking metrics for the month of February 2026. As of month end, the Company held approximately 155,434 ETH versus 155,239 ETH at the end of January. Included in the ETH holdings were approximately 15,283 ETH and ETH-equivalents held in an externally managed fund. The Company’s total staked ETH was approximately 138,269, or about 89% of its total holdings as of February 28th.
Yield and Value. Staking operations generated approximately 314 ETH in rewards during the period, representing an annualized yield of approximately 2.7%. Based on a closing ETH price of $1,965, as of February 28, 2026, the market value of the Company’s ETH holdings was approximately $305.4 million.
Information Services Group (III/$4.53 | Price Target: $6.5) Joe Gomes jgomes@noblefcm.com | 561-999-2262 Jacob Mutchler jmutchler@noblefcm.com | AI Demand Drives Solid Results Rating: OUTPERFORM
Q425. Operating performance in 4Q25 was solid and came in at the upper end of management’s guidance. Revenue came in at $61.2 million, up 6% y-o-y. Adjusted EBITDA grew 24% to $8.1 million, and adjusted EBITDA margin expanded 189 basis points to 13.2%. ISG reported GAAP net income of $2.6 million, or EPS of $0.05/sh, compared to $3.0 million, or EPS of $0.06/sh, last year, which included a $2.3 million gain from the sale of the automation unit. Adjusted EPS was $0.08 versus $0.06 last year.
AI and Recurring Revenue. Management noted AI-related activities represented nearly 35% of quarterly revenue, up from approximately 10% a year ago. For the full year, AI-related revenue accounted for nearly 30% of total revenue, roughly three times last year’s proportion. Recurring revenue totaled $112 million, representing 46% of annual revenue, while recurring revenues grew 13% year-over-year in the fourth quarter. We expect both AI-related and recurring revenue to increase going forward.
Noble Capital Markets Research Report Friday, March 6, 2026
Companies contained in today’s report:
FreightCar America (RAIL)/OUTPERFORM – RAIL To Host FY2025 Earnings Call on March 10 InPlay Oil (IPOOF)/OUTPERFORM – Pembina Assets Shine, Disciplined Outlook
FreightCar America (RAIL/$13.15 | Price Target: $18) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 RAIL To Host FY2025 Earnings Call on March 10 Rating: OUTPERFORM
Fourth quarter and FY2025 earnings. FreightCar will release its fourth quarter and FY2025 financial results after the market close on Monday, March 9. Management will host an investor teleconference and webinar on Tuesday, March 10, at 11:00 am ET. We expect management to release corporate guidance for FY2026 railcar deliveries, revenue, and adjusted EBITDA. In addition to a market outlook, we think management will discuss its strategy for growing its aftermarket parts business along with its plans to enter the tank car market.
Noble estimates. Our fourth quarter 2025 revenue, EBITDA, and adjusted EPS estimates are $139.9 million, $12.5 million, and $0.18, respectively. For FY2025, we forecast $515.3 million, $46.8 million, and $0.58, respectively. For 2026, our revenue, EBITDA, and EPS estimates are also unchanged at $636.7 million, $59.4 million, and $0.76, respectively.
InPlay Oil (IPOOF/$12.46 | Price Target: $17) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Pembina Assets Shine, Disciplined Outlook Rating: OUTPERFORM
2025 financial results. InPlay Oil reported full-year 2025 adjusted funds flow (AFF) of C$114.4 million, or C$4.68 per share, above our estimate of C$112.9 million, or C$4.58 per share. Revenue for the year totaled C$291.4 million, ahead of our C$290.6 million forecast, as stronger Q4 production of 19,589 boe/d exceeded our estimate of 19,419 boe/d, in addition to stronger than expected AECO pricing. Full-year production averaged 17,043 boe/d, slightly above our 17,000 boe/d estimate.
Updated 2026 estimates. In the first quarter of 2026, we expect now revenues of C$79.9 million, AFF of C$27.4 million, and AFF per share of C$0.98, compared to prior estimates of C$79.0 million, C$26.6 million, and C$0.95, respectively. For the full-year 2026, we now estimate revenues of C$340.1 million, AFF of C$126.7 million, and AFF per share of C$4.53, up from C$340.1 million, C$125.2 million, and C$4.45. We are maintaining our production estimate of 18,605 boe/d in the first quarter and 18,900 boe/d for the year. These estimates are reflective of slightly higher commodity pricing.
Noble Capital Markets Research Report Thursday, March 5, 2026
Companies contained in today’s report:
First Phosphate Corp. (FRSPF)/OUTPERFORM – Gaining Government Support and Commercial Momentum NN (NNBR)/OUTPERFORM – First Look: 4Q25 and Full Year 2025 Results Ocugen (OCGN)/OUTPERFORM – FY2025 Reported With All Three Clinical Trials On Schedule
First Phosphate Corp. (FRSPF/$0.76 | Price Target: $1.65) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Gaining Government Support and Commercial Momentum Rating: OUTPERFORM
Canadian government steps up with financial support. First Phosphate received conditional approval for up to C$16.7 million in non-repayable funding through Natural Resources Canada under the Global Partnerships Initiative. The contribution will fund the assessment of technical and engineering parameters, including processing circuits and equipment, needed to validate the company’s ability to produce battery-grade phosphate concentrate aligned with its definitive offtake agreement. The funding supports study activities through 2028. First Phosphate received US$523,017 under a long-term phosphate concentrate offtake agreement, reinforcing commercial validation and establishing initial cash flow tied to downstream demand.
Phosphate added to Canada’s critical minerals list. The Canadian federal government amended the 2025 budget to include phosphate as a critical mineral essential for clean technology. This designation makes First Phosphate eligible for the 30% Critical Mineral Exploration Tax Credit (CMETC) and the 30% Clean Technology Manufacturing Investment Tax Credit (CTM). The CMETC enhances the company’s ability to raise exploration capital, while the CTM offers the potential to materially reduce downstream capital intensity for the planned phosphoric acid and LFP cathode active material facilities.
NN (NNBR/$1.53 | Price Target: $6) Joe Gomes jgomes@noblefcm.com | 561-999-2262 First Look: 4Q25 and Full Year 2025 Results Rating: OUTPERFORM
Overview. For the full year 2025, NN delivered a third consecutive year of improved financial performance, although 4Q25 results were modestly below our expectations. Importantly, NN completed the most capital-intensive portion of its transformation plan that included plant closures, significant headcount realignment, and exiting dilutive business. As a result, NN enters 2026 as a healthier, leaner, and more focused company, performing on multiple fronts, which should result in the next chapter of net sales growth.
4Q25 Results. Sales in 4Q25 were $104.7 million, down 1.7% y-o-y, primarily due to rationalization of underperforming business and plants and lower volumes. Adjusted EBITDA for the fourth quarter of 2025 was $12.9 million, or 12.3% of sales, compared to $12.1 million, or 11.3% of sales, for the same period of 2024. Adjusted net loss for the fourth quarter of 2025 was $0.1 million, or $0.00 per diluted share, compared to adjusted net loss of $0.9 million, or $0.02 per share, in 4Q24. We had estimated $107.5 million, $14.5 million, and $0.04, respectively.
Ocugen (OCGN/$1.96 | Price Target: $8) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 FY2025 Reported With All Three Clinical Trials On Schedule Rating: OUTPERFORM
FY2026 Reported With Important Milestones Ahead. Ocugen reported a loss for 4Q25 of $17.7 million or $(0.06) per share, with a FY2025 loss of $67.8 million or $(0.23) per share. Cash on December 31, 2025, was $18.6 million, not including $22.5 million from a common stock offering in January 2026. Importantly, the company confirmed several clinical trial milestones had been achieved or were on schedule for announcement later in 2026. This maintains the goal of submitting three BLAs for three products during the next three years.
Topline Data From OCU400 Expected In March 2027. The Phase 3 liMeliGhT trial testing OCU400 for retinitis pigmentosa (RP) has completed enrollment. The patients have a 1-year evaluation after treatment, with top-line data expected during March 2027. Ocugen plans to begin a rolling BLA submission with the Manufacturing and Preclinical Data sections later in 2026. The Phase 3 data and clinical sections are expected to be filed shortly after the final analysis. The full filing is expected to be completed in 1Q27. We anticipate 6-month review, with FDA approval received in Fall 2027.
Noble Capital Markets Research Report Wednesday, March 4, 2026
Companies contained in today’s report:
Greenwich LifeSciences, Inc. (GLSI)/OUTPERFORM – FLAMIMGO-01 Trial Screening Rate Now Higher Than Expected Power Metallic Mines Inc. (PNPNF)/OUTPERFORM – Drilling Expands Lion Mineralization and Identifies High-Grade Gold Zone Star Equity Holdings, Inc. (STRR)/OUTPERFORM – A Mini Berkshire In the Making Superior Group of Companies (SGC)/OUTPERFORM – Efficiency Initiatives Drive Earnings Growth
Greenwich LifeSciences, Inc. (GLSI/$27.26 | Price Target: $45) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 FLAMIMGO-01 Trial Screening Rate Now Higher Than Expected Rating: OUTPERFORM
Patient Screening Is Ahead Of Expectations. Greenwich LifeSciences reported a large increase in the rate of patient screening in the FLAMINGO-01 Phase 3 trial. The rate increased to about 200 patients per quarter, reaching an annual rate of over 800 per year, compared with the previous rate of 600 patients per year. The reflects an increased number of patients at existing sites as well as opening of additional sites in Europe. We see this increase in same-site and additional site screening as a positive sign for the trial.
Additional Data Release Coming Soon. In late February, Greenwich announced that two abstracts were accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held April 17-22, 2026. The AACR plans to publish the abstract titles on March 17, followed by the full abstracts on April 17. The full posters will be published on the date of presentation at the conference.
Power Metallic Mines Inc. (PNPNF/$0.86 | Price Target: $2.65) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Drilling Expands Lion Mineralization and Identifies High-Grade Gold Zone Rating: OUTPERFORM
Expansion of Lion mineralization. Recent drilling at Lion East and Lion West resulted in a newly identified shallow eastward plunging structural trend that controls high grade copper mineralization and extends the Lion system beyond its previously defined limits. Step-out drilling expanded mineralization both east and west, and the emerging structural model may vector toward a larger nickel copper source at depth, enhancing the project’s long-term potential.
Encouraging results at Lion West. Drilling intersected massive nickel-bearing sulphide within the UM zone, indicating the presence of a deeper nickel-palladium-copper system much like mineralization observed at Tiger. Follow-up drilling is underway to better define the geometry and relationship to the Lion geological stratigraphy.
Star Equity Holdings, Inc. (STRR/$9.9 | Price Target: $16) Joe Gomes jgomes@noblefcm.com | 561-999-2262 A Mini Berkshire In the Making Rating: OUTPERFORM
Initiation. We are initiating equity research coverage on Star Equity Holdings, Inc. with an Outperform rating and $16 price target. A diversified holding company, Star is seeking to replicate the Berkshire Hathaway playbook in the micro-cap space. The Company currently operates through 3 operating divisions, growing both organically and through acquisitions, and a fourth investment division, which makes strategic investments in public companies.
Multi-Pronged Growth Strategy. Management is pursuing a multi-pronged growth strategy. First and foremost is organic growth in the existing operating verticals. The second strategy is growth via acquisitions, with both the public and private arenas targeted. Lastly, through the Investments division, Star will make targeted investments in select microcaps. These could be potential acquisition targets or just strategic investments in companies that management has determined are trading at a discount to fair value.
Superior Group of Companies (SGC/$10.07 | Price Target: $16) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Efficiency Initiatives Drive Earnings Growth Rating: OUTPERFORM
Solid finish to the year. The company reported Q4 revenue of $146.6 million and adj. EBITDA of $9.9 million, both of which were largely in line with our estimates of $145.4 million and $9.1 million, respectively. Furthermore, revenue increased 1% year over year and 6% sequentially, reflecting the expected back-end weighted cadence, while strong cost controls drove meaningful profitability improvement.
Cost discipline drives earnings growth. SG&A declined $1.4 million year over year, and EBITDA increased 19% to $8.6 million, resulting in a 90 basis point improvement in EBITDA margin. EPS of $0.23, nearly doubled from the comparable prior-year quarter.
Noble Capital Markets Research Report Tuesday, March 3, 2026
Companies contained in today’s report:
Gyre Therapeutics, Inc (GYRE)/OUTPERFORM – Cullgen Acquisition Adds New Platform To Build Long-Term Pipeline Kratos Defense & Security (KTOS)/OUTPERFORM – Funds to Pursue Growth
Gyre Therapeutics, Inc (GYRE/$8.76 | Price Target: $20) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 Cullgen Acquisition Adds New Platform To Build Long-Term Pipeline Rating: OUTPERFORM
Gyre To Acquire Cullgen. Gyre Therapeutics announced the acquisiton of Cullgen, a privately-held company developing targeted protein degrader (TPD) and degrader antibody conjugate (DAC) therapies. The all-stock transaction valued Cullgen at approximately $300 million. We believe this acquisition adds a novel technology platform to the mid-term to long-term product pipeline.
The Cullgen Acquisition Transforms Gyre. Cullgen was private company founded in 2018. It has been developing its proprietary technology platform, uSMITE (ubiquitin-mediated small molecule-induced target elimination), to create targeted protein degrading drugs and antibody conjugates. These drugs are in development to treat pain, cancer, inflammation, autoimmune diseases, and neurodegenerative diseases.
Kratos Defense & Security (KTOS/$90.72 | Price Target: $145) Joe Gomes jgomes@noblefcm.com | 561-999-2262 Funds to Pursue Growth Rating: OUTPERFORM
A Raise. Kratos raised a net $1.35 billion through the sale of 16,285,571 KTOS shares at $84/sh, including the Underwriters exercising the 30-day allotment in full. The offering closed on March 2, 2026. Noble Capital participated in the raise.
Uses. The net funds will be used to continue to make important capital expenditures to scale operations and meet the growing demands of The Department of War and National Security customers with respect to existing programs, recently awarded contracts and new opportunities, (ii) to continue to invest in new product, system and software product development, (iii) to strengthen the Company’s balance sheet to allow the Company to be responsive to anticipated contract awards from the large, strategic pipeline of opportunities, (iv) to fund the recent acquisition of Nomad, pending acquisition of Orbit, and select future strategic M&A opportunities, and (v) for general corporate purposes.
Solid Q4 Results. The company reported Q4 revenue of €60.7 million and adj. EBITDA of €6.7 million, both of which surpassed our estimates of €57.0 million and €3.0 million, respectively. Notably, the company benefited from strong user activity in the quarter, both in monthly active users and first time deposits (FTD), as well as an improved cost per acquisition (CPA).
Favorable fundamentals. Notably, in Q4, the company benefited from strong activity in Mexico, which generated revenue of €32.8 million, up 31% YoY. The favorable performance in Mexico was supported by 99,000 average monthly users, up 43% YoY. On a consolidated basis, the company averaged 177,000 monthly active users, up 20% YoY. Furthermore, the company benefited from efficient CPA spend of €166, with 89,000 FTD recorded in Q4, which is up 22% over the prior year period.
MAIA Biotechnology (MAIA/$2.26 | Price Target: $14) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 Ateganosine Moves Forward With A Pivotal Year Ahead Rating: OUTPERFORM
Building On Success In 2025, Ateganosine Continues Moving Forward. MAIA has been conducting the Phase 2 THIO-101 trial, testing ateganosine (also known as THIO) in combination with cemiplimab, a checkpoint inhibitor. The trial is now in its third stage after the data showed meaningful improvements in median survival, overall response rates, and disease control rate. Separately, a Phase 3 trial has begun. Based on the reported results, we believe both trials have a high probability of success and could lead to FDA approvals.
Phase 2 THIO-101 Could Support Early Approval. The THIO-101 trial was designed with three stages. Part A confirmed safety and tolerabity, while Part B tested three doses to determine the optimal dosing regimen. In December 2025, the Part C Expansion/Registration stage began. This is an open-label arm designed to determine the Overall Response Rate (ORR). Positive data could lead to an application for Early Approval from the FDA.
Titan International (TWI/$9.73 | Price Target: $11) Joe Gomes jgomes@noblefcm.com | 561-999-2262 Reports Fourth Quarter Results Rating: OUTPERFORM
Overview. Titan ended 2025 with another positive quarter as fourth quarter revenue, gross margin, and adjusted EBITDA exceeded fourth quarter 2024 results. These results are ahead of management’s revenue guidance and also better than adjusted EBITDA expectations. The EMC segment was the standout performer, with revenue growth of 21% and gross margin expansion of 3.4 percentage points.
4Q25 Results. Revenue grew 7.0% to $410.4 million. Ex foreign exchange, the Ag segment was flat, EMC up nicely, and Consumer down modestly. Adjusted EBITDA came in at $11 million, up 18% y-o-y. Due to non-cash valuation allowances, Titan recorded a GAAP net loss of $56 million in the quarter, compared to net income of $1.3 million in 4Q24. Adjusted net loss was $17.4 million, or $0.27/sh, compared to net income of $5.8 million, or $0.09/sh, in 4Q24.
Noble Capital Markets Research Report Friday, February 27, 2026
Companies contained in today’s report:
Aurania Resources (AUIAF)/OUTPERFORM – Making Progress at the Balangero Green Nickel Project Codere Online (CDRO)/OUTPERFORM – Delivers Operating Leverage E.W. Scripps (SSP)/OUTPERFORM – Transformation Plan Underscores Compelling Valuation Nicola Mining Inc. (HUSIF)/OUTPERFORM – Building Momentum
Aurania Resources (AUIAF/$0.16 | Price Target: $0.3) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Making Progress at the Balangero Green Nickel Project Rating: OUTPERFORM
Recent assay results confirm strong nickel-cobalt grades. Aurania reported results from 28 new samples at the Balangero Nickel-Cobalt Project in northern Italy, returning nickel values between 1,560 and 2,015 parts per million (ppm) and averaging 1,763 ppm, along with 81.5 to 108 ppm cobalt and 16.2 to 146 ppm copper. These results align with more than 200 historical samples and validate the presence of awaruite, a nickel-iron alloy suitable to be used as a direct source of furnace feed for stainless steel production or processed downstream EV battery-grade nickel sulphate production. Notably, samples from development rock piles were confirmed to be asbestos-free, potentially expanding the resource base beyond tailings.
A differentiated alternative to greenfield peers. Unlike comparable awaruite-focused projects, which require full mine development, Balangero’s potential resource consists primarily of dry-stacked, pre-crushed tailings and surface rock already extracted from the ground. This eliminates the need for drilling, blasting, and underground haulage. The project benefits from electric power, rail access, highway connectivity, and an available skilled workforce, positioning it as a potentially accelerated development opportunity with significant cost advantages.
Solid Q4 Results. The company reported Q4 revenue of €60.7 million and adj. EBITDA of €6.7 million, both of which surpassed our estimates of €57.0 million and €3.0 million, respectively, as illustrated in Figure #1 Q4 Results. Notably, the company benefited from strong user activity in the quarter, both in monthly active users and first time deposits (FTD), as well as an improved cost per acquisition (CPA).
Favorable fundamentals. Notably, in Q4, the company benefited from strong activity in Mexico, which generated revenue of €32.8 million, up 31% YoY. The favorable performance in Mexico was supported by 99,000 average monthly users, up 43% YoY. On a consolidated basis, the company averaged 177,000 monthly active users, up 20% YoY. Furthermore, the company benefited from efficient CPA spend of €166, with 89,000 FTD recorded in Q4, which is up 22% over the prior year period.
E.W. Scripps (SSP/$3.69 | Price Target: $10) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Transformation Plan Underscores Compelling Valuation Rating: OUTPERFORM
Better than expected Q4. Total Q4 revenues of $560.3 million was better than our $550.9 million estimate, due to better than expected Core Local advertising and better Scripps Networks revenue. Adj. EBITDA of $86.4 million beat our $75.6 million estimate on lower segment expenses, particularly in its Networks segment.
Core advertising stronger than expected. Core Advertising revenue increased a strong 12.2% to $165.4 million, better than our estimate of $162.0 million. It is not surprising given the record amount of year earlier Political advertising that there would be a large level of Core Advertising displacement. Importantly, management indicated that Core Advertising momentum continues to be favorable into the first quarter 2026.
Nicola Mining Inc. (HUSIF/$0.9 | Price Target: $1.25) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Building Momentum Rating: OUTPERFORM
Operational momentum continues. Nicola reported a significant increase in throughput of high-grade gold and silver mill feed from its partnership with Blue Lagoon Resources at the Dome Mountain Gold Project. Processing at the Merritt Mill has shifted from a gravity-and-flotation circuit to a flotation-only flowsheet, better aligning with the sulphide-hosted mineralization and enhancing recoveries, concentrate grades, and payable metal output. Ongoing plant upgrades are expected to improve efficiency and throughput. Underground development at Dome Mountain is progressing, with additional mining faces being prepared to support sustainable increases in mill feed tonnage.
Advancing the next phase of gold production at Dominion Creek. Dominion represents an additional driver of growth, targeting high-grade gold mineralization. Nicola is procuring needed mobile equipment and personnel ahead of the planned extraction in July 2026 under a bulk sample permit. The bulk sample program is intended to validate grade continuity, metallurgical performance, and mining selectivity, while also contributing incremental cash flow.
Noble Capital Markets Research Report Thursday, February 26, 2026
Companies contained in today’s report:
1-800-Flowers.com (FLWS)/MARKET PERFORM – Sets The Table For Investors Cardiff Oncology (CRDF)/OUTPERFORM – FY2025 Reported With Onvansertib Phase 2b Data Review E.W. Scripps (SSP)/OUTPERFORM – Foundation for 2026 Upside Euroseas (ESEA)/OUTPERFORM – Solid 4Q and FY2025 Results Amid Sustained Strength in Containership Market Kratos Defense & Security (KTOS)/OUTPERFORM – Reports Fourth Quarter Results
1-800-Flowers.com (FLWS/$3.34) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Sets The Table For Investors Rating: MARKET PERFORM
Updates it corporate presentation. Management recently updated its corporate presentation to provide more detail around the company’s four pillar initiative to transform it toward a more profitable, scalable, growth oriented company. The four key pillars: achieving cost savings and operational efficiency, strengthening customer focus, expanding reach beyond e-commerce, and enhancing talent alignment and accountability.
Omnichannel Expansion. The company is expanding distribution channels beyond its owned e-commerce platforms. The Company is meeting customers where they already shop by leveraging leading third-party marketplaces to lower acquisition friction and expand reach. These marketplace channels are intended to complement owned platforms, while selective physical retail testing will occur under strict ROI thresholds.
Cardiff Oncology (CRDF/$1.91 | Price Target: $12) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 FY2025 Reported With Onvansertib Phase 2b Data Review Rating: OUTPERFORM
FY2026 Reported With Onvansertib Review. Cardiff reported a FY2025 loss of $45.8 million or $(0.69) per share and reviewed the clinical data for onvansertib, its drug for RAS-mutated metastatic colorectal cancer (mCRC). Updated plans for Phase 3 are expected after discussions with the FDA during 1H26. On December 31, 2025, Cardiff ended the year with $58.3 million in cash and equivalents, which it believes can fund operations through 1Q27.
Phase 2 CRDF-004 Trial Design. The CDRF-004 Phase 2 trial was designed to test two doses of onvansertib in combination with two standard-of-care (SOC) regimens against each standard of care regimen alone. It enrolled 110 patients with RAS-mutated mCRC. The primary endpoint was objective response rate (ORR).
E.W. Scripps (SSP/$3.63 | Price Target: $10) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Foundation for 2026 Upside Rating: OUTPERFORM
Better than expected Q4. Total Q4 revenues of $560.3 million was better than our $550.9 million estimate, due to better than expected Core Local advertising and better Scripps Networks revenue. Adj. EBITDA of $86.4 million beat our $75.6 million estimate on lower segment expenses, particularly in its Networks segment.
Core advertising stronger than expected. Core Advertising revenue increased a strong 12.2% to $165.4 million, better than our estimate of $162.0 million. It is not surprising given the record amount of year earlier Political advertising that there would be a large level of Core Advertising displacement. But, we are pleased that Core Advertising reflected a strong rebound in the quarter, even better than what we were looking for.
Euroseas (ESEA/$62.99 | Price Target: $85) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Solid 4Q and FY2025 Results Amid Sustained Strength in Containership Market Rating: OUTPERFORM
Solid Q4 and FY2025 financial results. Fourth quarter net revenue increased 7.7% to $57.4 million compared to $53.3 million during the prior year period. Adjusted EBITDA and EPS were $40.7 million and $4.48, respectively, compared to $32.8 million and $3.33 during the prior year quarter. During the fourth quarter, the average time charter equivalent rate amounted to $30,268 per day compared to $26,479 during the prior year period. The company reported FY2025 adjusted EBITDA and EPS of $155.9 million and $16.74, respectively, compared to $135.8 million and $14.87 in 2024.
Revenue and earnings visibility. For 2026, Euroseas has secured 86.6% of available voyage days at an average rate of ~$30,700 per day and 71.1% of 2027 available voyage days at an average rate of $31,890 per day. For 2028, 40.8% of available voyage days are covered at ~$32,400 per day. This robust charter coverage not only underpins earnings but also provides a strong buffer against rate volatility, positioning the company to benefit from sustained high utilization in 2026.
Overview. Kratos finished 2025 exceeding management’s financial objectives for the fourth quarter, generating approximately 20% year- over-year organic revenue growth, generating a 1.3 to 1.0 book-to-bill ratio on top of the organic growth, having a record backlog of $1.573 billion, and a record opportunity pipeline of $13.7 billion.
4Q25 Results. Fourth quarter revenue of $345.1 million reflected 20% y-o-y organic growth and exceeded our $320 million estimate. Unmanned Systems’ organic revenue growth was 12.1%, while Government Solutions saw 22.2% organic growth. Kratos recorded adjusted EBITDA of $34.1 million, up from $25.2 million a year ago and our $31 million estimate. Adjusted EPS came in at $0.18 versus $0.13 last year and our $0.14 estimate.
Noble Capital Markets Research Report Wednesday, February 25, 2026
Companies contained in today’s report:
Cadrenal Therapeutics (CVKD)/OUTPERFORM – CAD-1005 Phase 2 Results Announced, With FDA Guidance Meeting Scheduled InPlay Oil (IPOOF)/OUTPERFORM – 2026 Guidance Points to Disciplined Growth and Continued Deleveraging Perfect (PERF)/OUTPERFORM – Revenue Growth Story Intact V2X (VVX)/OUTPERFORM – A Strong End to the Year
Cadrenal Therapeutics (CVKD/$7.79 | Price Target: $45) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 CAD-1005 Phase 2 Results Announced, With FDA Guidance Meeting Scheduled Rating: OUTPERFORM
Cadrenal Announced Phase 2 Data With End-of-Phase-2 Meeting Scheduled. Cadrenal announced data from the Phase 2 trial of its anti-thrombotic CAD-1005 (formerly known as VLX-1005) for HIT, or heparin-induced thrombocytopenia. Cadrenal has also been granted an End-of-Phase 2 meeting with the FDA to discuss the trial results and design of a Phase 3 trial. These are important milestones in the development of CAD-1005.
Phase 2 Produced Unexpected Findings. The Phase 2 trial tested safety and efficacy of CAD-1005 in patients receiving standard anticoagulant therapy. Its Primary Endpoint was designed to show CAD-1005 improved platelet recovery, testing platelet count recovery as a biomarker for thrombosis and outcome. This Primary Endpoint did not meet statistical significance, and did not find a correlation between platelet count normalization and thrombotic events.
InPlay Oil (IPOOF/$11.47 | Price Target: $15.75) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | 2026 Guidance Points to Disciplined Growth and Continued Deleveraging Rating: OUTPERFORM
2026 guidance. InPlay approved a C$66 to C$74 million capital program targeting average production of 18,600 to 19,200 boe/d (~61% light oil and NGLs), representing approximately 11% growth over the estimated 2025 production of ~17,000 boe/d. Management forecasts adjusted funds flow (AFF) of C$122 to C$129 million and free adjusted funds flow (FAFF) of C$48 to C$63 million, implying an 11% to 15% FAFF yield. Year-end net debt is guided to C$199 to C$206 million, reflecting continued deleveraging.
Estimate revisions. We have adjusted our 2026 estimates to average production of 18,900 boe/d, revenue of C$338.3 million, and AFF of C$125.2 million, or C$4.45 per share. For Q1 2026, we have assumed production of 18,605 boe/d, revenue of C$79.0 million, and AFF of C$26.6 million, or C$0.95 per share. The first quarter carries heavier drilling activity, with five wells drilled and completed, most coming onstream late in the period, marking Q1 as the lightest production quarter of the year. We forecast 2026 capital expenditures of C$70 million.
Perfect (PERF/$1.3 | Price Target: $5) Patrick McCann pmccann@noblefcm.com | (314) 724-6266 Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Revenue Growth Story Intact Rating: OUTPERFORM
Q4 results. Perfect reported Q4 revenue of $18.1 million, up 14.2% Y/Y and largely in line with our estimate of $18.2 million, while adj. EBITDA of $1.4 million exceeded our forecast of $1.0 million, representing 8% margins. Excluding a one-time goodwill write-off, the company would have generated operating income, underscoring improving cost discipline and operating leverage.
B2C momentum the primary growth driver. Management noted that strong demand for AI-powered content creation is driving engagement across the YouCam app portfolio. Generative AI photo and video tools remain key contributors, and we believe Perfect’s expertise with these technologies positions it well to benefit from sustained demand for personalized, AI-enabled digital experiences.
V2X (VVX/$70 | Price Target: $72) Joe Gomes jgomes@noblefcm.com | 561-999-2262 A Strong End to the Year Rating: OUTPERFORM
Overview. In the fourth quarter, V2X drove record quarterly revenue, adjusted EBITDA, and adjusted cash flow. These results reflect the strength of the Company’s strategy and alignment with national security priorities for readiness and modernization. V2X continues to see momentum across the business coming through contract wins in key growth areas, and we are encouraged by the ongoing demand for the Company’s mission solutions.
4Q25 Results. Revenue increased 5% y-o-y to a record $1.22 billion. Adjusted EBITDA was $88.7 million for the quarter, also a record for the Company. and exceeding management’s expectations. Adjusted net income was $49.3 million and adjusted EPS was $1.56, both representing double-digit year-over-year growth. We were at $1.19 billion, $81 million, and $1.33, respectively.
Noble Capital Markets Research Report Tuesday, February 24, 2026
Companies contained in today’s report:
Bitcoin Depot (BTM)/OUTPERFORM – Reverse Stock Split Century Lithium Corp. (CYDVF)/OUTPERFORM – Updated Angel Island Feasibility Study Highlights Great Lakes Dredge & Dock (GLDD)/MARKET PERFORM – Going Out On Top SEGG Media Corporation (SEGG)/OUTPERFORM – Strengthens Its Portfolio
BTM 1-for-7 reverse stock split. On February 23, 2026, the company’s Class A common stock began trading on a split-adjusted basis on Nasdaq. The action had been previously authorized by shareholders and approved by the Board and did not reflect any change in operating performance or strategy.
No alteration to economic ownership or fundamentals. Every seven shares outstanding were consolidated into one share, with fractional shares cashed out based on the pre-split VWAP. Authorized shares and par value remained unchanged, while public warrants, equity awards, and other convertible securities were adjusted proportionally, including a mechanical increase in the BTMWW warrant exercise price.
Century Lithium Corp. (CYDVF/$0.44 | Price Target: $2.35) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Updated Angel Island Feasibility Study Highlights Rating: OUTPERFORM
Updated feasibility study. Century released the results of its 2026 NI 43-101 feasibility study for the 100%-owned Angel Island Lithium Project in Esmeralda County, Nevada. The updated study reflects engineering optimization and improvements that materially strengthen the project’s economic profile and highlight Angel Island as one of the most significant and economically robust sedimentary lithium developments in the United States.
Lower initial capital expenditures. Phase I initial capital expenditures are estimated to be $997 million, a significant reduction from the $1.5 billion outlined in the 2024 Study. The updated study streamlines development into a two-phase approach. Phase I contemplates 7,500 tonnes per day (tpd) of mill feed, expanding to 15,000 tpd in Phase II beginning in Year 5. Phase II expansion capital is estimated at $660 million. A previously planned third expansion phase has been eliminated, lowering overall capital requirements. The economic analysis is based on a 40-year production schedule, with planned life-of-mine average production of 26,500 tonnes per annum of battery-grade lithium carbonate.
Great Lakes Dredge & Dock (GLDD/$16.87) Joe Gomes jgomes@noblefcm.com | 561-999-2262 Going Out On Top Rating: MARKET PERFORM
Overview. Great Lakes reported solid 4Q25 results in its likely last quarter as a public company. A full quarter of work from the Amelia Islandand higher capital and offshore energy revenue drove the results. Offshore energy revenue rose to $24.1 million in the quarter, up from $6.1 million in 3Q25. Higher costs associated with the pending merger and increased incentive compensation impacted operating income, which rose to $32.6 million from $30 million in 4Q24.
4Q25 Results. Revenue was $256.5 million, up from $202.8 million in 4Q24 and above our $220.5 million estimate. Adjusted EBITDA totaled $44 million compared to $40.2 million last year and in-line with our $44.5 million estimate. Adjusted net income was $20.7 million, or $0.30/sh, compared to $19.7 million, or $0.29/sh, last year.
SEGG Media Corporation (SEGG/$1.12 | Price Target: $15.5) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Strengthens Its Portfolio Rating: OUTPERFORM
Increases its stake in Veloce Media Group. SEGG Media increases its stake from 12.4% to over 51% in Veloce Media Group, a UK-based digital media and gaming company focused on esports, gaming content, and motorsport entertainment, valuing the company at $61 million. Veloce current management is expected to manage the business and the company has nominated Daniel Bailey, co-founder and CEO of Veloce, to the SEGG board.
Could own up to 75%. The purchase was for cash and stock, with the vast majority for stock. The company issued 2.52 million shares in the transaction, valuing the SEGG shares at $10 per share. SEGG extended the offer for a portion of the remaining interest in Veloce it does not own, and, as such, SEGG may control a larger percentage once the transaction is completed within the next few weeks.
Noble Capital Markets Research Report Monday, February 23, 2026
Companies contained in today’s report:
EuroDry (EDRY)/OUTPERFORM – Finishing 2025 Strong; Building Momentum into 2026 Kratos Defense & Security (KTOS)/OUTPERFORM – An Acquisition, Awards, and More
EuroDry (EDRY/$18.5 | Price Target: $29) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Finishing 2025 Strong; Building Momentum into 2026 Rating: OUTPERFORM
Fourth quarter and full year results. EuroDry reported fourth-quarter net revenues of $17.4 million, exceeding our estimate of $16.5 million, driven by a stronger average TCE rate of $16,262 per day versus our $15,900 estimate and lighter drydocking of 13.7 days against our 22-day assumption. Adjusted EBITDA of $7.5 million and adjusted EPS of $0.88 came in ahead of our estimates of $6.7 million and $0.78, respectively. For the full year, net revenues of $52.3 million, adjusted EBITDA of $12.5 million, and an adjusted net loss of $2.50 per share all modestly surpassed our estimates of $51.4 million, $11.7 million, and a loss of $2.57.
Market update. Dry-bulk fundamentals strengthened in the fourth quarter, with average TCE rates rising to the highest levels in approximately two years. The global order book remains near historically low levels, at approximately 13.4% of the existing fleet, providing structural support. Near-term demand tailwinds include growing bauxite trade from West Africa, continued grain flows following the U.S.–China trade truce, and longer voyage distances due to Red Sea disruptions, though geopolitical uncertainty and tariff-related volatility remain risks.
Kratos Defense & Security (KTOS/$96.08 | Price Target: $145) Joe Gomes jgomes@noblefcm.com | 561-999-2262 An Acquisition, Awards, and More Rating: OUTPERFORM
Acquisition. In a 424B3 filing, Kratos disclosed that it acquired Nomad Global Communication Solutions, Incorporated, for an initial amount of 972,136 KTOS shares or approximately $100 million. Nomad provides mobile command, control, and communications systems for space and satellite systems, UAVs, counter UAVs, and other systems, with clients including all branches of the U.S. armed forces, Homeland Security, and other Agencies, among others. We expect management to provide additional detail and color on the earnings call.
Drone Dominance. Kratos has been selected to participate in the initial Phase 1 Gauntlet for the Office of the Secretary of War’s Drone Dominance Program. This opportunity seeks to identify and evaluate platforms capable of demonstrating multiple one-way attack missions through a live competition. Upon successful completion of the Gauntlet, participants will be ranked and extended a prototype delivery award based on their performance and placement. The Drone Dominance Program represents a $1.1 billion investment in groundbreaking unmanned systems technologies. The program aims to procure approximately 350,000 units.
Noble Capital Markets Research Report Friday, February 20, 2026
Companies contained in today’s report:
Cocrystal Pharma (COCP)/OUTPERFORM – CDI-988 Norovirus Phase 1 Data to be Presented at ICAR 2026 Travelzoo (TZOO)/OUTPERFORM – Near Term Revenue Growth Throttles Back
Cocrystal Pharma (COCP/$0.98 | Price Target: $6) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 CDI-988 Norovirus Phase 1 Data to be Presented at ICAR 2026 Rating: OUTPERFORM
CDI-988 Data Selected For Presentation At ICAR. Cocrystal announced that it has been selected to present data from its Phase 1 clinical trial and updates from the ongoing Phase 1b challenge study testing CDI-988 against norovirus infection at the 38th International Conference on Antiviral Research, to be held April 27 to May 1 in Prague, Czech Republic. We see the presentation at this important conference as recognition of the potential of CDI-988 for an indication that has serious medical and economic consequences.
Phase 1 and 1b Data Expected. We expect Dr. Sam Lee, President and Co-CEO, to present initial Phase 1 safety and tolerability data. Previously announced data from the single ascending dose (SAD) and multiple ascending dose (MAD) study showed safety and tolerability across all dose cohorts tested. Additional data from the ongoing Phase 1b norovirus challenge study testing CDI-988 as both a prophylactic and therapeutic may also be included.
Travelzoo (TZOO/$5.05 | Price Target: $20) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Near Term Revenue Growth Throttles Back Rating: OUTPERFORM
Softer than expected Q4 Results. The company reported Q4 revenue of $22.5 million, an increase of 9%, and adj. EBITDA of $1.0 million, both of which were below our estimates of $23.0 million and $3.3 million, respectively. Importantly, the modestly softer than expected results were largely driven by weakness in advertising and commerce revenue. Increased marketing spend and elevated G&A expenses due to a non-recurring corporate event adversely affected EBITDA.
Customer acquisition efficiency. Customer acquisition costs averaged $34 per member in Q4, compared to $28 in Q1, $38 in Q2, and $40 in Q3, reflecting continued investment in subscriber growth. Management highlighted rapid payback economics, with annual membership fees collected upfront and supplemented by transaction revenue. Acquisition costs are expensed immediately, impacting near-term profitability, though the strategy is intended to expand recurring revenue and strengthen the advertising platform over time.
Noble Capital Markets Research Report Thursday, February 19, 2026
Companies contained in today’s report:
NeuroSense Therapeutics Ltd. (NRSN)/OUTPERFORM – Post-Phase 2b Analysis Demonstrates Survival Benefit and Mortality Risk Reduction Power Metallic Mines Inc. (PNPNF)/OUTPERFORM – Recent Assay Results and Observations from the Summer-Fall 2025 Drilling Program
PrimeC Demonstrates Survival Benefit and 65% Mortality Risk Reduction. NeuroSense announced a Post-Phase 2b Analysis of its trial testing PrimeC in ALS. New data shows PrimeC patients had an additional 14 months (about 70%) survival with 65% reduction in risk of death. These improvements in overall survival correlate with previous Phase 2b Paradigm data that showed improvements in several endpoints of function, biomarkers, and survival.
New Data Shows Continued Improvement In Survival. The newly released data show the PrimeC treated patients had a median survival benefit of 36.3 months compared with 21.4 months for the group that received placebo then PrimeC during the extension study. This improvement of about 14.9 months was a benefit of 70% in survival. The Hazard Ratio (HR, the probability of an event occurring) reduced risk of death by 65% (p=0.0037).
Power Metallic Mines Inc. (PNPNF/$0.96 | Price Target: $2.65) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Recent Assay Results and Observations from the Summer-Fall 2025 Drilling Program Rating: OUTPERFORM
Expanding the High-Grade Core at Lion. Summer-Fall 2025 drilling successfully extended high-grade mineralization down plunge at the Lion Zone, with impressive intercepts including 8.40 meters grading 8.05% copper equivalent recovered, and 5.10 meters grading 9.86% copper equivalent recovered, reinforcing strong vertical continuity.
Precious Metals Significantly Enhance Value. Assays revealed substantial palladium, platinum, and gold contributions, materially boosting copper-equivalent grades and highlighting the robust polymetallic nature of the deposit.
Noble Capital Markets Research Report Wednesday, February 18, 2026
Companies contained in today’s report:
Seanergy Maritime (SHIP)/OUTPERFORM – Strong 2025 Finish; Favorable 2026 Outlook
Seanergy Maritime (SHIP/$12.66 | Price Target: $20) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Strong 2025 Finish; Favorable 2026 Outlook Rating: OUTPERFORM
Q4’25 financial results. Seanergy reported Q4 net revenues of $49.4 million and adjusted EBITDA of $28.9 million, exceeding our estimates of $48.3 million and $28.2 million, respectively. Adjusted net income and adjusted EPS were $14.2 million and $0.68, ahead of our $11.7 million and $0.56 estimates. The stronger than expected earnings were due to a higher average time charter equivalent (TCE) rate of $26,614 per day versus our $26,000 estimate.
Favorable Capesize market. The Capesize market is supported by favorable supply and demand fundamentals. The global orderbook stands at roughly 12% of the fleet, while approximately 40% of Capesize, Newcastlemax, and VLOC vessels are over 15 years old, with special surveys expected to reduce effective supply by 1.5% to 2.5% annually. Additionally, Brazilian iron ore exports and West African bauxite shipments continue to expand, with Simandou expected to add incremental long-haul volumes in 2026 and 2027. In our view, this combination of structural supply constraints and steady commodity trade flows supports a constructive rate environment throughout 2026.
Noble Capital Markets Research Report Tuesday, February 17, 2026
Companies contained in today’s report:
AZZ (AZZ)/OUTPERFORM – Updating Estimates; Raising PT to $160 Per Share Commercial Vehicle Group (CVGI)/OUTPERFORM – Major Shareholder Appointed to Board Conduent (CNDT)/OUTPERFORM – New CEO Unveils Action Plan CoreCivic, Inc. (CXW)/OUTPERFORM – A Strong End to the Year Kelly Services (KELYA)/OUTPERFORM – Reports 4Q25 Results The GEO Group (GEO)/OUTPERFORM – Solid 4Q25 Results
AZZ (AZZ/$140.24 | Price Target: $160) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Updating Estimates; Raising PT to $160 Per Share Rating: OUTPERFORM
FY27 Corporate Guidance. AZZ recently provided financial guidance for FY27 ending on February 28, 2027. Sales are expected to be in the range of $1.725 to $1.775 billion, adjusted EBITDA is expected to be in the range of $360.0 to $400.0 million, and adjusted diluted EPS is expected to be in the range of $6.50 to $7.00.
Updating Estimates. We have adjusted our FY27 sales, adjusted EBITDA, and adjusted EPS to $1.750 billion, $386.0 million, and $6.70, respectively, from $1.746 billion, $388.0 million, and $6.60. We have also adjusted our forward estimates through 2031, which are included in the financial model at the end of this report. Our FY27 estimates reflect modestly higher sales growth and lower interest expense of $40.0 million compared to our prior estimate of $43.4 million. Our FY26 estimates remain within the company’s corporate guidance ranges.
Commercial Vehicle Group (CVGI/$1.67 | Price Target: $4) Joe Gomes jgomes@noblefcm.com | 561-999-2262 Major Shareholder Appointed to Board Rating: OUTPERFORM
On The Board. Commercial Vehicle Group has added Ari Levy of Lakeview Investment Group as an independent director. Lakeview owns approximately 8.9% of the outstanding shares of the Company. In connection with Mr. Levy’s appointment, the Board was expanded to 7 members. Mr. Levy will serve on the Board’s Nominating, Governance and Sustainability, and Audit Committees.
Ari Levy. Mr. Levy is the founder, President, and Chief Investment Officer of Lakeview, a Chicago based investment manager focused on the public markets. Mr. Levy was the President of Levy Acquisition Corp, a NASDAQ listed acquisition vehicle, and subsequently served on the Board of the resulting public company, Del Taco, until it was acquired by Jack in the Box in early 2022.
Conduent (CNDT/$1.54 | Price Target: $5) Patrick McCann pmccann@noblefcm.com | (314) 724-6266 Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 New CEO Unveils Action Plan Rating: OUTPERFORM
Q4 results. Q4 revenue of $770 million was modestly below our estimate of $778 million, driven by ongoing softness in the Commercial segment, while adj. EBITDA of $50 million exceeded our estimate of $41 million as cost performance improved, resulting in a 6.5% adj. EBITDA margin.
New CEO outlines action plan. CEO Harsha V. Agadi outlined a framework centered on faster decision-making, reduced organizational complexity, and a “fix, sell, or grow” review of every business unit, with emphasis on financial discipline, cost reduction, and converting the pipeline into sustainable organic revenue and EBITDA growth.
CoreCivic, Inc. (CXW/$18.92 | Price Target: $28) Joe Gomes jgomes@noblefcm.com | 561-999-2262 A Strong End to the Year Rating: OUTPERFORM
Overview. CoreCivic reported a strong 4Q25, with management revenue from U.S. Immigration & Customs Enforcement (ICE), CXW’s largest government partner, more than doubling from the fourth quarter of 2024. Revenue from state customers increased 5.0% y-o-y. CoreCivic’s balance sheet remains strong, ending the quarter with leverage, measured as net debt to adjusted EBITDA, at 2.8x for the trailing twelve months.
4Q25 Results. Revenue was $603.9 million, up from $479.3 million in 4Q24 and our $595.8 million estimate, driven by higher populations. Adjusted EBITDA totaled $92.5 million, compared to $74.2 million last year and our $80.9 million projection. Adjusted EPS was $0.27 versus $0.16 last year.
Kelly Services (KELYA/$9.79 | Price Target: $17) Joe Gomes jgomes@noblefcm.com | 561-999-2262 Reports 4Q25 Results Rating: OUTPERFORM
Overview. Kelly’s fourth quarter continued to be impacted by many of the same trends evident in previous quarters, most notably discrete impacts associated with reduced demand for U.S. federal government contractors and from three large commercial customers. Employers continue to take a cautious approach to hiring amid a mixed labor market. However, the Company was able to capitalize on positive trends in each of the segments.
4Q25 Results. Revenue was $1.05 billion, down 11.9% y-o-y, but down only 3.9% excluding the discrete impacts associated with reduced demand for U.S. federal government contractors and from three large commercial customers. Gross margin declined 150 bps to 18.8%. Adjusted EBITDA totaled $12 million, or a 2.0% margin, compared to $43.5 million, or 3.7% margin, last year. Adjusted EPS was $0.16 versus $0.79 in 4Q24.
The GEO Group (GEO/$14.21 | Price Target: $28) Joe Gomes jgomes@noblefcm.com | 561-999-2262 Solid 4Q25 Results Rating: OUTPERFORM
Overview. The GEO Group reported solid fourth quarter operating results. The census across the Company’s active ICE facilities have continued to steadily increase from the third quarter at approximately 22,000 to presently approximately 24,000, which is the highest level of ICE populations in the Company’s history. Mix change in the ISAP program could lead to higher revenue, even with relatively stable populations.
4Q25 Results. Revenue of $707.7 million was above our $665 million estimate and is up 16.5% year-over-year. Adjusted EBITDA for the fourth quarter of 2025 was approximately $126 million, up from approximately $108 million reported for the prior year’s fourth quarter. We were at $120 million. Adjusted EPS came in at $0.25 compared to $0.13 in 4Q24.
Noble Capital Markets Research Report Friday, February 13, 2026
Companies contained in today’s report:
Alliance Entertainment Holding (AENT)/OUTPERFORM – A Disappointing Quarter, But Profitability and Margin Execution Was Strong Snail (SNAL)/OUTPERFORM – Noble Virtual Conference Highlights
Alliance Entertainment Holding (AENT/$6.38 | Price Target: $9) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 A Disappointing Quarter, But Profitability and Margin Execution Was Strong Rating: OUTPERFORM
Softer than expected revenue and adj. EBITDA. Fiscal Q2 revenue of $369.0 million was below our $402.1 million estimate and down from $394.0 million a year earlier. The largest revenue variance appeared to be attributable to the lack of arcade inventory in its gaming division due to the bankruptcy of one of its vendors. Adj. EBITDA of $18.1 million was below our $25.3 million estimate, as a result of higher than expected costs in its licensing business.
Maintains strong margin dynamics. The company maintained strong gross margins at 12.8%, a 210 basis point improvement year over year, but down from our 16.2% estimate. The gross margin was surprisingly solid when considering the significant revenue shortfall. Margins benefited from favorable product mix, structural improvement and cost discipline. In addition, adj. EBITDA margins improved year over year as well (5.0% vs 4.1%).
Noble Virtual Conference. On February 4th, Heidy Chow, CFO, and Peter Lin, Senior Manager FP&A, presented at the Noble Virtual Conference to the investment community. The presentation highlighted strong engagement on its core franchise and recent releases, a busy 2026 release roadmap, and the advancement of its digital assets strategy. The full presentation is available here.
Strong ARK Engagement. The ARK franchise remains a key driver of engagement and monetization for the company, generating nearly $1 billion in revenue, more than 100 million installs, and 4.2 billion gameplay hours since its release. Management noted that the ARK franchise benefits from a highly active core audience, with 42% of players averaging 380 hours of total gameplay. Furthermore, management noted a 55% paid downloadable content (DLC) conversion rate for ARK, with new content releases driving spikes in player activity.
Noble Capital Markets Research Report Thursday, February 12, 2026
Companies contained in today’s report:
E.W. Scripps (SSP)/OUTPERFORM – Enterprise Transformation Plan EuroDry (EDRY)/OUTPERFORM – Increasing 2026 Estimates; Upgrading Rating to Outperform Euroseas (ESEA)/OUTPERFORM – Tight Feeder Market Supports Rate Upside; Coverage Strengthens Through 2028 Great Lakes Dredge & Dock (GLDD)/MARKET PERFORM – Going Private At All-Time High InPlay Oil (IPOOF)/OUTPERFORM – Updating 2025 Estimates; Bond Offering Completed
E.W. Scripps (SSP/$3.64 | Price Target: $10) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Enterprise Transformation Plan Rating: OUTPERFORM
Transformation plan announced. E.W. Scripps launched an enterprise-wide restructuring targeting $125 million to $150 million of incremental annualized EBITDA by 2028, driven by structural cost actions and revenue yield initiatives leveraging AI, automation, and operational realignment. Management emphasized a shift toward a leaner, startup-like operating model while reaffirming investment in journalism and sales capabilities, setting the framework for detailed execution priorities discussed below.
Execution framework. The company identified major cost buckets across administrative functions, technology consolidation, and process redesign, with modeling work underway to refine savings cadence. Management expects months of operational review before final staffing decisions, maintaining a baseline EBITDA framework near $450 million even under softer demand conditions. Beyond expense controls, leadership highlighted opportunities to improve monetization, which informs the evolving growth strategy outlined next.
EuroDry (EDRY/$14.32 | Price Target: $23.5) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Increasing 2026 Estimates; Upgrading Rating to Outperform Rating: OUTPERFORM
Increasing FY 2026 estimates. We have increased our FY 2026 revenue, adjusted EBITDA, and adjusted EPS estimates to $60.8 million, $25.5 million, and $2.82, respectively, from $57.3 million, $22.4 million, and $1.46. The upward revisions are driven by higher expected vessel earnings, with our forecast average TCE rate rising to $14,743 from $13,873 previously.
Eurodry’s sweet spot. Eurodry owns and operates vessels in the middle of the size range of dry bulk carriers, or 50,000 to 85,000 dead weight tons (dwt), which present the most flexible employment opportunities. EDRY’s fleet consists of 11 vessels with a total carrying capacity of 766,420 dwt. With two Ultramax vessels of 63,500 dwt each under construction and scheduled for delivery in the second and third quarters of 2027, the total carrying capacity will increase to 893,000 dwt. Growth will be driven by the charter rate environment, coupled with fleet growth. While EDRY continues to renew and modernize its fleet, it expects to acquire and consolidate smaller owners.
Euroseas (ESEA/$57.46 | Price Target: $72) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Tight Feeder Market Supports Rate Upside; Coverage Strengthens Through 2028 Rating: OUTPERFORM
New time charter for the EM Spetses. Euroseas Ltd. announced a new time charter for its 1,740 twenty-foot equivalent feeder containership, EM Spetses, for a minimum period of 22 to a maximum period of 24 months, at the option of the charterer, at a gross daily rate of $21,500. The new charter will commence on April 12, 2026, in direct continuation of its present charter, and represents a daily increase of over $3,000 compared to the vessel’s current rate.
Incremental EBITDA with Expanded Coverage. The charter is expected to generate approximately $8.9 million in EBITDA over the minimum term and increase Euroseas’ charter coverage to approximately 87% in 2026, 71% in 2027, and 41% in 2028. The higher rate on the new time charter reflects a tight container market with limited vessel availability. Demand in the feeder segment remains strong as operators secure vessels to meet their requirements.
Great Lakes Dredge & Dock (GLDD/$16.95) Joe Gomes jgomes@noblefcm.com | 561-999-2262 Going Private At All-Time High Rating: MARKET PERFORM
To Be Acquired. Yesterday, Great Lakes announced a definitive agreement for Saltchuk Resources, Inc. to acquire Great Lakes for $17 per share, in cash, an aggregate equity value of $1.2 billion, and a total transaction value of $1.5 billion. The $17 per share consideration is in line with our $17 price target on GLDD shares. The per share purchase price represents a 25% premium to Great Lakes’s 90-day volume-weighted average price as of February 10, 2026, as well as a 5% premium to the Company’s all-time high closing price.
A Surprise. We are somewhat surprised by the timing as Great Lakes has substantially completed its new build program and should begin to generate substantial amounts of free cash flow that could be used to repay outstanding debt, repurchase shares, or grow the business. Nonetheless, shareholders are receiving a premium to the shares’ all-time high closing price.
InPlay Oil (IPOOF/$11.4 | Price Target: $15.75) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Updating 2025 Estimates; Bond Offering Completed Rating: OUTPERFORM
Q4 2025 Estimate Revisions. We are adjusting Q4 estimates to reflect softer commodity pricing, with WTI averaging $59.10 per barrel versus our prior $60.00 estimate and wider differentials reducing realized Canadian pricing. We are lowering our revenue, adjusted funds flow (AFF), and AFF per share estimates to C$80.7 million, C$29.1 million, and C$1.04, respectively, from C$88.8 million, C$35.8 million, and C$1.28. Our production estimate remains unchanged at 19,419 boe/d.
FY 2025 Estimate Revisions. We are modestly lowering our full-year revenue, AFF, and AFF per share estimates to reflect lower fourth-quarter estimates. We now forecast revenue of C$290.6 million, AFF of C$112.9 million, and AFF per share of C$4.58, down from C$298.7 million, C$119.5 million, and C$4.85, respectively. Our outlook continues to assume average 2025 production of approximately 17,000 boe/d. We will update our 2026 estimates following the release of InPlay’s 2026 guidance.
Noble Capital Markets Research Report Wednesday, February 11, 2026
Companies contained in today’s report:
Aurania Resources (AUIAF)/OUTPERFORM – A Growing Portfolio of Precious Metals and Critical Mineral Projects DLH Holdings (DLHC)/OUTPERFORM – First Quarter 2026 Results Townsquare Media (TSQ)/OUTPERFORM – Noble Virtual Conference Highlights
Aurania Resources (AUIAF/$0.11 | Price Target: $0.3) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | A Growing Portfolio of Precious Metals and Critical Mineral Projects Rating: OUTPERFORM
Advancing a multi-project portfolio. Auraniais advancing two projects in France: a gold exploration project in Brittany and a nickel recovery project in Corsica. Aurania is also evaluating the recovery of nickel and cobalt from the waste tailings of the former Balangero asbestos mine near Turin, Italy. The projects in Corsica and Italy offer significant environmental benefits for the nearby communities, along with the economic benefit of recovering valuable critical metals. In Ecuador, the company is having productive discussions with government officials to advance its project while pursuing potential strategic partnerships.
Exploration Licenses in Brittany. Aurania, through a wholly owned French subsidiary, was granted three exploration licenses for polymetallic metals, including gold, in the Brittany Peninsula of northwestern France. The three license areas, Epona, Taranis, and Belenos, are in southern Brittany and northern Pays de la Loire in France. Aurania is in the process of identifying all the landowners to seek their support for exploration.
DLH Holdings (DLHC/$5.56 | Price Target: $10) Joe Gomes jgomes@noblefcm.com | 561-999-2262 First Quarter 2026 Results Rating: OUTPERFORM
1Q26 Results. DLH reported revenue of $68.9 million, down from $90.8 million y-o-y, and modestly below our $70.1 million projection. The decline reflects the loss of certain programs to small business set-aside contractors. Adjusted EBITDA was $6.5 million versus our $6.2 million estimate. Net loss was $1.3 million, or a loss of $0.09/sh, versus our estimate of a loss of $1 million, or a loss of 0.07/sh.
Cost Scaling Initiatives. With the loss of the Head Start program and winding down of the CMOP contracts in 2026, DLH undertook some cost reduction measures in the first and second fiscal quarters to align expenses with current revenue volumes. We expect management to closely watch expenses until top line improvement returns.
Townsquare Media (TSQ/$7.18 | Price Target: $15) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Noble Virtual Conference Highlights Rating: OUTPERFORM
Noble Virtual Conference. On February 4th, Bill Wilson, CEO, Stu Rosenstein, co-founder and CFO, and Claire Yenicay, EVP of IR, participated in a fireside chat at the Noble Virtual Conference. The discussion focused on the company’s successful evolution into a digital-first local media powerhouse, sustainable financial model and improving revenue trends. A replay of the presentation can be found here.
Favorable Digital Advertising Outlook. Digital advertising trends are stabilizing, with management noting sequential page view growth from December to January, which is expected to continue in February. While remnant inventory remains a near-term headwind, underlying growth in owned-and-operated sales and core programmatic activity remains strong. Management expects digital advertising to return to mid-single-digit growth in 2026, with a high-single-digit CAGR anticipated over the next five years.
Noble Capital Markets Research Report Tuesday, February 10, 2026
Companies contained in today’s report:
The Beachbody Company (BODI)/OUTPERFORM – Noble Virtual Conference Highlights
The Beachbody Company (BODI/$9.99 | Price Target: $15) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Noble Virtual Conference Highlights Rating: OUTPERFORM
Noble Virtual Conference. On February 5th, the company presented at the Noble Virtual conference. The presentation conducted by Carl Daikeler, Co-founder and CEO, Mark Goldston, Executive Chairman, and Brad Ramberg, CFO, highlighted the completion of a multi-year operational turnaround and favorable growth drivers in its digital fitness and nutrition businesses. A replay of the presentation can be viewed here.
Operational turnaround. Over the past several years, the company has significantly lowered its break-even point from $900 million in 2022 to roughly $180 million today, driven largely by SG&A optimization and the elimination of multi-level marketing sales costs. The new model offers enhanced operating leverage, enabling profitability at lower revenue levels and improving the long term outlook of the company.
Noble Capital Markets Research Report Monday, February 9, 2026
Companies contained in today’s report:
Bit Digital (BTBT)/OUTPERFORM – January Ethereum Metrics Graham (GHM)/MARKET PERFORM – FY3Q26 Results Seanergy Maritime (SHIP)/OUTPERFORM – Increasing Estimates; Raising PT to $17 Titan International (TWI)/OUTPERFORM – Noble Virtual Conference Highlights
Bit Digital (BTBT/$1.8 | Price Target: $5.5) Joe Gomes jgomes@noblefcm.com | 561-999-2262 January Ethereum Metrics Rating: OUTPERFORM
Data. Bit Digital reported its monthly Ethereum (“ETH”) treasury and staking metrics for the month of January 2026. As of month end, the Company held approximately 155,239 ETH versus 155,227 ETH at the end of December. Included in the ETH holdings were approximately 15,236 ETH and ETH-equivalents held in an externally managed fund. The Company’s total staked ETH was approximately 138,266, or about 89% of its total holdings as of January 31st.
Yield and Value. Staking operations generated approximately 344 ETH in rewards during the period, representing an annualized yield of approximately 2.9%. Based on a closing ETH price of $2,449, as of January 31, 2026, the market value of the Company’s ETH holdings was approximately $380.2 million.
Graham (GHM/$83.24) Joe Gomes jgomes@noblefcm.com | 561-999-2262 FY3Q26 Results Rating: MARKET PERFORM
Overview. For 3Q26, Graham delivered another strong quarter, with results supported by the timing of key project milestones, particularly within the defense business, along with contributions from new programs and continued growth across existing platforms.
3Q26 Results. Revenue increased 21% to $56.7 million, driven by solid performance across end markets. We were at $52.5 million. GM of 23.8% was below our 26.7% projections due to mix. Adjusted EBITDA increased 50% to $6 million with an adjusted EBITDA margin of 10.7%. We had forecast $5.8 million. GHM reported adjusted net income of $3.5 million, or $0.31/sh, compared to our estimates of $3.0 million and $0..27/sh.
Seanergy Maritime (SHIP/$10.67 | Price Target: $17) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Increasing Estimates; Raising PT to $17 Rating: OUTPERFORM
Increasing Q4 and FY 2025 estimates. We have increased our FY 2025 revenue, adjusted EBITDA, and adjusted earnings per share (EPS) estimates to $157.0 million, $81.0 million, and $1.14, respectively, from $153.2 million, $77.9 million, and $1.07. Our full year estimates reflect higher fourth quarter revenue, adjusted EBITDA, and EPS of $48.3 million, $28.2 million, and $0.56, respectively, compared to our previous estimates of $44.5 million, $25.0 million, and $0.49. We are now forecasting fourth quarter and full year average time charter equivalent rates of $26,000 per day and $20,672 per day, versus prior forecasts of $23,900 and $20,147. We forecast fourth quarter and full year operating days of 1,800 and 7,163, respectively, compared to our prior estimates of 1,780 and 7,143.
Raising FY 2026 estimates. We have also increased our FY 2026 revenue, adjusted EBITDA, and adjusted EBITDA estimates to $176.2 million, $96.7 million, and $1.70, respectively, from $165.2 million, $89.1 million, and $1.44. We now forecast an average TCE rate of $24,063 compared to our previous estimate of $22,238.
Leadership Changes. In early December, Titan announced CFO David Martin transitioned into a new role as Chief Transformation Officer, while Tony Eheli, former Chief Accounting Officer, was named CFO. In the new CTO role, Mr. Martin will oversee the critical alignment of information technology, including the acceleration of AI adoption, along with human capital and risk management functions and initiatives.
Noble Capital Markets Research Report Friday, February 6, 2026
Companies contained in today’s report:
InPlay Oil (IPOOF)/OUTPERFORM – InPlay Broadens Capital Access with Israeli Bond Issuance SelectQuote (SLQT)/OUTPERFORM – Solid Fiscal Q2 Execution but Carrier Pullback Creates Near-Term Pressure The GEO Group (GEO)/OUTPERFORM – Thoughts on Current Environment
InPlay Oil (IPOOF/$10.97 | Price Target: $15.75) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | InPlay Broadens Capital Access with Israeli Bond Issuance Rating: OUTPERFORM
Bond offering details. InPlay announced a senior unsecured bond issuance in Israel for up to 550 million New Israeli Shekels (NIS), or approximately C$241 million. Three amortization payments of 6% of the principal amount of the bonds will be due on December 15 of 2027, 2028, and 2029, and the fourth and last amortization payment of the remaining 82% will be due on December 15, 2030. The offering is expected to close on or around February 12, 2026, subject to certain conditions.
Expanding capital market access. Beyond the financing itself, we view the transaction as a strategic expansion of InPlay’s funding base outside of Canada. InPlay received interest from over 40 institutional investors in the oversubscribed offering and, to date, has accepted tenders for NIS 550 million of the bonds. The transaction further strengthens InPlay’s diversified financing sources while reducing its overall cost of capital.
SelectQuote (SLQT/$1.03 | Price Target: $5) Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266 Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Solid Fiscal Q2 Execution but Carrier Pullback Creates Near-Term Pressure Rating: OUTPERFORM
Fiscal Q2 results. SelectQuote reported fiscal Q2 revenue of $537.1 million, above our $520.0 million estimate, driven by stronger-than-expected Senior performance. Adj. EBITDA of $84.7 million exceeded our $82.0 million forecast, reflecting near-record 39% adj. EBITDA margins in Senior that more than offset pharmacy reimbursement pressure.
Medicare Advantage headwinds. Management cited pressure from a large national carrier’s decision to reduce strategic marketing spend across all channels. We believe this reflects a deliberate effort to moderate enrollment growth and protect plan profitability following above-trend member additions, rather than any deterioration in underlying demand.
The GEO Group (GEO/$15.48 | Price Target: $35) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Thoughts on Current Environment Rating: OUTPERFORM
Environment. The current operating environment remains charged, as evidenced by the daily news. Nonetheless, we would point out that a key platform of the Trump Administration remains illegal immigration, and we do not expect that to change. Funding remains available under The One Big Beautiful Bill. And, historically, enforcement operations remain ongoing even in the face of a government shutdown.
Less New Awards Than Anticipated. The pace of new awards has been less than we had expected over the past few months. Whether this is just a temporary pause due to the significant number of new awards in 2025, the most recent new contract for GEO was the December skip tracing services contract worth up to $121 million of revenue over a two year period.
Noble Capital Markets Research Report Thursday, February 5, 2026
Companies contained in today’s report:
Lucky Strike Entertainment (LUCK)/OUTPERFORM – Event Business Turns A Corner
Lucky Strike Entertainment (LUCK/$7.33 | Price Target: $14.5) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Event Business Turns A Corner Rating: OUTPERFORM
Q2 Results. The company reported revenue of $306.9 million, largely in line with our estimate of $310.0 million, while adj. EBITDA of $77.5 million, missed our estimate of $97.3 million by roughly 20%. Notably, the quarter was driven by increased investment, largely related to marketing, which supported top-line results while pressuring adj. EBITDA in the quarter.
Clear inflection point. The company reported same-store sales growth of 0.3%, while this figure may seem modest, we view it as a favorable development. Notably, the events business, which has been the primary drag on same-store sales in recent periods, improved significantly during the quarter and was roughly flat y-o-y. Furthermore, in January, the event business experienced double-digit growth before being impacted by a major snowstorm.
Noble Capital Markets Research Report Wednesday, February 4, 2026
Companies contained in today’s report:
Alliance Resource Partners (ARLP)/OUTPERFORM – Q4 and FY2025 Financial Results Exceed Expectations Comstock (LODE)/MARKET PERFORM – Operational Update Following Webinar Sky Harbour Group (SKYH)/OUTPERFORM – $150 Million Bond Pricing The Beachbody Company (BODI)/OUTPERFORM – Executing Strategic Growth Initiatives V2X (VVX)/OUTPERFORM – Some Recent News
Alliance Resource Partners (ARLP/$25 | Price Target: $33) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Q4 and FY2025 Financial Results Exceed Expectations Rating: OUTPERFORM
Fourth quarter and full year 2025 financial results. Alliance reported adjusted fourth quarter revenue, adj. EBITDA and earnings per unit (EPU) of $535.5 million, $191.1 million, and $0.64, respectively, compared to $590.1 million, $124.0 million, and $0.12 during the prior year period. We had forecast revenue, adj. EBITDA and EPU of $560.1 million, $182.9 million, and $0.57, respectively. While the quarter was impacted by lower coal sales, which impacted revenue, operating expenses were lower, and net income on equity method investments exceeded our estimate. Full year 2025 adj. EBITDA and EPU of $698.7 million and $2.40, respectively, were above our estimates of $690.5 million and $2.33, respectively.
Management guidance for 2026. Total coal sales are expected to be in the range of 33.75 million to 35.25 million tons, while the sales price of coal per ton is expected to be in the range of $54.00 to $56.00. Segmented adjusted EBITDA expense per ton sold is expected to be $37.00 to $39.00. ARLP has committed and priced 32.2 million tons of its 2026 sales volume, including 30.5 million tons for the domestic market and 1.7 million tons for the export market.
Comstock (LODE/$2.94) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Operational Update Following Webinar Rating: MARKET PERFORM
Industry-scale facility fully permitted. Comstock has received all required regulatory approvals for its first industry-scale solar recycling facility in Silver Springs, Nevada, including the Written Determination Permit and the Air Quality Permit from the Nevada Division of Environmental Protection. The permits cover the full scope required to commission a facility designed to process more than 3.0 million panels per year, representing up to 100 thousand tons of end-of-life solar materials. Installation, testing, and commissioning are expected to occur during the first quarter of 2026.
Unit economics. Comstock’s recycling process is certified as a zero-landfill solution and designed to handle all major solar panel types, eliminating contaminants and recovering aluminum, glass, and metal-rich tailings. Comstock estimates that facility-level economics reflect a combination of upfront processing fees and proceeds from recovered materials, resulting in revenue of ~$750 per ton against all-in operating costs of roughly $150 per ton. Based on current operating data, profitability is achievable at relatively low utilization levels.
Sky Harbour Group (SKYH/$9.31 | Price Target: $23) Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266 Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 $150 Million Bond Pricing Rating: OUTPERFORM
Pricing announced for upcoming bond issuance. Sky Harbour priced $150 million of Series 2026 private activity tax-exempt bonds at par to yield 6.0%, with a mandatory tender on January 1, 2031, and an expected closing on or about February 12, 2026. The transaction is another example of the company’s tax-advantaged financing toolkit and deepens its access to institutional municipal investors.
Deal upsized on strong investor demand. The transaction was initially marketed at $100 million but was upsized to $150 million after receiving approximately $450 million of orders from 18 institutional investors. In our view, the oversubscription supports growing investor comfort in the asset base, the cash flow ramp, and the repeatable development playbook.
The Beachbody Company (BODI/$11.65 | Price Target: $15) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Executing Strategic Growth Initiatives Rating: OUTPERFORM
P90X Generation Next. On February 3, the company launched P90X Generation Next, the first new P90X fitness program in over a decade. Notably, the P90X franchise launched in 2005 and became one of the best-selling home fitness programs of all time, with more than 20 million people worldwide participating. Furthermore, the new exercise program is available on the company’s digital streaming platform BODi, and supported by brand partners and a new line of exercise supplements.
Digital streaming platform. Importantly, P90X Generation Next is available on the company’s digital platform, BODi, with a subscription. Moreover, subscribers can access the full P90X catalog of 145 workouts, including the original P90X, for $9.99/month. Additionally, the company offers a broader BODi membership priced at $19/month or an annual plan for $179/year that includes 8,000+ workouts, 140+ step-by-step programs, and nutrition plans.
V2X (VVX/$66.4 | Price Target: $72) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Some Recent News Rating: OUTPERFORM
Recent News. There has been a flurry of positive recent news on V2X, from confirmation of the T-6 award to new partnerships with Amazon and Google to an award under the Missile Defense Agency’s (MDA) Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) to support Golden Dome to advancement to Phase II of the U.S. Army’s Flight School Next (FSN) competition. Below, we highlight three of the developments.
T-6 Award. The U.S. Court of Federal Claims denied the protest and upheld the Air Force’s selection of V2X for the $4.3 billion T-6 Contractor Operated and Maintained Base Supply (COMBS) contract. With a period of performance through July 2034, the $4.3 billion award could generate an average of $475 million in annual revenue.
Noble Capital Markets Research Report Monday, February 2, 2026
Companies contained in today’s report:
Eledon Pharmaceuticals (ELDN)/OUTPERFORM – Phase 1b Data Presented But Tegoprubart Remains Misunderstood Kelly Services (KELYA)/OUTPERFORM – We Have Assumed Control Resources Connection (RGP)/OUTPERFORM – More Cost Out
Eledon Pharmaceuticals (ELDN/$2.2 | Price Target: $10) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 Phase 1b Data Presented But Tegoprubart Remains Misunderstood Rating: OUTPERFORM
Phase 1b Data For Second Year After Transplantation Presented. Eledon presented data from its Phase 1b trial at the American Society of Transplant Surgeons (ASTS) meeting in January 2026. The presentation included data from 8 patients that had reached 24 months after transplantation, compared with 12 patients evaluated 12 months after transplantation presented in August 2025. These new data show a continued improvement in kidney function during the second year.
New Data Show Durability With Improvements. The 24-month data shows eGFR in tegoprubart patients continued to improve during months 12 to 24 after transplantation. The eGFR levels were restored to normal levels within 1 month after transplantation and were maintained for up to 2 years. Although this is a small number of patients, we see the result as consistent with prior data and our expectations for organ survival.
Kelly Services (KELYA/$10.79 | Price Target: $17) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 We Have Assumed Control Rating: OUTPERFORM
Sale Completed. On Friday, Hunt Equity Opportunities, a subsidiary of Hunt Companies, acquired the 3,039,240 Class B shares previously held by the Terence E. Adderley Revocable Trust K. Hunt now has effective control of Kelly, as owner of 92.2% of the voting Class B shares. According to James Christopher Hunt, CEO of Hunt, “Hunt is very excited about the value creation opportunities ahead for Kelly. We look forward to supporting Chris Layden, CEO of Kelly, and the rest of the Company’s management team as they focus on accelerating growth and realizing Kelly’s full potential.”
Board Changes. As part of the transition, four Hunt designees have been named to Kelly’s Board, with five former Kelly directors leaving the Board, which will now consist of 8 members. Mr. Hunt has been named Chairman of the Board.
Resources Connection (RGP/$4.53 | Price Target: $10) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 More Cost Out Rating: OUTPERFORM
Cost Out. Last week, RGPauthorized a reduction of its global management and administrative workforce intended to reduce cost structure through enhanced efficiencies and streamlined operations. The Company expects the reduction in force to result in annual cost savings of $6-$8 million. Restructuring charges of approximately $3 million are expected to be recognized in the third and fourth quarters of fiscal 2026. The workforce reduction should be substantially completed by the end of fiscal 2026.
Additive. Last week’s announcement is on top of the October RIF, which also is expected to yield annual savings of $6 million to $8 million. Combined, the two actions could reduce expenses in the $12-$16 million range. These efforts are part of an even deeper assessment across the entire organization to streamline organizational structure, simplify processes, and adopt automation and AI to ensure RGP’s cost structure is adequately sized to the current revenue levels.
Noble Capital Markets Research Report Friday, January 30, 2026
Companies contained in today’s report:
1-800-Flowers.com (FLWS)/MARKET PERFORM – Leaning Into Its Efficiency Initiatives AZZ (AZZ)/OUTPERFORM – Secular Tailwinds Expected to Sustain Sales and Cash Flow Growth Unicycive Therapeutics (UNCY)/OUTPERFORM – OLC Resubmission Accepted For FDA Review
1-800-Flowers.com (FLWS/$4.63) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Leaning Into Its Efficiency Initiatives Rating: MARKET PERFORM
Difficult quarter. Fiscal Q2 revenue of $702.2 million declined by a disappointing 9.5%, but was in line with our conservative estimate of $702.0 million. Adj. EBITDA was $98.1 million, beating our estimate of $89.5 million by 9.6%. In our view, the results reflect the company’s initiative to focus on efficient use of marketing spend.
Cost actions are working, but benefits are not fully visible yet. Operating expenses declined meaningfully year over year, and the company has already achieved approximately $15 million in annualized run-rate cost savings. However, temporary consulting and incentive compensation costs related to the transformation are delaying the full earnings benefit. As these costs roll off, underlying profitability should improve.
AZZ (AZZ/$124.97 | Price Target: $140) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Secular Tailwinds Expected to Sustain Sales and Cash Flow Growth Rating: OUTPERFORM
Updating estimates. While our FY2026 and FY2027 estimates are unchanged, we anticipate higher gross margins in the AZZ Metal Coatings and Precoat Metals segments beginning in FY2028. The company’s three-year plan established a goal of generating EBITDA margins of greater than 22.0% of revenue by 2028. Our revisions more closely align our forward estimates with this goal, and our estimates through FY2031 may be found in the financial model at the end of this report.
Secular growth drivers. We think AZZ is poised to benefit from multi-year secular drivers of growth. These include: 1) growth in infrastructure spending, 2) reshoring/nearshoring manufacturing, 3) migration to pre-painted steel and aluminum, 4) conversion from plastics to aluminum, 5) conversion to coil coating, and 6) growth in data centers.
Unicycive Therapeutics (UNCY/$6.67 | Price Target: $60) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 OLC Resubmission Accepted For FDA Review Rating: OUTPERFORM
Unicycive Announced FDA Acceptance Of The NDA. Unicycive announced FDA acceptance of its resubmission of the New Drug Application (NDA) for OLC (oxylanthanum citrate). The resubmitted application has been classified as a Class II complete response, with a six-month review period. June 29, 2026 is the new PDUFA date, the statutory date for the application to be answered. This is consistent with our expected timeframe for OLC approval and launch.
We See NDA Acceptance As A Significant Milestone. In June 2025, an FDA manufacturing inspection found compliance deficiencies at the facility of a contract manufacturer. This stopped the NDA approval process just weeks before the PDUFA (Prescription Drug User Fee Act) date of June 28, 2025. The review of the preclinical, clinical, safety, and manufacturing data had been completed. We believe this will result in prompt approval.
Noble Capital Markets Research Report Thursday, January 29, 2026
Companies contained in today’s report:
Alliance Resource Partners (ARLP)/OUTPERFORM – Upcoming FY 2025 Financial Results and 2026 Corporate Guidance Great Lakes Dredge & Dock (GLDD)/OUTPERFORM – Updated Model; Raising Price Target Hemisphere Energy (HMENF)/OUTPERFORM – 2026 Corporate Guidance Released, Revising Estimates
Alliance Resource Partners (ARLP/$24.31 | Price Target: $33) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Upcoming FY 2025 Financial Results and 2026 Corporate Guidance Rating: OUTPERFORM
Fourth quarter and full year 2025 financial results. Alliance will report its fourth quarter and full year 2025 financial results before the market opens on Monday, February 2, 2026. Management will host an investor conference call and webcast the same day at 10:00 am ET. Along with the 2025 operational and financial results, we expect ARLP to release its 2026 corporate guidance and outlook.
Noble Estimates. We forecast fourth quarter 2025 revenue, EBITDA, and EPU of $560.1 million, $182.9 million, and $0.57, respectively. Our full year 2025 revenue, EBITDA, and EPU estimates are $2.2 billion, $690.5 million, and $2.33, respectively. Our fourth quarter EPU estimate reflects an expected unrealized and non-cash loss on the marked-to-market value of ARLP’s bitcoin holdings, which has no impact on our EBITDA estimate. We forecast 2026 revenue, EBITDA, and EPU of $2.3 billion, $700.5 million, and $2.65, respectively.
Great Lakes Dredge & Dock (GLDD/$15.32 | Price Target: $17) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Updated Model; Raising Price Target Rating: OUTPERFORM
Updated Model. We tweaked our 4Q25 projections to include higher expected interest expense and the projected $3 million charge related to the payoff of the second lien term loan. As a result, our 4Q25 EPS estimate drops to $0.22 from a prior $0.26. The drop is not related to operational performance, and the debt swap will reduce overall interest expense going forward.
Cash Flow. With the completion of the new build program in early 2026, we expect Great Lakes to use the substantial free cash flow generation towards debt reduction. Over the past 5 years, capex has averaged $136 million annually. Roughly $25 million is for maintenance capex, and we do expect some additional capex as Great Lakes modernizes its fleet. Nonetheless, we estimate there should be at least $90 million on an annual basis for debt reduction.
Hemisphere Energy (HMENF/$1.53 | Price Target: $2.6) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | 2026 Corporate Guidance Released, Revising Estimates Rating: OUTPERFORM
Outlook for 2026. Hemisphere Energy released 2026 guidance outlining a C$12.0 million capital program, expected to support ~6.3% growth in average annual production to approximately 3,900 boe/d, compared to our estimated 2025 average of 3,670 boe/d. The capital program is expected to be fully funded from adjusted funds flow and is designed to provide disciplined year-over-year growth while protecting the balance sheet and maintaining shareholder returns. Production is expected to remain 99% heavy oil, supported primarily by polymer flood enhanced oil recovery at Atlee Buffalo.
Updating estimates. We are trimming our 2026 revenue estimate to C$89.9 million from C$93.7 million due to lower production and commodity price estimates. Our production and WTI crude oil price estimates are now 3,900 boe/d and US$60 compared to our previous estimates of 4,080 boe/d and US$65. Despite the lower revenue outlook, adjusted funds flow (AFF) increased modestly to C$40.0 million from C$39.7 million, reflecting lower assumed operating costs, improved differentials, and a reduced royalty burden. AFF per share remains unchanged at C$0.40.
Noble Capital Markets Research Report Wednesday, January 28, 2026
Companies contained in today’s report:
Cardiff Oncology (CRDF)/OUTPERFORM – Phase 2 Data Announced With Management Changes Conduent (CNDT)/OUTPERFORM – New CEO Appointment FAT Brands (FAT)/NOT RATED – Files Voluntary Chapter 11; Terminating Research Coverage Kuya Silver (KUYAF)/OUTPERFORM – Letter of Intent to Purchase the Camila Processing Plant; Expansion Planned Twin Hospitality (TWNP)/NOT RATED – Files Voluntary Chapter 11; Terminating Research Coverage
Cardiff Oncology (CRDF/$2 | Price Target: $12) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 Phase 2 Data Announced With Management Changes Rating: OUTPERFORM
Cardiff Made Two Significant Announcements. New data from the Phase 2 CRDF-004 trial testing onvansertib as a first line treatment for metastatic colorectal cancer was announced as expected. Patients in the high-dose onvansertib group showed a large benefit in overall response rates (ORR) and progression free survival (PFS). Separately, the CEO and CFO have left the company. Board Member Dr. Mani Mohindru was named Interim CEO.
Phase 2 Trial Design. As discussed in our January 5 report,CDRF-004 is a Phase 2 dose-finding trial testing two doses of onvansertib in combination with two standard-of-care (SOC) regimens against the standard of care regimens alone. It enrolled 110 patients with RAS-mutated metastatic colorectal cancer, mCRC. Its primary endpoint is objective response rate (ORR). Secondary endpoints include progression-free survival (PFS), duration of response (DOR) and safety. These endpoints were selected to guide the design of Phase 3.
Conduent (CNDT/$1.61 | Price Target: $7) Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266 Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 New CEO Appointment Rating: OUTPERFORM
Leadership transition at a natural inflection point. Conduent announced that Harsha V. Agadi has been appointed Chief Executive Officer, succeeding Cliff Skelton, with Margarita Paláu-Hernández named independent Chair of the Board. The change follows a multi-year period of portfolio rationalization, asset divestitures, and balance sheet repair. In our view, the move marks a clear emphasis on operational execution.
A shift toward speed and accountability. We view Agadi’s appointment as a logical next step for the company. His background includes senior operating and leadership roles across large, complex organizations such as Little Caesars, Church’s Chicken, Friendly’s, and Crawford & Company. We expect an early focus on leadership depth, decision velocity, and operational accountability, with an emphasis on accelerating the company’s return to revenue and cash flow growth. In our view, this signals a move from stabilization to performance.
FAT Brands (FAT/$0.26) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Files Voluntary Chapter 11; Terminating Research Coverage Rating: NOT RATED
Chapter 11. Late Monday night, FAT Brands announced it has commenced voluntary chapter 11 proceedings in the U.S. Bankruptcy Court for the Southern District of Texas. The Company plans to use the filings to deleverage the balance sheet, maximize value for its stakeholders, and support continued growth of its brands.
Precipitating Factor? It appears the tipping point for FAT to file the voluntary chapter 11 was Investor 352 Fund, the Company’s largest bondholder, earlier on Monday announcing it was suing FAT Brands for $109 million and promised Class B Common stock tied to ownership of Twin Peaks, as it was issued by Twin Hospitality.
Kuya Silver (KUYAF/$0.82 | Price Target: $3.5) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Letter of Intent to Purchase the Camila Processing Plant; Expansion Planned Rating: OUTPERFORM
Processing plant acquisition. Kuya Silver signed a Letter of Intent (LOI) to purchase 100% of SMRL Camila, the company that owns the Camila conventional flotation plant, for US$7.8 million, subject to closing conditions. The Camila plant is currently processing Kuya Silver’s mineralized material to produce silver and other metal concentrates on a toll-milling basis. The plant is located on a key transport corridor between the Bethania mine and Lima, Peru, where concentrate is shipped to port. Execution of a definitive agreement is subject to the completion of legal, financial, environmental, and technical due diligence.
Scalable processing capacity. The Camila plant currently operates at 150 metric tonnes per day with plans to increase production capacity to 300 to 350 tonnes per day, which Kuya Silver expects to undertake after closing the acquisition. The expansion is projected to require an additional capital investment in the range of US$0.7 million to US$1.0 million.
Twin Hospitality (TWNP/$0.35) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Files Voluntary Chapter 11; Terminating Research Coverage Rating: NOT RATED
Chapter 11. Along with parent company FAT Brands, Twin Hospitality commenced voluntary chapter 11 proceedings in the U.S. Bankruptcy Court for the Southern District of Texas. Twin Hospitality plans to use the filings to deleverage the balance sheet, maximize value for its stakeholders, and support the continued growth of its brands.
Precipitating Factor? It appears the tipping point for Twin Hospitality to file the voluntary chapter 11 was Investor 352 Fund, FAT Brands’ largest bondholder, earlier on Monday announcing it was suing FAT Brands for $109 million and promised Class B Common stock tied to ownership of Twin Peaks, as it was issued by Twin Hospitality. FAT Brands and Twin Hospitality are seeking joint administration of the Chapter 11 cases under the caption “In re FAT Brands Inc., et al.”
Noble Capital Markets Research Report Tuesday, January 27, 2026
Companies contained in today’s report:
Graham (GHM)/MARKET PERFORM – Adds a Third Pillar
Graham (GHM/$76.25) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Adds a Third Pillar Rating: MARKET PERFORM
An Acquisition. Graham has acquired FlackTek, a pioneer in advanced mixing and material processing solutions. The acquisition adds advanced materials processing as a third core platform for Graham, alongside Graham Manufacturing, specializing in vacuum & heat transfer, and Barber-Nichols, specializing in turbomachinery. FlackTek adds a proven and defensible product portfolio with a shared customer base and an installed footprint that extends across the full value chain, from upstream to downstream production and quality control.
Details. The purchase price is $35 million, which was paid 85% in cash and 15% using 75,818 GHM shares. There is a potential $25 million in future performance-based cash earnouts over 4 years based upon achieving progressively increasing adjusted EBITDA performance targets. The base purchase price is approximately 12x FlackTek’s projected 2026 adjusted EBITDA. FlackTek generates approximately $30 million in annualized revenue.
Noble Capital Markets Research Report Monday, January 26, 2026
Companies contained in today’s report:
The GEO Group (GEO)/OUTPERFORM – Expansion of Credit Facility
The GEO Group (GEO/$18.55 | Price Target: $35) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Expansion of Credit Facility Rating: OUTPERFORM
Credit Facility. The GEO Group amended its Credit Agreement, increasing GEO’s revolving credit facility to $550 million from a prior $450 million. The increase was effective as of January 20th. The increase provides the Company with additional financial flexibility, in our view, to further invest in growth opportunities and/or increase the share repurchase activity.
Share Repurchases. Recall, back in November, GEO announced an expansion of its share repurchase authorization to $500 million and extended the expiration date to December 31, 2029. As of November 6, 2025, the Company had approximately $458 million of repurchase authorization available under the share repurchase program. At the current price, the $100 million, if all used to repurchase shares, would further reduce the share count by approximately 5.38 million shares.
Noble Capital Markets Research Report Friday, January 23, 2026
Companies contained in today’s report:
Commercial Vehicle Group (CVGI)/OUTPERFORM – Some Green Shoots? Updated Estimates Kuya Silver (KUYAF)/OUTPERFORM – Mine Development and Balance Sheet Strength Support 2026 Ramp-Up
Commercial Vehicle Group (CVGI/$1.63 | Price Target: $4) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Some Green Shoots? Updated Estimates Rating: OUTPERFORM
Updated Estimates. We tweaked our fourth quarter 2025 estimates after speaking with management. The changes do not impact our belief in the investment case for Commercial Vehicle Group. We maintained our revenue estimate at $146 million. Gross margin has been lowered to 10.3% from 11% previously. We are now estimating an adjusted net loss of $5 million, or $0.15 per share. Adjusted EBITDA is now $2.8 million. For the full year, we are at revenue of $640.2 million and adjusted EBITDA of $18.3 million.
Green Shoots? Recent data from FTR and ACT could indicate an improved Class 8 truck environment in 2026, although we would need to see multiple months of positive developments before jumping in with both feet. According to FTR, December Class 8 truck orders of 42,200 units were the highest level since October 2022. Meanwhile, ACT raised its expectation for Class 8 production in 2026 to 246,000 units, up from a prior 205,000, and nearly flat with 2025.
Kuya Silver (KUYAF/$0.73 | Price Target: $3.5) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Mine Development and Balance Sheet Strength Support 2026 Ramp-Up Rating: OUTPERFORM
Fourth Quarter Performance. The company mined 1,999 tonnes of mineralized material and processed 1,570 tonnes. Average processed grades were 6.0 oz/t silver (186.6 g/t), 1.40% lead, and 1.10% zinc, or 8.5 oz/t silver equivalent (264 g/t). Recoveries averaged 73.3% for silver, 79.1% for lead, and 57.1% for zinc. Metal processed included 7,724 ounces of silver, 18 tonnes of lead, and 15 tonnes of zinc. Sales included 5,441 ounces of silver, 15 tonnes of lead, and 8 tonnes of zinc, representing 6,194 silver-equivalent ounces, with silver contributing 88%.
Private Placement Financing. Kuya closed a brokered private placement raising gross proceeds of C$25.5 million. The company intends to pursue either the acquisition of an operating plant near the mine or the construction of a plant at the Bethania site to vertically integrate silver concentrate production. As mine production expands toward the Phase 1 target of 350 tonnes per day, Kuya expects more consistent processing, improved silver recoveries, and the recovery of minor gold and copper currently lost in the toll-milling process.
Noble Capital Markets Research Report Wednesday, January 21, 2026
Companies contained in today’s report:
NN (NNBR)/OUTPERFORM – Adds a New Director Power Metallic Mines Inc. (PNPNF)/OUTPERFORM – From Legacy Nickel to District-Scale Polymetallic System
NN (NNBR/$1.48 | Price Target: $6) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Adds a New Director Rating: OUTPERFORM
A Board Addition. NN added T ed White to its Board of Directors, effective immediately. Mr. White is co-founder of Legion Partners Asset Management, one of NN’s largest shareholders, owning approximately 9.55% of the outstanding common as of the date of the agreement, as well as economic exposure to another 5.99% of the Company’s shares. Mr. White will join the Board’s Strategic Committee, which was formed to evaluate a broad range of strategic, financing, and other alternatives to enhance shareholder value.
Cooperation Agreement. In connection with this appointment, the Company entered into a cooperation agreement with Legion Partners. The Legion cooperation agreement contains a customary standstill, voting commitment, and related provisions. Legion’s ownership is capped at 19.9% of the outstanding NNBR shares.
Power Metallic Mines Inc. (PNPNF/$1.17 | Price Target: $2.65) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | From Legacy Nickel to District-Scale Polymetallic System Rating: OUTPERFORM
Initiating Coverage with an Outperform rating. Power Metallic Mines Inc. (OTCQB: PNPNF, TSXV: PNPN) is a Québec-based mineral exploration company advancing a high-grade polymetallic discovery that has evolved into a district-scale opportunity. Recent discoveries at the Nisk Project have shifted the investment thesis from a legacy nickel-sulphide asset to a high-grade copper-platinum group elements (PGE), nickel, gold, and silver system with emerging scale and continuity. Target metals, including copper, nickel, cobalt, platinum, and palladium, are integral to electrification, industrial manufacturing, and critical mineral markets. Our price target is US$2.65 per share or C$3.65 per share.
Lion Zone Discovery. The investment case is anchored by the Lion Zone, a high-grade, copper-dominant orthomagmatic polymetallic discovery that represents the core value driver within the broader Nisk land package. Drilling at Lion has returned exceptional grades, including 11.6 meters grading 8.3% copper, 9.6 g/t palladium, and 2.6 g/t platinum, materially enhancing the project’s value profile beyond nickel alone. Follow-up drilling at the nearby Tiger Zone has confirmed the presence of similar mineralization along trend, supporting the interpretation that Lion-style mineralization is repeatable rather than isolated.
Noble Capital Markets Research Report Tuesday, January 20, 2026
Companies contained in today’s report:
Information Services Group (III)/OUTPERFORM – AI Acquisition Kratos Defense & Security (KTOS)/OUTPERFORM – A Strong Start to the Year
Information Services Group (III/$5.89 | Price Target: $6.5) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 AI Acquisition Rating: OUTPERFORM
AI Maturity Index. Information Services Group has acquired the AI Maturity Index, a SaaS platform that allows organizations to assess the AI readiness of their workforces and improve their employees’ ability to leverage AI technology. The AI Maturity Index provides ISG with a high-impact, scalable entry point into every client’s AI journey. In its short time on the market, the AI Maturity Index has assessed more than 6,000 individual AI users and collected more than 400,000 data points—adoption that will expand exponentially as the platform gains broader use. Terms of the deal were not released.
Acceleration. The acquisition is part of a broader AI acceleration strategy by ISG that includes the formation of an AI Acceleration Unit that brings an integrated, expert-led approach to helping clients rapidly scale AI, and the upcoming launch of a proprietary insights platform with an AI-powered “intelligence advisor” to give organizations real-time access to highly sought-after ISG data and analysis.
Kratos Defense & Security (KTOS/$130.72 | Price Target: $145) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 A Strong Start to the Year Rating: OUTPERFORM
Raising PT to $145. We are maintaining our Outperform rating and raising our price target on KTOS shares to $145 from a previous $95. KTOS shares are up 72% YTD, compared to 1.4% for the S&P 500, continuing the outperformance seen over the past three years. We believe the abundant opportunities across the business, potential positive increases in the defense budget, and solid execution present strong financial upside potential.
Defense Budget. Interest in the defense sector is partially being driven by the Trump Administration’s goal to increase the 2027 Defense budget by 50% to $1.5 trillion, up from approximately $1 trillion in 2026. Significantly, as relates to Kratos, a key focus of any increased spending will be on drones, autonomous systems, cybersecurity, and space, all key areas of Kratos.
Noble Capital Markets Research Report Friday, January 16, 2026
Companies contained in today’s report:
Alliance Entertainment Holding (AENT)/OUTPERFORM – Acquires Formidable Technology Company CoreCivic, Inc. (CXW)/OUTPERFORM – Some Model Refinements Ocugen (OCGN)/OUTPERFORM – Preliminary Phase 2 Data From OCU410 Shows Improvements in dAMD Geographic Atrophy
Alliance Entertainment Holding (AENT/$7.6 | Price Target: $11) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Acquires Formidable Technology Company Rating: OUTPERFORM
Dynamic acquisition. On December 31, 2025, the company acquired Endstate, a technology company focused on NFC-enabled authentication, digital product identity, and authenticated resale infrastructure for physical goods. Following the acquisition, the company formed a new wholly owned subsidiary, Endstate Authentic LLC. Details of the acquisition were not disclosed.
Vinyl is just the start. Notably, the Endstate technology is currently used by Alliance Authentic for the sale of limited-edition, numbered, blockchain-authenticated vinyl records and a commission-based secondary marketplace that is expected to generate high-margin recurring revenue. Importantly, while the company currently only offers vinyl on this platform, we believe there is a significant opportunity for product category growth, given the company’s large selection of physical media and collectables.
CoreCivic, Inc. (CXW/$19.91 | Price Target: $28) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Some Model Refinements Rating: OUTPERFORM
Model Refinements. Pre fourth quarter earnings, we went over our model and made some modest adjustments, as well as incorporated 2026 quarterly estimates. With the strong new contract awards in 2025, increased detention populations, and potential for additional awards in 2026, we believe CoreCivic is well positioned to post strong 2026 full year results.
Populations Continue to Rise. Overall, the ICE detainee population continues to increase, hitting just under 69,000 at year-end. This is up from approximately 39,000 at the end of 2024. We expect to see ICE detainee populations continue to increase over the course of 2026 as ICE brings on additional enforcement personnel. Increased populations bode well for CoreCivic.
Ocugen (OCGN/$1.62 | Price Target: $8) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 Preliminary Phase 2 Data From OCU410 Shows Improvements in dAMD Geographic Atrophy Rating: OUTPERFORM
Positive Preliminary Data From The OCU410 Trial. Ocugen announced first data from its Phase 2 ArMaDa trial testing OCU410 in Geographic Atrophy associated with dry Age-related Macular Degeneration (GA-dAMD). The announcement included the patients who have reached 12 months after treatment, with 23 out of the total 51 patients enrolled. The data shows an overall 46% reduction in lesion growth compared with controls. We see this as a highly meaningful difference.
OCU410 Is A Single-Treatment Gene Therapy. OCU410 is being developed as gene therapy for patients with GA secondary to dry AMD. A single OCU410 intravitreal injection delivers RORA (retinoid-related orphan receptor alpha), a nuclear receptor that regulates key pathways involved in retinal homeostasis with four mechanisms of action.
Noble Capital Markets Research Report Thursday, January 15, 2026
Companies contained in today’s report:
Nicola Mining Inc. (HUSIF)/OUTPERFORM – Preparing for Growth: Expanding Milling Capacity
Nicola Mining Inc. (HUSIF/$0.72 | Price Target: $1.2) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Preparing for Growth: Expanding Milling Capacity Rating: OUTPERFORM
Upsized Private Placement Financing. Due to strong support from shareholders and new institutional investors, Nicola Mining upsized its previously announced non-brokered private placement from C$1.0 million to C$3.0 million with the issuance of up to a total of ~3.3 million units at a price of C$0.90 per unit, including ~1.1 million issued during the first closing on the same terms. Each unit will consist of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of C$1.10 per share for a period of three years following the closing of the offering. The expiry of the warrants may be accelerated subject to certain conditions.
Use of Proceeds. Nicola’s Merritt Mill is the sole facility in British Columbia permitted to receive and process third-party gold and silver feed from across the province. Funds generated from the financing will be used for the purchase and installation of milling equipment to expand Merritt Mill processing capacity from ~200 tonnes per day to ~500 tonnes per day, the addition of a secondary ball mill, supplementary cleaner flotation cells, and associated pumping infrastructure. Spare bowl and mantle assemblies may be procured to support routine crusher maintenance and ensure operational reliability.
Noble Capital Markets Research Report Tuesday, January 13, 2026
Companies contained in today’s report:
Alliance Entertainment Holding (AENT)/OUTPERFORM – Another Exclusive Partnership Kelly Services (KELYA)/OUTPERFORM – Trust To Sell Controlling Stake; Kelly Adopts Shareholders Rights Plan ONE Group Hospitality (STKS)/OUTPERFORM – Releases Preliminary 4Q and FY25 Sales Results SelectQuote (SLQT)/OUTPERFORM – Extended Maturities Enhances Balance Sheet Flexibility SKYX Platforms (SKYX)/OUTPERFORM – Joining NVIDIA Connect
Alliance Entertainment Holding (AENT/$7.74 | Price Target: $11) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Another Exclusive Partnership Rating: OUTPERFORM
Amazon MGM Studios partnership. Notably, on January 12, the company announced an exclusive multi-year home entertainment licensing agreement with Amazon MGM Studios Distribution. Furthermore, the partnership positions the company as the sole physical media distributor for Amazon MGM titles across DVD, Blu-ray, UHD/4K, and premium collector options in the U.S. and Canada.
Extensive catalog. Notably, Amazon MGM Studios has a number of favorable releases this year, including Fallout Season 2 and Mercy. Additionally, the new releases build on an extensive content catalog, which includes globally recognized franchises such as James Bond and Rocky, as well as several other popular titles, including The Silence of the Lambs and Legally Blonde.
Kelly Services (KELYA/$9.56 | Price Target: $17) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Trust To Sell Controlling Stake; Kelly Adopts Shareholders Rights Plan Rating: OUTPERFORM
A Surprise Sale. Yesterday morning, Kelly Services announced that last Friday, the Terence E. Adderley Revocable Trust K notified Kelly’s Board that it entered into a definitive agreement to sell its entire holding, which constitutes 92.2% of the voting Class B common stock, to a private party. In an amended Schedule 13D filing after the market closed yesterday, the buyer was identified as Hunt Equity Opportunities.
A Large Premium. Hunt is purchasing the 3,039,940 B shares held by the Trust for $106 million, or the equivalent of $34.87/sh. The B shares closed on Friday at $8.86. Historically, the A and B shares have traded in tandem, although there have been periods in which one class has outpaced the other. There is a potential $15.2 million additional payout if the market capitalization of Kelly is equal to or greater than $1.2 billion at any time over the next 48 months. The deal is expected to close by the end of January.
ONE Group Hospitality (STKS/$2.46 | Price Target: $5) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Releases Preliminary 4Q and FY25 Sales Results Rating: OUTPERFORM
4Q25. Preliminary total GAAP revenues for 4Q25 are expected to be approximately $207 million, a 6.8% decrease from $222 million in 4Q24 and below the $223 million consensus estimate. This decline was primarily driven by RA Sushi and Kona Grill closures as part of the portfolio optimization and the change in the Company’s fiscal year. The Grill closures are expected to reduce total GAAP revenues by approximately 2.4%, representing 35% of the expected total GAAP revenue decline.
Calendar Impacts. The fiscal calendar change to 4 equal quarters in 2025 created timing differences that impacted quarterly comparisons: 4Q25 had 91 days versus 92 days in 4Q24. Additionally, the New Year’s Eve holiday shifted from fiscal 2025 to fiscal 2026. The exclusion of New Year’s Eve in the current year impacted total GAAP revenues by approximately 2.5%, representing 37% of the expected total GAAP revenue decline. Fourth quarter comparable sales are expected to decrease by approximately 1.8%.
SelectQuote (SLQT/$1.72 | Price Target: $7) Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266 Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Extended Maturities Enhances Balance Sheet Flexibility Rating: OUTPERFORM
Extended maturity. The company completed a comprehensive refinance that extends its primary debt maturities to January 2031, removing the prior 2027 overhang. The new $325M senior secured term loan and $90M revolver replace the legacy structure and provide a multi-year runway. We view this as a structural reset that repositions the balance sheet to be better-aligned with the company’s long-term growth strategy.
Cost of capital improvements. The new facility delivers immediate interest savings on the revolver (SOFR + 400 bps versus SOFR + 500 bps previously) and embeds a clear path to lower term-loan pricing. The term loan begins at SOFR + 650 bps, with step-downs to SOFR + 600 bps and ultimately SOFR + 550 bps as leverage and Cash EBITDA improve. Operating performance will now have the potential to directly translate into interest savings.
SKYX Platforms (SKYX/$2.21 | Price Target: $5) Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266 Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Joining NVIDIA Connect Rating: OUTPERFORM
NVIDIA partnership elevates SKYX’s technology profile. SKYX joined the NVIDIA Connect Program, gaining access to NVIDIA’s cloud and AI ecosystem to support development of its All-In-One Smart Platform. Management described the relationship as “game-changing,” reinforcing SKYX’s positioning as a technology platform company.
The Smart Platform is designed to be the ceiling-based hub of the home. The SkyPlatform embeds connectivity, safety, and intelligence into a single ceiling-based hub, combining Wi-Fi, voice and app control, speakers, thermostat functions, emergency lighting, and safety features. The platform is designed to be compatible with leading smart assistants such as Apple’s Siri and Amazon’s Alexa, simplifying how homes adopt and manage connected technology.
Noble Capital Markets Research Report Monday, January 12, 2026
Companies contained in today’s report:
Comstock (LODE)/MARKET PERFORM – All Permits Received for Comstock Metals’ Industry-Scale Recycling Facility MustGrow Biologics Corp. (MGROF)/MARKET PERFORM – A Raise V2X (VVX)/OUTPERFORM – A Board Refresh
Comstock (LODE/$3.74) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | All Permits Received for Comstock Metals’ Industry-Scale Recycling Facility Rating: MARKET PERFORM
Receipt of Written Determination Permit. Comstock Metals received its Written Determination Permit from the Nevada Division of Environmental Protection for the processing of waste solar panels and photovoltaics at its planned industry-scale materials recovery facility in Silver Springs, Nevada. Receipt of the permit will result in a fully permitted operation and facility, and is expected to enable Comstock to install, test, and commission the facility on schedule during the first quarter of 2026.
Receipt of Air Quality Permit. Earlier this month, Comstock Metals received approval for the associated Air Quality control permit. Both permits represent the complete scope of required regulatory approvals for commissioning the scale up of a facility designed for processing more than 3.0 million panels per year representing up to 100 thousand tons per year of waste materials. The facility integrates technologies for crushing, conditioning, extracting, and recycling metal concentrates from photovoltaics.
MustGrow Biologics Corp. (MGROF/$0.4328) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 A Raise Rating: MARKET PERFORM
Raise. MustGrow has announced a raise of up to $2 million in a non-brokered private placement of up to 4,000,000 units of the Company at a price of $0.50 per Unit. Each unit will consist of (i) one common share of the Company and (ii) one common share purchase warrant. Each whole warrant will be exercisable for a period of 60 months from the closing date and will entitle the holder to purchase one additional share at an exercise price of $0.70 per warrant share. The closing of the Offering is expected to take place on January 22, 2026, but may take place in one or more tranches, provided that the final tranche closing will occur no later than February 22, 2026.
Use of Proceeds. The Company intends to use the net proceeds raised from the LIFE Offering for inventory production for its mustard-derived organic biofertility product TerraSante, inventory for agricultural products to sell via its Canadian distribution platform NexusBioAg, and working capital and general corporate purposes. Recall, MustGrow ran out of TerraSante product in the second and third quarters last year as demand exceeded management’s initial forecasts.
V2X (VVX/$62.78 | Price Target: $72) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 A Board Refresh Rating: OUTPERFORM
Refresh. V2X’s Board recently elected to increase the size of the Board from 7 members to 10 members and appointed Nicole B. Theophilus, Gerard A. Fasano, and Ross S. Niebergall, effective immediately, as new members of the Board to serve as Class I, Class II, and Class III Directors, respectively.
Theophilus. Ms. Theophilus currently serves as EVP and Chief Administrative Officer of Wabtec Corporation, a global provider of equipment, systems, digital solutions, and value-added services, since July 2024. She previously served as Wabtec’s EVP and Chief Human Resources Officer from August 2020 to March 2024. She was also the EVP and Chief Human Resources Officer for West Corporation from April 2016 to February 2018 and for ConAgra Foods from November 2009 to August 2015.
Noble Capital Markets Research Report Friday, January 9, 2026
Companies contained in today’s report:
AZZ (AZZ)/OUTPERFORM – Third Quarter FY26 Review and Outlook Direct Digital Holdings (DRCT)/MARKET PERFORM – Year End Review: 2026 Could Be A Pivotal Year Resources Connection (RGP)/OUTPERFORM – Pricing Discipline Holds as Volume Pressure Persists
AZZ (AZZ/$117.04 | Price Target: $130) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Third Quarter FY26 Review and Outlook Rating: OUTPERFORM
FY 2026 third-quarter financial results. AZZ reported adjusted net income of $46.0 million, or $1.52 per share, compared to $41.9 million, or $1.39 per share, during the prior year period. We had forecast adjusted net income of $44.9 million, or $1.48 per share. Compared to the third quarter of FY 2025, total sales increased 5.5% to $425.7 million. We had projected sales of $424.6 million. Gross margin of $101.9 million was modestly below our estimate of $103.2 million. Operating income of $69.5 million exceeded our estimate of $64.9 million, due to lower selling, general, and administrative expenses. Adjusted EBITDA increased modestly to $91.2 million compared to $90.7 million during the prior year period and our estimate of $93.3 million.
Updating estimates. With one quarter remaining, we have lowered our FY 2026 EBITDA estimate to $368.0 million from $369.2 million, and increased our EPS estimate to $6.03 from $5.98. We have increased our 2027 EBITDA and EPS estimates to $388.0 million and $6.60, respectively, from $387.4 million and $6.45. Our longer-term estimates through FY 2031 reflect multi-year growth and are summarized at the end of this report. Our estimates do not reflect the impact of acquisitions until announced.
Direct Digital Holdings (DRCT/$0.05) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Year End Review: 2026 Could Be A Pivotal Year Rating: MARKET PERFORM
Direct Digital remained a key strategic channel, supporting customer acquisition, margin mix improvement, and first-party data ownership despite a challenging macro and media cost environment. The channel continued to evolve toward a full-funnel model, with increasing contribution from returning customers, improved conversion rates, and greater emphasis on retention and lifecycle engagement.
Repositioning for strategic growth. Ongoing headwinds from media cost inflation, intensifying competition, and platform volatility have persisted in 2025, prompting a strategic shift toward owned-channel development, tighter audience targeting, and stronger cross-functional execution. Looking forward, Direct Digital is increasingly aligned around a more disciplined growth model, prioritizing customer retention, lifetime value, and earnings durability over volume-driven top-line expansion.
Resources Connection (RGP/$4.5 | Price Target: $10) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Hans Baldau hbaldau@noblefcm.com | Pricing Discipline Holds as Volume Pressure Persists Rating: OUTPERFORM
Continued Revenue Pressure. RGP reported second quarter revenue of $117.7 million, down 19% year-over-year. On a same-day constant currency basis, revenue declined 18.4%, driven almost entirely by lower billable hours across the core On-Demand and Consulting segments. Importantly, the weakness remains volume-driven rather than price-driven, as average bill rates were largely stable and improved in several key geographies.
Pricing Discipline, Volume Weak. The Company continues to make progress with its value-based pricing initiatives. U.S. bill rates increased 2.5% year over year, Consulting bill rates rose 6.6%, and On-Demand bill rates increased 2.6%. However, these gains were more than offset by sharp declines in billable hours, particularly in Consulting (-33.8%) and On-Demand (-21.5%). Management specifically highlighted reduced demand for traditional finance roles as clients adopt automation and AI, underscoring that part of the On-Demand softness may be structural rather than purely cyclical.
Noble Capital Markets Research Report Thursday, January 8, 2026
Companies contained in today’s report:
ACCO Brands (ACCO)/OUTPERFORM – 2025 Review and 2026 Expectations AZZ (AZZ)/OUTPERFORM – Third Quarter FY 2026 Results Outpace Expectations Bit Digital (BTBT)/OUTPERFORM – Monthly ETH Production Comstock (LODE)/MARKET PERFORM – Comstock Metals Achieves a Major Permitting Milestone
ACCO Brands (ACCO/$3.79 | Price Target: $9) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 2025 Review and 2026 Expectations Rating: OUTPERFORM
2025 Review. ACCO Brands’ 2025 narrative was dominated by a clear priority: defend profitability and cash generation in a soft demand environment, using restructuring and cost takeout as the primary levers while the top line remained pressured. Across the first three quarters of 2025, demand was weak and uneven globally, and Q3 in particular underscored that as sales came in lower than expected; however, the Company still delivered adjusted earnings in line with its outlook by expanding gross margin and lowering SG&A, demonstrating meaningful operating discipline.
2026 Preview. Looking into 2026, we believe the key question for investors is whether ACCO can convert its 2025 operational progress into a durable and investable story rather than a purely defensive one. The most important variable remains organic revenue stabilization: the Company has demonstrated the ability to protect earnings despite sales declines, but the market will require evidence that declines are moderating, particularly in the Americas, and that channel inventories and promotional intensity are improving rather than worsening.
FY 2026 third-quarter financial results. AZZ reported adjusted net income of $46.0 million, or $1.52 per share, compared to $41.9 million, or $1.39 per share, during the prior year period. We had forecast adjusted net income of $44.9 million, or $1.48 per share. Compared to the third quarter of FY 2025, total sales increased 5.5% to $425.7 million. We had projected sales of $424.6 million. Gross margin of $101.9 million was modestly below our estimate of $103.2 million. Operating income of $69.5 million exceeded our estimate of $64.9 million, due to lower selling, general, and administrative expenses. Adjusted EBITDA increased modestly to $91.2 million compared to $90.7 million during the prior year period and our estimate of $93.3 million. Adjusted EBITDA margin as a percentage of sales amounted to 21.4% compared to 22.5% during the third quarter of FY 2025.
Segment results. While Metal Coatings sales were up 15.7% compared to the prior year quarter, Precoat Metals sales were down 1.8%. Metal Coatings delivered higher sales due to increased volume driven by infrastructure-related projects in several end markets. Precoat Metals experienced lower sales due to weaker end markets, including building construction, HVAC, and transportation, partially offset by container. Segment adjusted EBITDA margin amounted to 30.3% for Metal Coatings and 19.7% for Precoat Metals.
Bit Digital (BTBT/$2.19 | Price Target: $5.5) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Monthly ETH Production Rating: OUTPERFORM
Data. Bit Digital reported its monthly Ethereum (“ETH”) treasury and staking metrics for the month of December 2025. As of December 31, 2025, the Company held approximately 155,227 ETH versus 154,398.7 ETH at the end of November. Included in the ETH holdings were approximately 15,146.0 ETH and ETH-equivalents held in an externally managed fund. The Company staked an additional 642 ETH during the month. The Company’s total staked ETH was approximately 138,263, or about 89% of its total holdings as of December 31st.
Yield and Value. Staking operations generated approximately 389.6 ETH in rewards during the period, representing an annualized yield of approximately 3.5%. Based on a closing ETH price of $2,967, as of December 31, 2025, the market value of the Company’s ETH holdings was approximately $460.5 million.
Comstock (LODE/$3.97) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Comstock Metals Achieves a Major Permitting Milestone Rating: MARKET PERFORM
Receipt of Air Quality Permit. Comstock Metals received its Air Quality Permit from the Nevada Division of Environmental Protection – Bureau of Air Pollution Control for the processing of waste solar panels and photovoltaics at its planned industry-scale materials recovery facility in Silver Springs, Nevada. Receipt of the permit is expected to enable Comstock to install, test, and commission the facility on schedule during the first quarter of 2026.
Closing in on the Written Determination Permit. The Air Quality Permit follows a notification of eligibility for a written determination permit from the Nevada Division of Environmental Protection – Bureau of Sustainable Materials Management, which is now through the public notice period. Once the written determination permit is final, the two permits represent the complete scope of required regulatory approvals for commissioning the scale up of the recovery facility designed to process more than 3.0 million panels per year, representing up to 100 thousand tons per year of waste materials.
Updating 2025 estimates. We have lowered our Q4 and FY 2025 EPU estimates to $0.57 and $2.33, respectively, from $0.69 and $2.45. We have marked-to-market ARLP’s holding of bitcoins, which amounted to 568 bitcoins as of September 30. The price of bitcoin closed at $87,508.83 on December 31, 2025, compared to $114,056 on September 30. We anticipate the value of digital assets in Q4 2025 could decrease by approximately $15.1 million if all bitcoins were held through the fourth quarter. Because it would represent a non-cash unrealized loss, it has no impact on our adjusted EBITDA estimate.
Looking ahead. While our 2026 and 2027 estimates are unchanged, we think coal supply and demand fundamentals could strengthen going into 2027, which could have a positive impact on pricing. Actions taken by the Trump Administration are expected to support and sustain coal-fired power generation. Electricity demand growth is expected to be driven by industrial growth, electrification, and the expansion of AI infrastructure and data centers.
First Phosphate Corp. (FRSPF/$0.76 | Price Target: $1.55) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Transitioning from Exploration to Feasibility Rating: OUTPERFORM
Offtake agreement. First Phosphate recently amended an offtake agreement that includes a US$0.53 million upfront pre-payment during the fourth quarter of FY 2026. The funds will be used to advance the Begin-Lamarche project towards a feasibility study and later, production. The prepayment is subject to refund should First Phosphate decide not to pursue a feasibility study or production, neither of which we anticipate. In our view, the prepayment validates downstream interest and reinforces the strategic relevance of the Company’s integrated phosphate platform.
Final tranches of private placement. The Company closed the third and fourth tranches of its oversubscribed non-brokered private placement in December, raising approximately $9.6 million in gross proceeds and bringing total capital raised since June 2022 to approximately $49.7 million. Following recent warrant exercises and the offtake pre-payment, management indicates cash on hand of approximately $24 million, which we believe is sufficient to fund planned activities through 2026 and into 2027.
Kuya Silver (KUYAF/$0.7 | Price Target: $1.5) Mark Reichman mreichman@noblefcm.com | (561) 999-2272 Hans Baldau hbaldau@noblefcm.com | Vertically Integrating its Operation Rating: OUTPERFORM
Private Placement Financing. Kuya Silver Corporation (OTCQB: KUYAF, CSE: KUYA) announced a brokered private placement pursuant to the listed issuer financing exemption of up to 15.0 million units of the company at a price of C$1.00 per unit for aggregate gross proceeds of up to C$15.0 million. Each unit will consist of one common share and one half of one common share purchase warrant. Each warrant entitles the holder to purchase one common share at an exercise price of C$1.30 per common share for a period of 36 months from the date of issuance.
Use of Proceeds. Kuya intends to use the net proceeds of the offering to advance the company’s Bethania project with the acquisition of and/or development of concentrate processing capacity. Kuya is evaluating several options, each of which is fully permitted and will allow the company to vertically integrate its production capabilities. Funds may also be used to explore the Silver Kings Project in Ontario, discretionary growth capital, and for general corporate purposes.
Positive Guidance Received From CDE. Gyre announced that its majority-owned subsidiary in China, Gyre Pharmaceuticals Ltd, has completed pre-NDA discussions with the Chinese Center for Drug Evaluation (CDE). The CDE indicated that the Phase 3 data meets the requirements for approval in chronic hepatitis B-associated liver fibrosis, as expected. An NDA submission is planned for 1H26, meeting our expected milestones for the product and the company.
Approval Would Allow Full Commercialization. Under the CDE regulations, the Phase 3 supports Conditional Approval for Hydronidone, allowing full commercialization. As part of the approval, company agrees to conduct a Phase 3c study after commercialization to confirm the effects seen in Phase 3. This is similar to a Phase 4 study in the US. The study design has not be finalized, although we expect similar endpoints for confirmation of the Phase 3 data.
Noble Capital Markets Research Report Monday, January 5, 2026
Companies contained in today’s report:
Cardiff Oncology (CRDF)/OUTPERFORM – Onvansertib Could Treat Colorectal Cancers That Escape Other Treatments Vince Holding Corp. (VNCE)/OUTPERFORM – Emerging Growth Levers Provide Favorable 2026 View
Cardiff Oncology (CRDF/$2.66 | Price Target: $12) Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625 Onvansertib Could Treat Colorectal Cancers That Escape Other Treatments Rating: OUTPERFORM
Initiating Coverage With A $12 Price Target. Cardiff Oncology is developing onvansertib for the treatment of multiple cancer indications. Its lead program is in metastatic colorectal cancer for patients with a mutation that makes the cancer more aggressive and difficult to treat. This mutation, KRAS, is found in about 45% of the colorectal cancer patients. As a result of the mutation, several standard therapies are ineffective. We believe onvansertib’s unique mechanisms of action could be a breakthrough in cancer treatment.
Onvansertib Has Two Main Mechanisms of Action. Onvansertib inhibits PLK1, an intracellular protein needed for regulatory functions that control cell growth and division. This protein can be overexpressed in many cancers, including colorectal cancer, overriding the normal controls. A second mechanism stops a pathway that allows tumors to survive in low oxygen environments and resist treatment with bevacizumab (Avastin).
Vince Holding Corp. (VNCE/$4.19 | Price Target: $5.5) Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734 Jacob Mutchler jmutchler@noblefcm.com | Emerging Growth Levers Provide Favorable 2026 View Rating: OUTPERFORM
Execution inflection driven by digital and DTC momentum. 2025 marked a clear improvement in operating execution, led by stronger e-commerce performance, enhanced digital capabilities, and early traction from the dropship initiative, which collectively supported revenue growth and improved operating leverage.
Pricing power and profitability improved despite cost headwinds. The company demonstrated brand resilience through higher average selling prices, stable unit volumes, improved full-price sell-through, and disciplined cost management, allowing it to offset tariff and freight pressures and deliver meaningful adjusted EBITDA upside.
Noble Capital Markets Research Report Friday, January 2, 2026
Companies contained in today’s report:
ONE Group Hospitality (STKS)/OUTPERFORM – Development Update Twin Hospitality (TWNP)/MARKET PERFORM – A Management Change V2X (VVX)/OUTPERFORM – A Strong End to 2025 Awards
ONE Group Hospitality (STKS/$1.75 | Price Target: $5) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 Development Update Rating: OUTPERFORM
Milestones. ONE Group announced a number of development milestones achieved during 4Q25. These include: entering into ten restaurant asset-light development agreements; an expanded footprint in large-market, professional sports & entertainment stadiums; opening two new STK locations; launching Benihana-branded retail product; and planning capital-efficient growth for 2026.
Largest Agreement. The ONE Group has entered into its largest asset-light development agreement in the Company’s history, securing development rights for a total of ten restaurants, either Benihana or Benihana Express locations, throughout the Greater San Francisco Bay Area. The two Benihana joint venture locations are expected to open in 2026, with the remaining franchised and licensed locations to open over the next seven years.
Twin Hospitality (TWNP/$0.67) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 A Management Change Rating: MARKET PERFORM
Leadership Transition. Twin Hospitality announced Andy Wiederhorn has been named Chief Executive Officer of the Company and Roger Gondek has been named President of Twin Peaks, replacing former CEO and President Kim Boerema. While somewhat surprising, as Mr. Boerema was appointed CEO just this past May, the new leadership simplifies the leadership structure and optimizes resources while minimizing overhead, without any significant change in ability, in our view.
Roger Gondek. We believe the elevation of Mr. Gondek to President of Twin Peaks Restaurant to be the headline. Already serving as Chief Operating Officer of Twin Peaks since 2017, Mr. Gondek brings approximately 15 years of experience with the brand, including previous operations leadership roles with Twin Peaks’ largest franchisee. Mr. Gondek was the Executive Vice President of Operations of La Cima Restaurants, LLC, a franchiser of 43 Twin Peaks restaurants in Florida, Alabama, Georgia, South Carolina, North Carolina, and Tennessee, from June 2011 to July 2017. Prior to La Cima Restaurants, Mr. Gondek was a Divisional Vice President at Hooters of America from October 2001 to February 2011. Mr. Gondek has a deep understanding of Twin Peaks markets, in our opinion.
V2X (VVX/$54.55 | Price Target: $72) Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262 A Strong End to 2025 Awards Rating: OUTPERFORM
DMEA ATSP. V2X subsidiary Vertex Aerospace has been named as an awardee to the Defense Microelectronics Activity (DMEA) Advanced Technology Support Program (ATSP), according to the daily Department of War contract award activity. With multi-billion dollar potential, this award caps a strong year for V2X. The Company has won places on multiple billion dollar contracts, which bode well for the future.
Details. DMEA ATSP is an ID/IQ contract with a $23.357 billion ceiling. This multiple award contract has a base ordering period of five years with two option periods, three years and two years respectively, to establish a 10 year ordering period. There are a total of 10 awardees, including Vertex. As an ID/IQ, Vertex will need to compete for each award, but we are confident the Company will receive its fair share of wins under the contract.
Memory chip stocks took a beating Thursday after Google went public with research on a new algorithm that could dramatically reduce the amount of memory needed to run large language models — rattling a sector that had been riding an AI-fueled supply crunch straight up.
Samsung Electronics and SK Hynix, the South Korean heavyweights that dominate the high-bandwidth memory market, both fell at least 6% in Seoul trading. In the U.S., Micron Technology (MU) slid more than 7%, while Western Digital and Sandisk each dropped at least 5%. Nvidia (NVDA) was not spared either, shedding nearly 4% as broader AI infrastructure sentiment soured.
What Google Actually Did
Google’s TurboQuant algorithm, which the company publicized on X this week — though the underlying research originally surfaced last year — claims to cut the memory required to run large language models by at least a factor of six. The efficiency gain targets what’s known as the key value cache, a critical bottleneck in AI inference, or the process of running AI models to generate outputs.
If widely adopted, TurboQuant could reduce the memory footprint of AI workloads significantly, theoretically easing the supply crunch that has sent chip prices and margins soaring across the sector.
The Bull Case Didn’t Disappear Overnight
Context matters here. Memory chip stocks had been on an extraordinary run. SK Hynix and Samsung shares had each surged more than 50% year-to-date through Wednesday, fueled by insatiable demand from hyperscalers building out AI infrastructure at historic scale. SK Group Chairman Chey Tae-won as recently as this week said the memory chip shortage would persist through 2030.
Morgan Stanley analyst Shawn Kim pushed back on the panic in a note, arguing the impact of Google’s research should ultimately be net positive for the industry. His logic: if AI models can run with materially lower memory requirements without sacrificing performance, the cost per query drops, making AI deployment more profitable and accelerating adoption — which in turn drives more demand for memory, not less.
Kim and analysts at JPMorgan and Citigroup all invoked the Jevons Paradox — a 19th century economic concept holding that greater efficiency in resource use tends to increase total consumption rather than reduce it. The same argument made the rounds when DeepSeek’s low-cost AI model rattled markets last year.
The Bigger Picture for Investors
The four largest hyperscalers — led by Amazon and Google — are collectively on track to spend roughly $650 billion this year on data center infrastructure. That spending appetite doesn’t evaporate because of one efficiency algorithm, and Ortus Advisors analyst Andrew Jackson noted the Google development may make little practical difference to near-term demand given how constrained supply remains.
For small and microcap investors with exposure to the memory supply chain — component manufacturers, equipment makers, or specialty materials companies — Thursday’s selloff may be more noise than signal. The structural demand drivers behind AI infrastructure spending remain firmly intact.
The more pressing question isn’t whether TurboQuant reduces memory demand. It’s whether the market had already priced in perfection for a sector where any efficiency headline is now treated as an existential threat.
SpaceX, Elon Musk’s rocket and satellite giant, is reportedly weighing a fundraising target of approximately $75 billion in its upcoming initial public offering — a figure so staggering it would more than double the previous record holder, Saudi Aramco’s $29 billion listing in 2019. Earlier reports had pegged the target closer to $50 billion, but sources familiar with the matter suggest the company has since discussed raising north of $70 billion with potential investors.
The company is reportedly eyeing a June market debut, with a confidential IPO filing potentially hitting as early as this month. Nothing is finalized, and the timeline could shift, but preparations appear well underway.
At a projected valuation north of $1.75 trillion, SpaceX would sit comfortably among the most valuable companies on the planet — larger than all but five members of the S&P 500. Only Nvidia, Apple, Alphabet, Microsoft, and Amazon would rank above it. That places SpaceX ahead of Meta Platforms and, notably, Musk’s own Tesla. The company’s footprint expanded significantly after absorbing Musk’s AI startup xAI in a deal that valued the combined entity at $1.25 trillion.
For context, SpaceX isn’t just a rocket company anymore. Starlink, its satellite internet division, has become a legitimate global broadband player with millions of subscribers, a recurring revenue engine that makes the broader SpaceX story far more investable than a pure aerospace play. That commercial backbone is a big reason why the valuation math holds up — at least in the eyes of institutional buyers.
Why This Matters Beyond the Headline
For investors who operate in the small and microcap space, this deal carries real implications even if SpaceX is nowhere near your portfolio.
A transaction of this magnitude will consume enormous amounts of institutional capital. Fund managers allocating to a $75 billion raise are, by necessity, pulling liquidity from somewhere. In environments where mega-cap IPOs dominate investor attention, smaller names often get deprioritized — not because the fundamentals have changed, but because the oxygen in the room gets sucked up by the headline deal.
That dynamic has played out historically around blockbuster listings. The Aramco IPO in 2019, the Rivian offering in 2021, and the SPAC boom all coincided with periods of subdued interest in the lower end of the market cap spectrum. Whether SpaceX follows that pattern will depend heavily on the broader macro environment at the time of listing.
There’s also the sentiment angle. A successful SpaceX IPO — executed cleanly at a $1.75 trillion valuation — could serve as a confidence signal for the broader IPO pipeline, potentially unlocking deals that have been sitting on the sidelines waiting for a favorable window. If the market receives this one well, expect a flood of filings in Q3.
For now, the deal is still taking shape. But make no mistake — when a single IPO threatens to rewrite the record books twice over, the entire investment landscape takes note.
DALLAS–(BUSINESS WIRE)–Mar. 25, 2026–Resources Connection, Inc. (Nasdaq: RGP) (the “Company,” “we,” and “our”), a global consulting firm, will announce results of operations for its third quarter of fiscal 2026 ended February 28, 2026 after the close of market on Wednesday, April 8, 2026.
This release will be followed by a conference call at 5:00 p.m. ET, April 8, 2026. A live webcast of the call will be available on the “Investor Relations” Events section of the Company’s website. To access the call by phone, please go to this link (registration link), and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time by visiting the RGP Investor Events section of the Company’s website.
ABOUT RGP
RGP (Nasdaq: RGP) is an award-winning global professional services firm with three decades of experience helping the world’s top organizations navigate change and seize opportunity. With three integrated offerings—On-Demand Talent, Consulting, and Outsourced Services—we provide CFOs and C-suite leaders with the flexibility to solve today’s most pressing challenges on their terms, uniting strategy, execution, and talent across accounting and finance, digital transformation, data, and cloud, at a global scale. Our people-first approach continues to drive innovation across industries worldwide.
Based in Dallas, Texas, with offices worldwide, we annually engage with more than 1,500 clients around the world from 40 physical practice offices and multiple virtual offices. As of January 2026, RGP is proud to have served 90 percent of the Fortune 100 and has been recognized by U.S. News & World Report (2025–2026 Best Companies to Work For) and Forbes (America’s Best Midsize Employers 2026, America’s Best Management Consulting Firms 2025, World’s Best Management Consulting Firms 2025).
The Company is listed on the Nasdaq Global Select Market, the exchange’s highest tier by listing standards. To learn more about RGP, visit: http://www.rgp.com.
